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1. Introduction
Despite the fact that cancer is a disease known since ancient time, numerous efforts 
have been made to prevent, control and eradicate the malignant disease in the 21st
century. This illness is still one of the most devastating human problems in the world. 
Cancer is a group of diseases that are characterized by the abnormal and relatively fast 
growth of the cells present in some organs or tissues.1 Cancer cells growing in the local 
organs are lethal, they are able to spread directly through invasion and by metastases to 
other sites of the body via the blood and lymphatic streams. The uncontrollable cell 
division, which forms a malignant mass of cells called a neoplasm, is due to mutations 
that the cell’s DNA suffers when a person is exposed to certain cancer-causing agents 
(carcinogens), such as ultraviolet light, industrial chemicals, radiation, the tar of 
cigarettes, viruses and some metabolic products.1-4 Probably, the most important 
difference that cancer cells have compared to normal cells, is that malignant tumor cells 
have the ability to spread and infiltrate the tissues around them and may block passage 
ways, destroy nerves, and erode bone.1 Cancer is commonly observed in major organs 
including the lungs, breast, intestines, skin, stomach, prostate, colon, rectum, ovary, 
bladder and even in the blood cell-forming tissues of bone marrow.1-4
Cancer also cause a great social and economical problem globally since it has been 
estimated that there were more than 12 million cancer cases worldwide in 2007, of which 
5.4 million occured in economically developed countries and 6.7 million in economically 
developing countries (Figure 1).5 The corresponding estimates for total cancer deaths in 
2007 are 7.6 million (about 20,000 cancer deaths a day), 2.9 million in economically 
developed countries and 4.7 million in economically developing countries. The major 
kind of cancer death in 2007 was lung and bronchus cancer followed by cancers of the 
breast, colon & rectum, and prostate as shown in Figure 1. Because cancer is the second 
cause of death worldwide after heart diseases, and because little improvement has been 
made to reduce the cancer death rates, the fight against this lethal disease is still one of 
the biggest challenges for the scientific community. 
? 2
Figure 1. Major types of cancer that was cause death worldwide in 20075.
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The Strategy of Cancer Treatment 
The ideal cancer treatment is that all malignant cells should be destroyed, 
removed or neutralized to achieve cure. It has been proved in animal model that a single 
tumor cell can grow and eventually kill the host.2 However; it is very difficult to reach the 
ideal goal of treatment. There are four major strategies for cancer treatment, which are 
used in attempt to reduce malignant cells in organ or tissue:
(A) Surgery6
(B) Radiotherapy7
(C) Chemotherapy8
(D) Immunotherapy and other biological therapy9
The treatment that is chosen depends on many different factors including the type 
of cancer, extent of the disease, rate of progression, conditions of the patient and response 
to the therapy; however combination of two or more of these methods has been shown to 
yield better results.1,4 Localized cancer  can be removed by surgery, but cancer after 
metastasis has to be treated systematically by chemotherapy in combination with 
radiotherapy and surgery.
Cancer Chemotherapy
Cancer is regarded as a disease that began locally and then generally spread 
progressively to the regional lymph nodes. At at a late stage, the cancer cells can further 
spread to distant parts of the body via the blood streams. Thus the initial attempts to 
control cancer depended mainly on the aggressive local surgery with extirpation of 
regional lymph nodes. After introduction of radiotherapy in the 1930s, this strategy for 
killing local tumor has being added to the therapeutic armamentarium. In order to remove 
tumors, which may still remain in the primary site or may already spread to other organs 
(metastasis) after surgery and/or radiotherapy, systemic chemotherapy would be essential 
to cure the disease.  
Compounds that have the property of killing cells are called cytotoxic drugs. 
When cytotoxic compounds are designed to kill cancer cells, they are referred to as 
anticancer or antineoplastic agents, and their administration is known as cancer 
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chemotherapy.1,10  Using chemotherapy for treatment of cancer was recorded11 in the first 
century A.D. It is of interest that colchicine, prepared from the bark of the cinchona tree, 
was first used as an anticancer agent. Although there are many reports regarding use 
different chemicals in the treatment of cancer, systematic research was probably started 
by Paul Ehrlich in early this century. Though his interest was mainly directed towards 
chemotherapy of infectious diseases, he developed some models of transplantable 
tumours in rodents. It is agreed by most people that this systematic approach to the 
treatment of protozoal diseases and the use of animal models greatly influenced later 
research in cancer chemotherapy. Between 1910 and 1940 there was little advance in 
cancer chemotherapy. The implications of the observation that soldiers dying in the First 
World War after exposure of yellow mustard gas had aplasia of lymphoid organs and 
bone-marrow were only appreciated some 20 years later by the two renowned scientists 
namely Goodman and Gilman. The first ever successful drug nitrogen mustard was 
introduced into clinical practice in the treatment of lymphomas and leukemias from 1946 
onwards.10,12
Over the last fifty years about 500,000 natural and synthetic chemical compounds 
have been tested for anticancer activity, but only about 25 of these are widely used as 
anticancer agents today. During the first four decades in the history of chemotherapy, a 
period known as cellular chemotherapy, chemists killed malignant tumors by inhibiting 
different mechanisms of their cellular division using cytostatic/cytotoxic agents. Later, 
the rapidly expanding knowledge of molecular biology made possible the identification of 
new specific tumor targets which are responsible for cancer cell replication. These targets 
may be selectively blocked by molecules designed and synthesized for this purpose, 
opening the door to a new period called molecular chemotherapy.12 Although every year 
new targets for cancer therapy are identified, and several new drugs are entered into 
clinical trials, how to conquer multi-drug resistance generated from tumor cells, reduce 
unpleasant side-effects and the cost of drug development are still important subjects for 
research and development of new anticancer agents for chemotherapy. 
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Classification of Cytotoxic Agents 
Cytostatic drugs are usually classified according to their mechanism of action. The 
major classes of chemotherapeutic agents include: 
1. Alkylating Agents13: Molecules that permanently attach to the DNA, distorting 
its shape. Such as N-mustards (i.e. melphalan, chlorambucil, cyclophosphamide, 
ifosphamide etc.), Nitrosourea (carmustine, lomustine etc.), Busulfan, Tamador, 
Dacarbazine etc.  
2. Antimetabolites14: Molecules that appear to be nucleotides and so are 
incorporated into DNA, leading to non-functional DNA. i.e. Methotrexate, 5-Fu, 
etc. 
3. Mitotic inhibitors15: Molecules that block cell division by preventing 
microtubule function. Microtubules are vital for cell division, and, without them, 
cell division cannot occur. The main examples are vinca alkaloids and taxanes. 
Vincristine, Vinblastine, Vinorelbine, Vindesine, Docetaxel, Taxol, etc. 
4. Topoisomerases inhibitors16: Topoisomerases are essential enzymes that 
maintain the topology of DNA. Inhibition of type I or type II topoisomerases 
interferes with both transcription and replication of DNA by upsetting proper 
DNA supercoiling. Irinotecan, Topotecan, Amsacrine etc. 
5. Antitumor antibiotics17: The antitumor antibiotics are natural products and 
mostly serve as DNA binders and intercalators. i.e. Doxoruicin, Bleomycin, 
Miomycin etc;
6. Hormonal and related agents18: i.e. Prednisone, Prednisolone, tamoxifen etc.
7. Miscellaneous agents19: This group includes those chemical compounds whose 
mechanism of action is obscure or whose mechanism of action is differenct from 
the above classes. Such as Enzymes (L-asparagina), metal compounds (i.e. 
Cisplatin and Carboplatin) and other random synthetics such as, Hydroxyurea, 
Procarbazine, Hexamethylmelamine etc. 
8. Some newer agents do not directly interfere with DNA. These include monoclonal 
antibodies and the new tyrosine kinase inhibitors e.g. imatinib mesylate (Gleevec
or Glivec), which directly targets a molecular abnormality in certain types of 
cancer (chronic myelogenous leukemia, gastrointestinal stromal tumors).  
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2. Aim of the Current Work 
?
The goals of the current study are finding new anticancer agents with high 
therapeutic efficacy, low toxicity, good bioavailability, and effective against various 
multi-drug resistant tumor cells. In the past years, we have forcued on the research and 
development of DNA-alkylating agents as anticancer agents. The following two classes of 
DNA-alkylating have been designed and synthesized for antitumor evaluation:  
I. Bifunctional DNA alkylating agents, bis(hydroxymethyl) and bis(carbamates) 
derivatives of 3a-Aza-cyclopenta[a]indenes (Chapter 2) 
The chemical synthesis, in vitro and in vivo evalyation, and mechanism of action 
of bis(hydroxymethyl) and bis(carbamates) derivatives of 3a-aza-cyclopenta[a]indenes
are described in the Chapter 1. ?
II DNA-Directed Alkylating Agents, N-mustard-quinoline conjugates having urea 
ans hydrazinecarboxamide linker (Chapter 3, 4 and 5) 
The second chapter focuses on the design and synthesis of new aniline N-mustards 
derivatives as DNA-Directed Alkylating Agents. The N-mustards includes:  
1) Phenyl N-mustard-quinoline conjugates having a urea linker;
? 7
2) Phenyl N-mustard-quinoline conjugates having a hydrazinecarboximide linker; 
The chemical synthesis, in vitro and in vivo evaluation, mechanism of action and 
chemical stability of N-mustard-quinoline conjugates having urea ans 
hydrazinecarboxamide linker are described in the chapter 4 and 5. 
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2.1 Introduction  
It is 50 years since Watson and Crick determined that genetic material (DNA), 
which exists structurally as a double helix with now well-established characteristics1. Its 
role in the control of cellular functions immediately suggested DNA as an excellent target 
for treating illnesses of genetic origin, such as cancer. The first compounds discovered to 
act on DNA were the sulfur mustards, but their high toxicity prompted to a search for less 
toxic and more efficient compounds2. Over the past years, large numbers of synthetic and 
naturally occurring tumor inhibitory compounds were discovered to act as anticancer 
agents. A major proportion of these compounds contains at least one, often two or three, 
reactive electrophilic centers in the molecule.3 For example, many synthetic N-mustards4
bearing a N,N-bis(2-chloroethyl)amine active pharmacophore and cis-platinum 
complexes5 are currently used clinically for cancer chemotherapy.6 The antibiotic 
anticancer agent, mitomycin C7-9 (MMC, 1, Figure 1), and its analogue, indoloquinone 
EO9 (210), have been demonstrated to be able to cross-link to DNA double strands after 
bioreductive activation.11  DNA cross-linking also has been demonstrated with 
pyrrolizine alkaloids12 (i.e. seneciphylline, 3), the benzoquinones AZQ (413), the 
naphthoquinone ?-lapachone (514), azinomycins A and B (615), anthracycline derivatives 
(i.e. doxorubicin, 716), anthramycin (817), benzo[a]pyrenes (i.e. (+)-anti-BPDE, 918) and 
cyclopropylpyrroloindoles (i.e. duocarmycin, 1019). These compounds often exhibit 
potent antitumor activity due largely to the ability of such compound to shut down DNA 
strand separation events crucial to replication and transcription.
One of the most plentiful classes of biologically active natural products that 
exhibit wide-ranging biological properties are the pyrrolizidine alkaloids (PAs). As 
constituents of over 6000 species of plants with wide morphological and geographical 
diversity, these compounds express poisonous activities of endemic proportions.20 Dispite 
their poisonous traits, these agents have provided a fruitful avenue. These derivatives are 
able induce oxidative DNA bis-alkylation21 indicating that these compounds exhibit their 
biological activity because of they are capable of  inducing DNA-protein  cross-links.12
Pyrrolizidine alkaloids have been also reported to have antimitotic, hepatotoxic, and 
genotoxic activity in vivo and in vitro.22-23 
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Pyrrolizidine alkaloids (PAs) require metabolic activation to exert their biological 
activity.24 PAs are metabolically converted to two major products: the reactive, 
bifunctional electrophilic pyrrole and the less toxic N-oxide, by cytochrome P-450.25
Generation of the active pyrrolic moiety 13 from 3 via an oxidative transformation was 
previously proposed by Kim et al. (Figure 2).12 C-7 and C-9 ester substituents of PAs are 
activated forming an conjugation with the pyrrole nitrogen lone pair probably via 
electrophilic activation.
? 12
?
It was reported that mitomycines have some structural similarities with PAs.26
Mitomycin C (1, MMC) is one of the most famous and more well studied alkylating 
agents.8 MMC is activated by reductive activation under anaerobic conditions in certain 
hypoxia solid tumors. A proposed mechanism for the activation of MMC by quinine 
oxidoreductage (NQO1) is shown in Figure 3.27 Thus, electron reduction of MMC 
generates hydroquinone (16), which allows facile expulsion of the angular methoxy group 
and subsequent tautomerization to afford the intermediate 17. In a similar to PAs, C-1 and 
C-10 are activiated to form two reactive nucleophilic centers, which allow forming 
covalent bond with DNA (Cross-linking).28
? 13
From the mechanism of bioactivation of PAs and MMC, one can summarize their 
similarity as shown in Figure 4. 
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Early work  by Hopkins et al. also showed that dehydroretrorsine 23, and 
dehydromonocrotaline 24, simple diacete of pyrrolizidin 25 and 2,3-bis(acetoxymethyl)-
1-methylpyrrole 26, also cross-linked with DNA, where MMC targets, with a high degree 
of selectivity for 5-CpG3.29 
Structure activity relationship studies with many of natural products are often 
limited by the small quantity of material available and the number of modification on 
these complex molecules are limited. Insight into the relationship between structure and 
activity can only be gained through studies with simpler molecules. To synthesize this 
simple molecules for SAR study, one can use biological active natural products as the 
base template.30-32 Based o structural characteristics of the Pas, Anderson and co-workers 
have designed and synthesized a series of 2,3-dihydro-6,7-bis(hydroxymethyl)-1H-
pyrrolizine diesters with general formula 27.33 The potential electrophilic reactivity of the 
allylic esters in 27 (via O-alkyl cleavage) will be enhanced by participation of the ring 
nitrogen similar to that of MMC and PAs. A majority of the compounds of this series 
exhibited significant antileukemic activity against P-388 in animal model.  Of these 
derivatives, bis(carbamate) derivative 28 showed potent activity at lowest dose tested, 
0.78 mg/kg and 29, afforded “cures” at dose levels as low as 12.5 mg/kg. Several other 
compounds showed potent activity against P-388 over a greater than four-fold dose range 
without appeared acute toxicity. The most promising compound in this class was 5-(3,4-
dichloropehnyl)-2,3-dihydro-1H-pyrrolizidine-6-7-bis(isopropylcarbamate) (30),34 which 
had significant reproducible antitumor activity against a broad  range of experimental 
murine neoplasias and humor tumor xenografts in nude mice. This compound was 
selected for more extensive preclinical studies,35 but there was no further information has 
been published whether this agent was in clinical trials. Studies on the structure-activity 
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relationships of derivatives of 27 revealed that the nature of R and R1 substituent 
significantly affected both chemical reactivity and biological activity of the system. The 
chemical reactivity of 27 toward neleophiles was found to be decreased as the electron-
withdrawing power of the C-5 substituent increase indicating that the reactivity of this 
system is dependent upon the ?–electron density in the pyrrole ring and the ability of the 
C-5 substituent (R) to stabilize the formation of the positive charge on the heterocyclic 
nitrogen atom during the displacement of the ester moieties (via O-alkyl cleavage). In 
general, the electrophilic reactivity can be controlled by the electronic influence of the C-
5 substituent. The size of the R1 substituent does not appear to have any significant effect 
upon potency, activity, or toxicity. 
?
Subsequently, the same authors   various derivatives of pyrrole with the general 
formula of 3136 and 32.37-38 These compounds possessed significant reproducible activity 
in the P-388 lymphocytic leukemia (PS) assay with the effective dose of 12.5 mg/kg.  
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Studies on the mechanism of action showed that DNA interstrand cross-linking by 
bis(carbamate)pyrroles or pyrrolizines was probably via a SN1 electrophilic reaction 
(Figure 8).33,39  These derivatives are capable of forming an DNA interstrand cross-link 
with the short olignucleotide 5’-ACGT at the 5’-CG residues at the minor groove 
region.39 The potential electrophilic reactivity of these agents (the carbamates moieties are 
leaving group in an alkyl-oxygen cleavage mechanism) would be modulated by the 
degree of electronic perturbation in participating of the pyrrole. Thus, the electronic 
effects induced from the substituted phenyl groups at C-2 of pyrroles or substituent at C5 
of pyrrolizines would affect the cytotoxicity of these congeners. However, it was reported 
that the in vivo antileukemic activity and the host toxicity were not altered to considerable 
degree as a function of electronic properties of phenyl substituent probably due to the 
insignificance of the electronic effects.37,40 In contrast with pyrrole derivatives, the C-5-
phenyl and the pyrrole ring in 5-phenylpyrrolizines are coplanar. It was suggested that the 
planarity of the molecule may be required for their antitumor activity. Studies on the 
structure-activity relationships (SAR) of 5-phenylpyrrolizines revealed that compounds 
having electron-donating substituent(s) (OMe) on the phenyl ring were generally more 
toxic than those compounds bearing electron-withdrawing substituent(s) (halogen). 
While, the in vivo antitumor activities were comparable or slightly less potent in 
compounds having an electron-donating substituent.41 These studies also suggested that 
the lipophilicity of compound might affect its antitumor potency.  
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Figure 8. The proposed mechanism of DNA bis-alkylation by pyrrolizidine derivatives
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In order to synthesize water soluble analogues of 30 necessary for the oral 
availabity, Anderson et al.42 have design several series of compounds with general 
formula 39. The antineoplastic activities of this class of compounds were compared to 30
against murine P388 lymphocytic leukemia and B16 melanocarcinoma. The alcohol 39a
showed to have comparable activity to 30, while 39b was less active and 39d with very 
low activity. However, these compounds were found to be unstable in aqueous solution. 
In order to establish more lipophilic compounds, the same authors have synthesized 
hetero analogues of 27 with general formula 4043 in which the C-2 methylene was 
replaced by S, SO or SO2. However, these agents were found to be inactive. The water 
soluble derivatives 41 were also synthesized by using ?-halopyridinium moiety as the 
pyrrolizines C-5 substituent44 (Figure 9). The 4- and 5-pyrrolizinyl-2-halopyridinium 
iodides and the corresponding pyridones were evaluated against P388 lymphocytic 
leukemia in vivo. The ?-fluoropyridinium compounds were active but the ?-chloro
compounds were not. Compounds that were active in the P388 screen were evaluated in 
L1210 leukemia, M5076 carcinoma, and MX-1 mammary xenograft assays in mice. 
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Anderson et al. also synthesized a series of heterocyclic  analogs (42-46)45 of 
pyrroles (31 and 32) to examine differ from one and other in several aspects-aromaticity, 
pKa, lipophilicity, dipole moments, charge-transfer donor/acceptor. All the prepared 
derivatives were tested for antileukemic activity against murine P-338 lymphocytic 
leukemia. None of the compounds was active when compared to 31 and 32.
To synthesizing the water-soluble compound, Anderson et al. also synthesized 
imidazoles derivatives 4746 with DNA cross-linking potencial. Appropriate substituents 
were added to the imidazole ring to modulate the reactivity of the two electrophilic 
centers. A potent advantage of the imidazole is that it is sufficiently basic to allow for the 
preparation of salts to enhance water solubility. All the synthesized imidazole derivatives 
were tested against murine P-388 lymphocytic leukemia. The SAR studies of this series 
of compounds revealed that the electron-withdrawing susbstituents at either N-1 of C-2 
gave rise to inactive compounds. However, the electron-donating substituents gave active 
comounds and the 2-(methylthio)-1-methyl derivatives 48 (carmethizole) was found to be 
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very active. The derivative 48, referred to by the name of carmethizole, was also found to 
be active against the MX-1 mammary xenograft, the human amelanotic melanoma cell 
line LOX xenograft, the M-5076 sarcoma, and L-1210 lymphocytic leukemia. Finally, 48
were reached for clinical evaluation.47-49
2.2 Rational Drug Design of Bis(hydroxymethyl) and Bis(carbamates) 
Derivatives of 3a-Aza-Cyclopenta[a]indenes
The pharmacological and clinical profile of 27 and 48 as anticancer agents have 
drawn a lot of attention for medicinal chemist to develop a variety of derivatives or 
analogues in an effort to obtained better compounds.  Based on the potent antitumor 
activities and mechanism of action of MMC (1) and bis(carbamates)pyrrolizidines (27)
and carmethizole (42), it is of great interest to design and synthesize new 
bis(hydroxymethyl) of 3a-azacyclopenta[a]indene-1-yl and their bis(methylcarbamate) 
derivatives having structure as depicted in Figure 12. These agents can be considered as 
“benzologues” of pyrrolizines. One can expect that the newly synthesized compounds 
might be able to cross-link to the macromolecular DNA via a similar mechanism of action 
as that of pyrroles or pyrrolizines (Figure 13). 
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To study the structure-activity relationship and optimize the antitumor activity of 
these new targets, an alkyl or substituted phenyl moiety was introduced to C-3 of the 3a-
azacyclopenta[a]indene-1-yl. The results revealed that the newly synthesized compounds 
exhibited significant in vitro cytotoxicity and potent in vivo therapeutic efficacy. The 
synthesis of 3a-azacyclopenta[a]indene-1-yl derivatives and their structure-activity 
relationships for the growth inhibitory properties in a panel of tumor cell lines are 
included in this study. Furthermore, we also describe the capability of DNA interstrand 
cross-linking and influence on cell cycle of the newly synthesized derivatives. 
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2.3 Chemistry 
The (2-hydroxymethyl-3-phenyl-8H-3a-azacyclopenta[a]indene-1-yl derivatives 
(63a-l) and their bis(methylcarbamate) (64a-l) were synthesized by following the method 
developed by Anderson et al.33,40,46 with modification (Scheme 1). Treatment of indoline-
2-carboxylic acid (58) with appropriate acid chlorides afforded 1-acyl-indoline-2-
carboxylic acids (61b-k), which were reacted with dimethyl acetylenedicarboxylate 
(DMAD) in acetic anhydride by heating at 120 oC to yield diester 62b-k. The diester 62a
was prepared directly from 58 by reacting with acetic anhydride and DMAD. While, the 
diester 62l was synthesized starting from 5-methoxyindole 59 via N-acylation by treating 
with 4-methoxybenzoyl chloride in the presence of triethylamine followed by catalytic 
hydrogenation using PtO2/H2 in EtOH to give intermediate 61l. Reaction of 61l with 
acetic anhydride and DMAD afforded compound 62l. The diester functions of 62a-l were 
reduced to bis-alcohol derivatives 63a-l by treating with LiAlH4 in a mixture of 
ether/CH2Cl2 in an ice bath. Treatment of 63a-l with methyl isocyante afforded the 
desired bis(carbamate) derivatives 64a-l in good yield. Table 1 shows the yields and the 
physical data of the compounds 63a-l and 64a-l. The cycloaddition reaction of 61a-l with 
DMAD is depicted in scheme 2.  The reaction of 1-acyl-indoline-2-carboxylic acids (61a-
l) with dimethyl acetylenedicarboxylate (DMAD) in acetic anhydride provides mesoionic 
oxazolone intermediates 65a-l, which according to Huisgen pyrrole synthesis50 would 
undergo 1,3-dipol cycloaddition reaction to give unstable diates 66a-l, which rapidly 
eliminate carbon dioxide to give diesters 62a-l.
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Table 1. Yields and the physical data of the compounds 13a-l[a] and 14a-l[b].
N
R1
R2
OR3
OR3
Compound R1 R2 Yield (%) mp (oC) Formula Analysis
63a H Me 77 123–125 C14H15NO2 C, H, N 
63b H Et 64 131–133 C15H17NO2 C, H, N 
63c H C6H5 71 169–171 C19H17NO2 C, H, N 
63d H 4’-FC6H4 72 164–166 C19H16FNO2 C, H, N 
63e H 4’-ClC6H4 71 213–215 C19H16ClNO2 C, H, N 
63f H 3’,4’-diFC6H3 69 146–147 C19H15F2NO2 C, H, N 
63g H 4’-OMeC6H4 79 143–144 C20H19NO3 C, H, N 
63h H 2’-OMeC6H4 76 132–134 C20H19NO3 C, H, N 
63i H 3’,4’-diOMeC6H3 77 160–162 C21H21NO4 C, H, N 
63j H 2’,6’-diOMeC6H3 70 171–173 C21H21NO4 C, H, N 
63k H 3’,4’,5’-triOMeC6H2 75 132–134 C22H23NO5 C, H, N 
63l OMe 4’-OMeC6H4 90 186–187 C21H21NO4 C, H, N 
64a H Me 98 86–88 C18H21N3O4 C, H, N 
64b H Et 99 165–166 C19H23N3O4 C, H, N 
64c H C6H5 86 196–198 C23H23N3O4 C, H, N 
64d H 4’-FC6H4 87 199–200 C23H22FN3O4 C, H, N 
64e H 4’-ClC6H4 96 204–206 C23H22ClN3O4 C, H, N 
64f H 3’,4’-diFC6H3 85 151–152 C23H21F2N3O4 C, H, N 
64g H 4’-OMeC6H4 70 152–153 C24H25N3O5 C, H, N 
64h H 2’-OMeC6H4 87 200–203 C24H25N3O5 C, H, N 
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64i H 3’,4’-diOMeC6H3 91 165–168 C25H27N3O6 C, H, N 
64j H 2’,6’-diOMeC6H3 90 154–156 C25H27N3O6 C, H, N 
64k H 3’,4’,5’-triOMeC6H2 95 204–206 C26H29N3O7 C, H, N 
64l OMe 4’-MeOC6H4 93 110–112 C25H27N3O6 C, H, N 
[a]R3 = H; [b]R3 = CONHMe 
All the synthesized compounds were characeterized by using 1H NMR and 
Elemental analysis. For compounds 63a-l, the characteristic proton signals for 
hydroxymethyl (i.e., CH2OH) appeared at the range of 3.7–4.8 ? ppm. For compounds 
64a-l, the 1H NMR signals for the carbamate residue (i.e., CH2OCO) appeared at 3.9–5.1 
? ppm. The characteristic proton for NH of carbamate appeared at the range of 7.2–6.7as 
multiplate and D2O exchangeable single. The elemental analysis of the newly synthesized 
derivatives was within ±0.4% range of the calculated C, H, N data.
2.4 Biological results  
2.4.1 In vitro cytotoxicity
CCRF/CEM cell line is used frequently for comparing the cytotoxic potency of 
numerous compounds in our laboratory. Therefore, the structure-activity relationships of 
1,2-bis(hydroxylmethyl) of cyclopenta[a]indenes (63a-l) and their corresponding 1,2-
bis(methylcarbamate) derivatives against CCRF-CEM tumor cell growth will be 
discussed below. Table 2 shows the cytotoxicity of 1,2-bis(hydroxylmethyl) of 
cyclopenta[a]indenes (63a-l) and their counterparts 1,2-bis(methylcarbamate) derivatives 
(64a-l) against human lymphoblastic leukemia CCRF/CEM cell line and its subcell lines 
resistant to vinblastine and taxol. It shows that the size and the electron property of the 
substituent at C-3 altered the cytotoxicity of these agents. In the series of 
bis(hydroxymethyl) derivatives (63a-l), the C-3 alkyl substituted derivatives (63a,b) are 
more cytotoxic than the phenyl substituted derivatives (63c-l). In the series of C-3 alkyl 
substituted compounds, the C3-Me derivative (63a) is more potent than 63b (C3-Et), 
whereas the order of cytotoxic effects for the series of C-3 phenyl substituted derivatives 
is as follows: Ph > OMe-Ph > halo-Ph, with the exception of C2’,6’-diOMe derivative 
(63j; the least potent). It clearly demonstrated that the electron property of the substituent 
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at the C3 phenyl ring affected the cytotoxic effects of these agents; compounds having an 
electron-donating substituent were generally more potent than compounds bearing 
electron-withdrawing functionality. But, this effect was not shown in 
bis(methylcarbamate) derivatives. Among the OMe substituted derivatives, 63g, 63h, and 
63i, bearing OMe function(s) at C-4’, C-2’ and C-3’,4’, respectively, were more cytotoxic 
than those derivatives having the same substituent at C-2’,6’ and C-3’,4’,5’ (63j and 63k,
respectively), indicating that introduction of a bulky substituent at C3 decreased the 
cytotoxicity of cyclopent[a]indenes. A similar observation was found in the series of 
bis(methylcarbamate) derivatives. 
Table 2. The cytotoxicity of 1,2-Bis(methanol) derivatives (63a-l) and 1,2-
Bis(methylcarbamate) derivatives (64a-l) of cyclopenta[a]indenes against human 
lymphoblastic leukemia CCRF/CEM cell line and its subcell line resistant to 
Vinblastine and Taxol.
Compd. 
Cell Growth Inhibition (IC50, ?M)a
CCRF/CEM CCRF-CEM /VBLb CCRF-CEM/Taxol
b
63a 0.076±0.0004 0.0665±0.0002 [0.88?]c 0.0321±0.0019 [0.39?]
64a 0.118±0.073 0.063±0.005 [0.53?] 0.120±0.004 [0.67?]
63b 0.356±0.12 0.227±0.004 [0.64?] 0.140±0.009 [0.39?]
64b 0.068±0.005 0.099±0.0003 [1.46?] 0.078±0.003 [1.15?]
63c 0.248±0.004 0.252±0.028 [1.02?] 0.222±0.02 [0.90?]
64c 0.356±0.012 0.552±0.004 [1.6?] 1.672±0.052 [4.7?]
63d 4.502±0.252 11.149±0.119 [2.5?] 7.228±0.193 [1.6?]
64d 0.139±0.004 0.281±0.004 [2.0?] 0.30±0.008 [2.2?]
63e 4.31±0.004 4.458±0.185 [1.03?] 2.373±0.128 [0.55?]
64e 5.654±0.355 2.284±0.241 [0.40?] 3.255± 0.065 [0.58?]
63f 5.226±0.228 7.541±0.325 [1.4?] 7.539±0.189 [1.44?]
64f 0.639±0.007 0.645±0.02 [1.02?] 0.612±0.021 [0.97?]
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63g 1.156±0.005 1.642±0.019 [1.4?] 1.679±0.029 [1.5?]
64g 0.049±0.003 0.063±0.007 [1.3?] 0.070±0.004 [1.4?]
63h 1.007±0.206 2.663±0.034 [2.64?] 1.91±0.007 [1.90?]
64h 0.136±0.019 0.361±0.003 [2.65?] 0.238±0.005 [1.75?]
63i 1.042±0.298 1.856±0.069 [1.78?] 1.153±0.018 [1.11?]
64i 0.35±0.069 0.499±0.007 [1.43?] 0.390±0.015 [1.11?]
63j 8.144±0.244 7.467±0.090 [0.92?] 6.156±0.133 [0.76?]
64j 0.64±0.196 0.621±0.01 [0.97?] 0.719±0.045 [1.1?]
63k 2.213±0.117 0.986±0.037 [0.45?] 1.146±0.004 [0.52?]
64k 11.51±0.29 14.277±0.036 [1.24 ?] 8.404±0.003 [0.73?]
63l 0.118±0.005 0.136±0.004 [1.15?] 0.062±0.001 [0.53?]
64l 0.062±0.0001 0.098±0.01 [1.58?] 0.062±0.002 [1.0?]
Taxol 0.0031±0.0001 0.429±0.042 [330?] 1.274±0.052 [980?]
Vinblastine 0.00073±0.0009 0.078±0.011 [106.2?] 0.496±0.121 [679.5?]
a Cell growth inhibition was measured by the XTT assay51 for leukemic cells and the 
SRB assay52 for solid tumor cells after 72-hr incubation using a microplate 
spectrophotometer as described previously.53 Similar in vitro results were obtained 
by using the Cell Counting Kit-8 for the CCK-8 assays as described by technical 
manual of Dojindo Molecular Technologies, Inc. (Gaithersburg, MD.; Website: 
www.dojindo.com). IC50 values were determined from dose-effect relationship at six 
or seven concentrations of each drug by using the CompuSyn software by Chou and 
Martin54 based on the median-effect principle and plot.55,56 Ranges given for Taxol 
and Vinblastine were mean ± SE (n = 4). 
b CCRF-CEM/Taxol and CCRF-CEM/VBL are subcell lines of CCRF-CEM cells 
that are 330-fold resistant to Taxol, and 680-fold resistant to Vinblastine, 
respectively, when comparing with the IC50 of the parent cell line. 
cNumbers in the brackets are fold of cross-resistant determined by comparison with 
the corresponding IC50 of the parent cell line.  
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The antiproliferative activity of cyclopenta[a]indenes in inhibiting human solid 
tumors such as breast carcinoma MX-1 and colon carcinoma HCT-116 (Table 3) cell 
growth in vitro were also investigated. To explore further, compounds 63a, 63b, 63g, 63l,
64a, 64b, 64g and 64l were selected to study their cell growth inhibitory effect against 
other solid tumor such as lung carcinoma H1299, oral tumor OECM1, prostate tumor 
PC3, and brain glioma U87 (Table 3). The majority of the bis(methylcarbamate) 
compounds were more cytotoxic than the corresponding parent bis(hydroxymethyl) 
derivatives with the exception of compounds 63a, 63c, 63e, and 63k. These agents were 
more effective against CCRF/CEM, MX-1, and OECM1 cell growth among the tumor 
cell lines tested.  
Table 3. The cytotoxicity of 1,2-Bis(methanol) derivatives (63a-l) and 1,2-
Bis(methylcarbamate) derivatives (64a-l) of cyclopenta[a]indenes against human 
solid tumor (Breast carcinoma MX-1, Colon carcinoma HCT-116, Lung carcinoma 
H1299, Oral carcinoma OECM1, Prostate carcinoma PC3, and human glioma U87). 
No.
Cell Growth Inhibition (IC50, ?M)a
MX-1 HCT-116 H1299 OECM1 PC3 U87 
63a 0.364±0.034 0.342±0.0008 15.16±3.22 0.864±1.21 19.68±2.34 19.32±3.56 
64a 0.341±0.01 0.298±0.001 >50 1.45 27.18 >50 
63b 1.077±0.025 0.825±0.0024 14.14±2.69 1.24±2.51 16.56±4.10 18.20±1.33 
64b 0.661±0.009 0.708±0.001 >50 11.8±0.21 >50 >50 
63c 1.336±0.011 1.857±0.104 ND ND ND ND 
64c 5.90±0.017 0.745±0.013 ND ND ND ND 
63d 22.222±0.111 8.681±0.621 ND ND ND ND 
64d 0.737±0.038 0.403±0.007 ND ND ND ND 
63e 6.059±0.112 5.659±0.088 ND ND ND ND 
64e 9.853±0.384 8.918±0.410 ND ND ND ND 
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63f 7.013±0.021 11.223±0.409 ND ND ND ND 
64f 8.240±0.282 0.896±0.018 ND ND ND ND 
63g 10.823±0.005 6.061±0.228 50.3±1.98 9.26±2.85 55.5±3.18 45.49±3.11 
64g 1.928±0.012 2.612±0.133 42.55±2.47 4.63±1.25 38.17±0.93 34.35±2.83 
63h 8.681±0.038 11.641±1.535 ND ND ND ND 
64h 1.336±0.01 0.151±0.004 ND ND ND ND 
63i 11.141±0.046 4.31±0.285 ND ND ND ND 
64i 1.835±0.001 0.659±0.02 ND ND ND ND 
63j 26.318±0.535 43.372±0.321 ND ND ND ND 
64j 5.343±0.334 1.125±0.013 ND ND ND ND 
63k 17.450±0.402 29.06±1.50 ND ND ND ND 
64k 7.238±0.073 1.883±0.077 ND ND ND ND 
63l 1.516±0.001 0.665±0.033 19±3.01 1.54±0.72 23.2±1.12 24.36±1.83 
64l 0.874±0.004 0.442±0.015 20.89±2.45 1.27±1.13 21.97±3.25 38.28±2.98 
Taxol 0.046±0.0007 0.0011±0.0003 ND ND ND ND 
VBT 0.0022±0.0002 0.0011±0.0003 ND ND ND ND 
As shown in Table 2, the newly synthesized cyclopenta[a]indenes have little or no 
cross-resistance to either taxol or vinblastine. This suggests that all newly synthesized 
compounds are neither a good substrate of membrane multidrug resistance transporters 
(i.e., p-glycoprotein) nor mutated tubulin. Thus, the newly synthesized compounds are 
effective against multiple drug resistant tumors. 
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2.4.2 In vivo therapeutic efficacy 
Based on the results of the in vitro cytotoxicity, solubility and toxicity to the host, 
we selected compound 63a,b and 64g,h for further antitumor evaluation in animal model. 
Figure 14A and 14B show the therapeutic efficacy of 63a,b and 64g,h in nude mice 
bearing human breast carcinoma MX-1 xenograft. At the maximal tolerate doses [63b/50 
mg/kg and 64g/5 mg/kg, daily 3 times (QD?3); for 63a/18 mg/kg (Q2D?2) and 64h/15 
mg/kg (Q2D?4), via intravenous (i.v.) injection], these agents induce total tumor 
remission (complete remission, CR) with relatively low toxicity. In human prostate 
adenocarcinoma PC3 xenograft in nude mice (Figure 15A and 15B), compound 63b
produced complete tumor remission at the dose of 50 mg/kg, QD?4, i.v. inj. Although, 
15% of body weight loss was observed during the treatment, it recovered soon after the 
cessation of drug administration. The antitumor efficacy of 63a and 63b in nude mice 
bearing human ovarian adenocarcinoma SK-OV-3 xenograft was also studied (Figure 
16A and 16B). We found that 63a and 63b yielded 53 and 78% tumor suppression, 
respectively, on day 22 at the dose of 20 mg/kg, QD?4, and 50 mg/kg, QD?3),
respectively, via i.v. injection. These studies suggest that the newly synthesized 
cyclopent[a]indenes possess superior therapeutic efficacy against human breast MX-1 
and human prostate adenocarcinoma PC3 over human ovarian adenocarcinoma SK-OV-3 
xenograft.
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Figure 14. Therapeutic effect of 63a (18 mg/kg, Q2D×2, i.v. inj., n=5, p<0.0001 on day 
14-24, no relase on day 40), 63b (50 mg/kg, QD×3, i.v. inj., n=5, p<0.0001 on day 14-24, 
3/5 CR on day 22; 5/5 CR on day 24, no relapse on day 40), 64g (5 mg/kg, QD×3, i.v. 
inj., n=5, p<0.0001, on day 16-24, 4/5 CR on day 20, 5/5 CR on day 22, 2/5 relapse on 
D28, 3/5 no relapse on day 40), and 64h (15 mg/kg, Q2D×4, i.v. inj., n=4, p<0.0001 on 
day 12-24, 3/4 CR on day 16, 4/4 CR on day 18, 1/4 relapse on D28, 3/4 no relapse on 
day 40) in nude mice bearing human mammary carcinoma MX-1 xenograft, control 
(n=5); average tumor size changes (Figure 14A) and average body weight changes 
(Figure 14B).   
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Figure 15.  Therapeutic effect of 63b (50 mg/kg, QD×4, i.v. inj., n=5, p<0.002, day 18-
24) in nude mice bearing human prostate adenocarcinoma PC3 xenograft, average tumor 
size changes (Figure 15B) and average body weight changes (Figure 15B). 
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Figure 16. Therapeutic effects of 63a (20 mg/kg, QD×4, i.v. inj., n=5, p<0.05, day 22-
24), and 63b (50 mg/kg, QD×3, i.v. inj., n=5, p<0.002 day 20-24) in nude mice bearing 
ovarian adenocarcinoma SK-OV-3 xenograft; average tumor size changes (Figure 16A) 
and average body weight changes (Figure 16B). 
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2.4.3 DNA interstrand cross-linking in human non-small lung carcinoma H1299 
cell lines
Early works on the study of DNA interstrand cross-linking by IPP (30) and related 
compounds demonstrated that these agents preferentially cross-link deoxyguanosine 
residues at the duplex nucleotide (a short oligonucleotide 5’-ACGT) at the sequence 5’-
CG residues, a common target site in duplex DNA.57 To realize whether the newly 
synthesized derivatives are able to cross-link to DNA double-strands, bis(hydroxymethyl) 
63l and its bis(methylcarbamate) derivative 64l were selected as the representatives 
compounds for modified single cell gel electrophoresis assay (modified comet assay).57,58
It is based on the property of negatively charged DNA fragments migration when electric 
field is applied to the gel after cell lysis.59 DNA cross-linking agent mitomycin C (MMC) 
was chosen as a positive control. Human non-small lung carcinoma H1299 cells were 
treated with 63l, 64l and MMC for 1 h at various concentrations under aerobic conditions 
and then irradiated with a dose of 20 Gy to induce DNA strand breaks. Afterward, the 
irradiated cells were subjected for modified comet assay. Figure 17 shows the distribution 
of tail moment in H1299 cells. The length and fragment content of the tail is inversely 
proportional to the amount of DNA interstrand cross-linking. The results showed that the 
order of potency for DNA cross-linking induction by these agents is 64l > MMC > 63l.
Since interstrand crosslink formation can be represented as percent decrease in tail 
moment, Figure 18 shows the levels of cross-linked DNA varied with compound 
concentrations. Under the same experimental conditions (100 ?M drug concentration), 
64l, MMC, and 63l cause 97.9, 76.5, and 35.5% DNA interstrand cross-linking, 
respectively. It indicated that 64l bearing a better leaving bis(methylcarbamates) is a more 
potent DNA cross-linking agent than its corresponding bis(hydroxymethyl) 63l. In 
addition, 64l induced more DNA cross-linking than that of MMC under the aerobic 
conditions.
The DNA cross-linking ability of 64g was also investigated in human large-cell 
lung carcinoma H460 cell by modified Comet assay. Alkylating agent thiotepa was used 
as a positive control. Human large-cell lung carcinoma H460 was exposed to 64g for 1 h 
at various concentrations and then irradiated with a dose of 20 Gy to induce DNA strand 
breaks. The DNA fragments were collected and then applied to the gel after cell lysis.  
Figure 19 shows the DNA interstrand cross-linking in human large-cell lung carcinoma 
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H460 cell by 15g and thiotepa (control). The study revealed that compound 15g induced 
more DNA-interstrand cross-linking than that of thiotepa in a dose dependent manner. 
Figure 17. Typical comet images from H1299 cell treated ex vivo with 63l, 64l and
MMC at various concentrations for 1 h. Tail moment was used as a parameter for the 
detection of DNA damage. See the experimental section for details. 
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Figure 18. DNA interstrand cross-links in human non-small cell lung carcinoma H1299 
cells by 63l (IC50 = 19 μM), 64l (IC50 = 20.89 μM), and mitomycin C (control). Cells 
were treated with various concentrations of 63l, 64l and mitomycin C for 1 h. Interstrand 
crosslink formation represented as percent decrease in tail moment. Cross-linking agent, 
mitomycin C, act as a positive control here. Mean for 3 independent experiments; bars, 
SD. 
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Figure 19. DNA interstrand cross-links in human large-cell lung carcinoma H460 cell by 
64g and thiotepa (control). Cells were treated with various concentrations of 64g and 
thiotepa for 1 h. Interstrand crosslink formation represented as percent decrease in tail 
moment. Cross-linking agent, thiotepa, act as a positive control here. Mean for 3 
independent experiments; bars, SD.?
2.4.3 DNA cross-linking study by alkaline agarose gel shift assay
We further studied DNA interstrand cross-linking induced by 63l and 64l by 
alkaline agarose gel shift assay using mephalan for comparison. As depicted in Figure 20, 
the in vitro interaction of compound 63l and 64l with pEGFP-N1 plasmid DNA fragment 
effectively produced interstrand cross-links at the concentration of 10 and 20 ?M,
evidenced by formation of the double stranded band (DS) in a sample of denatured single 
strand (SS) DNA.60 It is also clear to find that 64l induced more DNA cross-linking than 
that of 63l at the same concentration. This result is consistent with the DNA interstrand 
cross-linking study of these compounds by the modified comet assay.  
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Figure 20. Gel shift assay showing the DNA interstrand cross-link formation by 63l and 
64l. pEGFP-N1 plasmid DNA were either unmodified or contained concentration-
dependent DNA interstrand crosslink formation by 63l, 64l and melphalan (positive 
control). pEGFP-N1 plasmid DNA were digested with BamHI to linearize prior to be 
subjected to electrophoresis on a 0.8% alkaline agarose gel. Ethidium bromide staining 
was used to visualize the DNA. Cross-links: double-stranded; ssDNA: single stranded. 
2.4.4 Cell cycle inhibition  
DNA interacting/damaging agents are known to induce cell cycle perturbations 
and arrest the cell cycle progression predominantly at the G2/M boundary.61 We further 
selected the bis(hydroxymethyl) derivative 63l and bis(methylcarbamate) derivative 64l
as the representatives compounds to investigate their influence on cell cycle after 24, 48, 
and 72 h treatment periods (Figure 21). The human non-small lung carcinoma H1299 
cells were treated with these agents, stained with propidium iodide (PI) and analyzed for 
cell cycle distribution. The results clearly showed that at the concentration of 10 ?M, both 
compounds initially induced statistically significant accumulation of cells in S phase and 
reduction of the G0/G1 phase. In control, non-treated samples, the majority of cells are 
arrested in the G0/G1 phase. After 72 h of treatment, both compounds induced additional 
drastic G2/M phase arrest of the cell cycle that persisted over all three treatment periods 
and was accompanied by the accumulation of cells in the sub-G1 phase. The number of 
cells in S phase were reduced from 50.45% to 24.63% for 63l and 51.11% to 9.19 for 64l
(Figure 21) after 72 h treatment. 
63l 64l
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Figure 21. DNA histograms obtained by flow cytometry, and the percentages of cells in 
sub G1 (apoptotic cells), G0/G1, S, and G2/M cell cycle phase, after the treatment of the 
human non-small lung carcinoma H1299 cells with 63l and 64l (both at 10 ?M) for 24, 
48, and 72 h 
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2.5 Conclusion  
In the light of the discussions made from the results obtained for the newly 
synthesized DNA bifunctional alkylating agents, bis(hydroxymethyl)-8H-3a-
azacyclopenta[a]indene-1-yl derivatives (13a-l) and their bis(carbamate) derivatives 
(64a-l) , it can be concluded that all of them have displayed excellent and reproducible 
anti-tumour activity in against human leukemia and various solid tumor cell growths in 
vitro. These agents can be considered as “benzologues” of pyrrolizines and may have a 
similar mechanism of action to bis-carbamoyloxymethyl derivatives of pyrroles and 
pyrrolizines or MMC. The present studies also demonstrated that these derivatives 
exhibited significant ‘curative’ antitumor efficacy in vivo with a relatively low toxicity. 
Detailed SAR studies demonstrated that the size and electron properties of the substituent 
at C3 affected the cytotoxicity of these agents. Compounds 63a,b and 64g,h were found 
to have potent therapeutic efficacy against human breast MX-1 xenograft in animal 
model. Complete tumor remission was achieved in nude mice bearing human breast 
carcinoma MX-1 xenograft by these derivatives. It is also interesting to note that 
compound 63b was able to significantly suppress human prostate adenocarcinoma PC3 
xenograft in nude mice. Studies on the DNA interstrand cross-linking suggested that the 
newly synthesized derivatives are potent bifunctional DNA cross-linking agents. It 
general, compounds bearing a better leaving bis(methylcarbamates) is a more potent 
DNA cross-linking agent than its corresponding bis(hydroxymethyl).  Furthermore, both 
derivatives induced substantial G2/M phase arrested of the cell cycle. All the above data 
support the excellent chemotherapeutic efficacy and potential candidature of newly 
synthesized derivatives for further drug development. 
2.6 Experimental Section 
General methods and materials: Melting points were determined on a Fargo melting 
point apparatus and are uncorrected. Column chromatography was carried out over silica 
gel G60 (70–230 mesh). Thin-layer chromatography was performed on silica gel G60 F254
plates with short wavelength UV light for visualization. Elemental analyses were done on 
a Heraeus CHN-O Rapid instrument. 1H NMR spectra were recorded on 400 MHz 
spectrometer with Me4Si as an internal standard. The chemical shifts were reported in 
ppm (?) relative to TMS. 
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5-Methoxy-1-(4-methoxybenzoyl)-1H-indole-2-carboxylic acid (58). To a solution of 
commercially available 5-methoxyindole-2-carboxilic acid 59 (6.69 g, 35 mmol) and 
triethylamine (10 mL, 71.74 mmol) in anhydrous CH2Cl2 (70 mL) containing catalytic 
amount of DMAP was added dropwise a solution of 4-methoxybenzoyl chloride (6.20 g, 
36.34 mmol) in CH2Cl2 (15 mL) at 0 ?C. The reaction mixture was stirred at this 
temperature for 15 min and then at room temperature for 4 h. The reaction mixture was 
washed successively with 5% aqueous KHSO4 solution (2×20 mL), brine (25 mL), dried 
over Na2SO4, and evaporated under reduced pressure to dryness. The solid residue was 
recrystallized from methanol to yield 60 as a white solid (7.4 g, 65%); mp 185–187 oC; 
1H NMR (400 MHz, DMSO-d6) ?=13.2 (brs, 1H), 7.59 (d, J=8.9 Hz, 2H), 7.38 (d, J=9.0
Hz, 1H), 7.33 (s, 1H), 7.28 (d, J=2.5 Hz, 1H), 7.07 (d, J=8.9 Hz, 2H), 7.02 (dd, J=9.0, 2.5 
Hz, 1H), 3.85 (s, 3H), 3.80 ppm (s, 3H); Anal. calcd. for C18H15NO5?0.1H2O: C 65.73, H 
4.65, N 4.25, found: C 65.77, H 4.61, N 4.24. 
1-Propionyl-2,3-dihydro-1H-indole-2-carboxylic acid (61b). To a solution of indoline-
2-carboxilic acid 58 (8.16 g, 50 mmol) and triethylamine (10 mL, 71.74 mmol) in 
anhydrous CH2Cl2 (60 mL) containing catalytic amount of DMAP was added dropwise a 
solution of propionyl chloride (5.55 g, 60 mmol) in CH2Cl2 (20 mL) at 0 ?C. The reaction 
mixture was stirred at this temperature for 15 min and then at room temperature for 2.5 h. 
The reaction mixture was washed successively with 5% aqueous KHSO4 solution (2×20 
mL), brine (25 mL), dried over Na2SO4, and evaporated under reduced pressure to 
dryness. The residue was crystallized from methanol to yield 61b (9.19 g, 83%); mp 173?
175 oC; ?=13.26 (brs, 1H), 8.09?8.07 (m, 1H), 7.23?7.15 (m, 2H), 7.01?6.98 (m, 1H), 
5.15 (d, J=16.0 Hz, 1H), 3.57 (dd, J=16.0, 11.0 Hz, 1H), 3.17 (d, J=16.0 Hz, 1H), 2.51 (q, 
J=7.6 Hz, 2H), 1.05 ppm (t, J=7.6 Hz, 3H); Anal. calcd. for C12H13NO3: C 65.74, H 5.98, 
N 6.39, found: C 65.73, H 6.07, N 6.34. 
By following the same procedure as describe for 61b, the following compounds 61c-k
were synthesized. 
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1-Benzoyl-2,3-dihydro-1H-indole-2-carboxylic acid (61c). Compound 61c was 
synthesized from indoline-2-carboxilic acid 58 (6.52 g, 40 mmol), triethylamine (11 mL, 
78 mmol), benzoyl chloride (5.62 g, 40 mmol); yield (10.66 g, 81%); mp 209–210 oC (lit. 
mp 191–193 oC)62; 1H NMR (400 MHz, DMSO-d6) ?=13.01 (brs, 1H), 8.17?8.14 (m, 
1H), 7.49 (m, 5H), 7.26?7.25 (m, 2H), 7.06 (m, 1H), 4.97 (s, 1H), 3.63–3.61 (m, 1H), 
3.09 ppm (d, J=16.3 Hz, 1H); MS: m/z 268.0 (M+H)+. Anal. calcd. for C12H13NO3: C 
65.74, H 5.98, N 6.39, found: C 65.73, H 6.07, N 6.34. 
1-(4-Fluorobenzoyl)-2,3-dihydro-1H-indole-2-carboxylic acid (61d). Compound 61d
was synthesized from indoline-2-carboxilic acid 58 (6.52 g, 40 mmol), triethylamine (11 
mL, 78 mmol) and 4-flourobenzoyl chloride (6.34 g, 40 mmol); yield (9.28 g, 81%); mp 
215–216 oC; 1H NMR (400 MHz, DMSO-d6) ?=12.98 (brs, 1H), 8.16?7.03 (m, 8H), 5.01 
(d, J=9.3 Hz, 1H) 3.63 (dd, J=16.3, 11.1 Hz, 1H), 3.10 ppm (d, J=16.5 Hz, 1H); Anal. 
calcd. for C16H12FNO3: C 67.36, H 4.24, N 4.91, found: C 67.22, H 4.58, N 4.72. 
1-(4-Chlorobenzoyl)-2,3-dihydro-1H-indole-2-carboxylic acid (61e). Compound 61e
was synthesized from indoline-2-carboxilic acid (58) (6.52 g, 40 mmol), triethylamine (11 
mL, 78 mmol) and 4-chlorobenzoyl chloride (5 g, 40 mmol); yield (9.35 g, 77%); mp 
184–187 oC; 1H NMR (MHz, DMSO-d6) ?=12.91 (brs, 1H), 7.81–7.53 (m, 4H), 7.27–
7.25 (m, 2H), 7.18–7.03 (m, 2H), 5.02 (d, J=9.8 Hz, 1H), 3.63 (dd, J=16.6, 11.2 Hz, 1H), 
3.13 ppm (d, J=16.6 Hz, 1H); Anal. calcd. for C16H12ClNO3: C 63.69, H 4.01, N 4.64, 
found: C 62.15, H 3.96, N 4.51. 
1-(3,4-Difluorobenzoyl)-2,3-dihydro-1H-indole-2-carboxylic acid (61f). Compound 
61f was synthesized from indoline-2-carboxylic acid (58) (6.52 g, 40 mmol), 
triethylamine (11 mL, 78 mmol) and 3,4-diflourobenzoyl chloride (7.06 g, 40 mmol); 
yield (8.53 g, 70%); mp 248?250 oC; 1H NMR (400 MHz, DMSO-d6) ?=12.99 (brs, 1H), 
8.15 (m, 1H), 7.64 (t, J=8.7 Hz, 1H), 7.60–7.55 (m, 1H), 7.41 (s, 1H), 7.28–7.06 (m, 3H), 
5.02 (dd, J=10.9, 2.9 Hz, 1H), 3.63 (dd, J=16.4, 11.2 Hz, 1H), 3.12 ppm (d, J=16.2 Hz, 
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1H); Anal. calcd. for C16H11F2NO3: C 63.37, H 3.66, N 4.62, found: C 63.12, H 3.97, N 
4.83.
1-(4-Methoxybenzoyl)-2,3-dihydro-1H-indole-2-carboxylic acid (61g). Compound 61g
was synthesized from indoline-2-carboxylic acid (58) (6.52 g, 40 mmol), triethylamine 
(11 mL, 78 mmol) and 4-methoxybenzoyl chloride (6.82 g, 40 mmol); yield (10.88 g, 
92%); mp 196–198 oC; 1H NMR (400 MHz, DMSO-d6) ?=12.91 (brs, 1H), 7.50–7.46 (m, 
2H), 7.24 (d, J=7.3 Hz, 1H), 7.09–6.97 (m, 5H), 5.01 (dd, J=11.0, 3.3 Hz, 1H), 3.82 (s, 
3H), 3.61 (dd, J=16.6, 11.0 Hz, 1H), 3.08 ppm (dd, J=16.6, 3.2 Hz, 1H); Anal. cacld. for 
C17H15NO4: C 68.68, H 5.09, N 4.71, found: C 68.10, H 5.06, N 4.62. 
1-(2-Methoxybenzoyl)-2,3-dihydro-1H-indole-2-carboxylic acid (61h). Compound 61h
was synthesized from indoline-2-carboxylic acid (58) (8 g, 49 mmol) and triethylamine 
(14 mL, 100 mmol) and 2-methoxybenzoyl chloride (6.82 g, 49 mmol); yield (13.17 g, 
91%); mp 189–192 oC; 1H NMR (400 MHz, DMSO-d6) ?=12.91 (brs, 1H), 7.49–7.47 (m, 
2H), 7.24–7.23 (m, 2H), 7.08 (m, 1H), 7.02–6.98 (m, 3H), 5.02 (dd, J=7.3, 2.2 Hz, 1H), 
3.82 (s, 3H), 3.61 (dd, J=10.9, 7.5 Hz, 1H), 3.08 ppm (dd, J=11.0, 1.6 Hz, 1H); Anal. 
caldc. for C17H15NO4: C 68.68, H 5.09, N 4.71, found: C 68.25, H 5.04, N 4.61. 
1-(3,4-Dimethoxybenzoyl)-2,3-dihydro-1H-indole-2-carboxylic acid (61i). Compound 
61i was synthesized from indoline-2-carboxylic acid (58) (5.03 g, 30.82 mmol), 
triethylamine (8.6 mL, 61.64 mmol) and 3,4-dimethoxybenzoyl chloride (6.18 g, 30.82 
mmol); yield (8.20 g, 81%); mp 113–115 oC; 1H NMR (400 MHz, DMSO-d6) ?=12.92
(brs, 1H), 7.26–7.24 (m, 1H), 7.10–6.98 (m, 6H), 5.00 (dd, J=10.9, 3.1 Hz, 1H), 3.82 (s, 
3H), 3.75 (s, 3H), 3.62 (dd, J=16.6, 11.1 Hz, 1H), 3.07 ppm (dd, J=16.6, 2.9 Hz, 1H); 
Anal. calcd. for C18H17NO5: C 66.05, H 5.23, N 4.28, found: C 65.47, H 5.74, N 4.28. 
1-(2,6-Dimethoxybenzoyl)-2,3-dihydro-1H-indole-2-carboxylic acid (61j). Compound 
61j was synthesized from indoline-2-carboxylic acid (58) (7.88 g, 48.28 mmol), 
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triethylamine (8.6 mL, 61.64 mmol) and 2,6-dimethoxybenzoyl chloride (9.69 g, 48.28 
mmol); yield (12.77 g, 81%); mp 84–85 oC; 1H NMR (400 MHz, DMSO-d6) ?=12.88
(brs, 1H), 7.25–7.23 (m, 1H), 7.10–6.97 (m, 6H), 5.00 (dd, J=10.9, 3.2 Hz, 1H), 3.82 (s, 
3H), 3.75 (s, 3H), 3.61 (dd, J=16.6, 11.1 Hz, 1H), 3.07 ppm (dd, J=16.6, 2.9 Hz, 1H); 
Anal. calcd. for C18H17NO5·H2O: C 62.60, H 5.54, N 4.05, found: C 62.54, H 5.25, N 
3.97.
1-(3,4,5-Trimethoxybenzoyl)-2,3-dihydro-1H-indole-2-carboxylic acid (61k). 
Compound 61k was synthesized from indoline-2-carboxylic acid (58) (6.01 g, 36.81 
mmol), triethylamine (10.4 mL, 74.61 mmol) and 3,4,5-trimethoxybenzoyl chloride (8.49 
g, 36.81 mmol); yield (9.92 g, 75%); mp 224–227 oC; 1H NMR (400 MHz, DMSO-d6)
?=13.01 (brs, 1H), 8.31 (s, 1H), 7.25 (d, J=7.49 Hz, 1H), 7.15 (m, 1H), 7.03–7.02 (m, 
1H), 6.77 (s, 2H), 4.97–4.95 (m, 1H), 3.77 (s, 6H), 3.71 (s, 3H), 3.65?3.59 (m, 1H), 3.10?
3.05 ppm (m, 1H); Anal. calcd. for C19H19NO6: C 63.86, H 5.36, N 3.92, found: C 62.27, 
H 5.29, N 3.76. 
5-Methoxy-1-(4-methoxybenzoyl)-2,3-dihydro-1H-indole-2-carboxylic acid (61l). To
a solution of 60 (7.02 g, 21.57 mmol) in ethanol (200 mL) was added platinum oxide (0.7 
g). The mixture was hydrogenated for 6 h at 32 psi. The reaction mixture was filtered 
through a pad of Celite. The filter cake was washed with ethanol. The combined filtrate 
and washings was evaporated in vacuo to dryness. The solid residue was recrystallized 
from ethanol to yield 61l (6.35g, 90%); mp 151–152 oC; 1H NMR (400 MHz, DMSO-d6)
?=12.92 (brs, 1H), 7.45 (d, J=8.6 Hz, 2H), 7.00 (d, J=8.6 Hz, 2H), 6.86 (m, 2H), 6.67 (s, 
1H), 5.01–4.97 (m, 1H), 3.81 (s, 3H), 3.70 (s, 3H), 3.63–3.56 (m, 1H), 3.05 ppm (m, 1H); 
Anal. Calcd. for C18H17NO5: C 66.05, H 5.23, N 4.28, found: C 65.69, H 5.47, N 4.14. 
3-Methyl-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid dimethyl ester (62a).
A mixture of indoline-2-carboxylic acid 58 (10.60 g, 65 mmol) and dimethyl 
acetylenedicarboxylate (9.24 mL, 80 mmol) in acetic anhydride (110 mL) was stirred in a 
flask equipped with a reflux condenser and a gas bubbler to monitor carbon dioxide 
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evolution during the reaction. The mixture was heated to 120 ?C where carbon dioxide 
evolution was most intense. The temperature was maintained until gas evolution had 
ceased. The dark solution was concentrated in vacuo and the solid residue was 
crystallized from methanol to yield 62a (14.40 g, 78%); mp 162?164 oC; 1H NMR (400 
MHz, DMSO-d6) ?=7.53?7.46 (m, 2H), 7.37?7.33 (m, 1H), 7.27?7.20 (m, 1H), 4.01 (s, 
2H), 3.89 (s, 3H), 3.85 (s, 3H), 2.74 ppm (s, 3H); Anal. calcd. for C16H15NO4: C 67.36, H 
5.30, N 4.91, found: C 67.30, H 5.31, N 4.85. 
3-Ethyl-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid dimethyl ester (62b). A
mixture of 61b (4.49 g, 20.5 mmol) and dimethyl acetylenedicarboxylate (5.68 mL, 40 
mmol) in acetic anhydride (40 mL) was stirred in a flask equipped with a reflux 
condenser and a gas bubbler to monitor carbon dioxide evolution during the reaction. The 
mixture was heated to 120 ?C where carbon dioxide evolution was most intense. The 
temperature was maintained until gas evolution had ceased. The dark solution was 
concentrated in vacuo to dryness and the solid residue was recrystallized from methanol 
to yield 62b (4.61 g, 75%); mp 86?88 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.64?7.59
(m, 2H), 7.47?7.43 (m, 1H), 7.31?7.27 (m, 1H), 4.07 (s, 2H), 3.76 (s, 3H), 3.75 (s, 3H), 
3.08 (q, J=7.4 Hz, 2H), 1.22 ppm (t, J=7.4 Hz, 3H); Anal. calcd. for C17H17NO4: C 68.21, 
H 5.72, N 4.68, found: C 68.22, H 5.74, N 4.65.
By following the same procedure as describe for 62b, the following compounds 62c-l
were synthesized. 
3-Phenyl-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid dimethyl ester (62c).  
Compound 62c was synthesized from 61c (7.48 g, 28 mmol) and dimethyl 
acetylenedicarboxylate (4 mL, 32 mmol) in acetic anhydride (40 mL); yield (7.5 g, 77%); 
mp 149–151 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.67?7.51 (m, 6H), 7.23?7.18 (m, 
2H), 6.67?6.60 (m, 1H), 4.15 (s, 2H), 3.79 (s, 3H), 3.62 ppm (s, 3H); Anal. calcd. for 
C17H17NO4: C 68.21, H 5.72, N 4.68, found: C 68.22, H 5.74, N 4.65. 
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3-(4-Flourophenyl)-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid dimethyl 
ester (62d). Compound 62d was synthesized from 61d (7.13 g, 25 mmol) and dimethyl 
acetylenedicarboxylate (4 mL, 32 mmol) in acetic anhydride (40 mL); yield (6.63 g, 
72%); mp 152?155 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.54?7.51 (m, 2H), 7.47 (d, 
J=7.4 Hz, 1H), 7.21?7.15 (m, 3H), 6.65 (d, J=7.93 Hz, 1H), 7.12 (t, J=7.4 Hz, 1H), 4.12 
(s, 2H), 3.89 (s, 3H), 3.72 ppm (s, 3H); Anal. calcd. for C16H12FNO3: C 67.36, H 4.24, N 
4.91, found: C 67.22, H 4.58, N 4.72. 
3-(4-Chlorophenyl)-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid dimethyl 
ester (62e). Compound 62e was synthesized from 61e (7.54 g, 25 mmol) and dimethyl 
acetylenedicarboxylate (4 mL, 32 mmol) in acetic anhydride (40 mL); yield (7.32 g, 
79%); mp 166–168 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.64?7.54 (m, 5H), 7.25?7.21
(m, 2H), 6.68–6.64 (m, 1H), 4.16 (s, 2H), 3.79 (s, 3H), 3.62 ppm (s, 3H); Anal. calcd. for 
C21H16ClNO4: C 66.06, H 4.22, N 3.67, found: C 65.92, H 4.22, N 3.64. 
3-(3,4-Diflouro-phenyl)-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid 
dimethyl ester (62f). Compound 62f was synthesized from 61f (8.14 g, 26.82 mmol) and 
dimethyl acetylenedicarboxylate (4.7 mL, 37.3 mmol) in acetic anhydride (40 mL); yield 
(8.37 g, 81%); mp 156–158 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.70–7.67 (m, 1H), 
7.64–7.59 (m, 2H), 7.41–7.40 (m, 1H), 7.25–7.22 (m, 2H), 6.68–6.65 (m, 1H), 4.16 (s, 
2H), 3.80 (s, 3H), 3.62 ppm (s, 3H); Anal. calcd. for C21H15F2NO4: C 65.80, H 3.94, N, 
3.65, found: C 65.83, H 4.03, N 3.62. 
3-(4-Methoxyphenyl)-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid dimethyl 
ester (62g). Compound 62g was synthesized from 61g (7.42 g, 25 mmol) and dimethyl 
acetylenedicarboxylate (4.7 mL, 37.3 mmol) in acetic anhydride (40 mL); yield (8.42 g, 
89%); mp 157–159 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.59–7.58 (m, 1H), 7.44 (d, 
J=8.3 Hz, 2H), 7.21–7.20 (m, 2H), 7.09 (d, J=8.3 Hz, 2H), 6.67–6.65 (m, 1H), 4.15 (s, 
2H), 3.85 (s, 3H), 3.78 (s, 3H), 3.60 ppm (s, 3H); Anal. calcd. for C22H19NO5: C 70.02, H 
5.07, N 3.71, found: C 69.80, H 6.08, N 3.62. 
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3-(2-Methoxy-phenyl)-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid 
dimethyl ester (62h). compound 62h was synthesized from 61h (9.07 g, 30.5 mmol) and 
dimethyl acetylenedicarboxylate (5 mL, 40.81 mmol) in acetic anhydride (40 mL); yield 
(8.90 g, 77%); mp 162–164 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.58–7.53 (m, 2H), 
7.36–7.34 (m, 1H), 7.21–7.19 (m, 3H), 7.11–7.07 (m, 1H), 6.53–6.51 (m, 1H), 4.23–4.09 
(m, 2H), 3.79 (s, 3H), 3.65 (s, 3H), 3.58 ppm (s, 3H); Anal. calcd. for C22H19NO5: C 
70.02, H 5.07, N 3.71, found: C 70.03, H 5.06, N 3.69. 
3-(3,4-Dimethoxyphenyl)-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid 
dimethyl ester(62i). Compound 62i was synthesized from 61i (9.01 g, 27.53 mmol) and 
dimethyl acetylenedicarboxylate (4 mL, 32 mmol) in acetic anhydride (40 mL); yield (8.9 
g, 79%); mp 186–187 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.60–7.58 (m, 1H), 7.24–
7.22 (m, 2H), 7.12 (s, 1H), 7.10 (s, 1H), 7.08–7.05 (m, 1H), 6.77–6.75 (m, 1H), 4.16 (s, 
2H), 3.85 (s, 3H), 3.79 (s, 3H), 3.75 (s, 3H), 3.63 ppm (s, 3H); Anal. calcd. for 
C23H21NO6: C 67.80, H 5.20, N 3.44, found: C 67.57, H 5.22, N 3.39. 
3-(2,6-Dimethoxyphenyl)-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid 
dimethyl ester (62j). Compound 62j was synthesized from 61j (12.11 g, 37 mmol) and 
dimethyl acetylenedicarboxylate (5.5 mL, 44.90 mmol) in acetic anhydride (55 mL); yield 
(10.53 g, 70%); mp 84–86 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.58–7.55 (m, 1H), 
7.49 (t, J=8.3 Hz, 1H), 7.22–7.18 (m, 2H), 6.82 (s, 1H), 6.80 (s, 1H), 6.50–6.55 (m, 1H), 
4.15 (s, 2H), 3.79 (s, 3H), 3.63 (s, 6H), 3.54 ppm (s, 3H); Anal. calcd. for C23H21NO6: C 
67.80, H 5.20, N 3.44, found: C 67.12, H 5.20, N 3.41. 
3-(3,4,5-Trimethoxyphenyl)-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic acid 
dimethyl ester (62k). Compound 62k was synthesized from 61k (9 g, 25.18 mmol) and 
dimethyl acetylenedicarboxylate (4.2 mL, 34.28 mmol) in acetic anhydride (45 mL); yield 
(9.62 g, 87%): mp 205–207 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.59 (d, J=6.9 Hz, 
1H), 7.29–7.21 (m, 2H), 6.87 (d, J=7.6 Hz, 1H), 6.80 (s, 2H), 4.16 (s, 2H), 3.99 (s, 3H), 
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3.77 (s, 3H), 3.76 (s, 6H), 3.65 ppm (s, 3H); Anal. calcd. for C24H23NO7: C 65.90, H 5.30, 
N 3.20, found: C 65.81, H 5.35, N 3.12. 
6-Methoxy-3-(4-methoxyphenyl)-8H-3a-aza-cyclopenta[a]indene-1,2-dicarboxylic
acid dimethyl ester (62l). Compound 62l was synthesized from 61l (4.24 g, 12.9 mmol) 
and dimethyl acetylenedicarboxylate (2.4 mL, 19.5 mmol) in acetic anhydride (24 mL); 
yield (3.75 g, 71%); mp 240–242 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.42 (d, J=6.9
Hz, 2H), 7.19 (d, J=2.4 Hz, 1H), 7.08 (d, J=8.7 Hz, 2H), 6.77 (dd, J=8.8, 2.6 Hz,  1H), 
6.55 (d, J=8.8 Hz, 1H), 4.09 (s, 2H), 3.85 (s, 3H), 3.77 (s, 3H), 3.73 (s, 3H), 3.60 ppm (s, 
3H); Anal. calcd. for C23H21NO5: C 67.80, H 5.20, N 3.44, found: C 67.83, H 5.19, N 
3.39.
(3-Methyl-2-hydroxymethyl-8H-3a-aza–cyclopenta[a]inden-1-yl)methanol (63a). A 
solution of 62a (3.14 g, 11 mmol) in anhydrous dichloromethane (30 mL) was added 
dropwise to a stirred suspension of LiAlH4 (1.04 g, 27.5 mmol) in anhydrous ether (45 
mL) at 0 ?C. The mixture was stirred for 15 min after the addition was complete. The 
excess LiAlH4 was carefully decomposed by the slow, sequential addition of water (1.3 
mL), 15 % NaOH aqueous solution (1.3 mL), and water (3.6 mL). The precipitated solid 
inorganic salt was removed by filtration and washed with dichloromethane. The 
combined filtrate and washings was concentrated in vacuo to dryness.  The residue was 
triturated with ether, the solid product was collected by filtration, and dried to give 63a
(1.95 g, 77%); mp 123?125 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.48?7.46 (m, 2H), 
7.33–7.29 (m, 1H), 7.10–7.07 (m, 1H), 4.61(t, J=5.2 Hz, 1H), 4.47(t, J=5.2 Hz, 1H), 4.44 
(d, J=5.2 Hz, 2H), 4.35 (d, J=5.2 Hz, 2H), 3.80 (s, 2H), 2.53 ppm (s, 3H); Anal. calcd. for 
C14H15NO2: C 73.34, H 6.59, N 6.11, found: C 73.08, H 6.59, N 6.04. 
By following the same procedure as describe for 13a, the following compounds 13b-l
were synthesized. 
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(3-Ethyl-2-hydroxymethyl-8H-3a-aza–cyclopenta[a]inden-1-yl)methanol (63b). 
Compound 63b was synthesized from 62b (2.5 g, 8.35 mmol) in anhydrous 
dichloromethane (30 mL)  and LiAlH4 (0.793 g, 20.87 mmol) in anhydrous ether (30 
mL); yield (1.31 g, 64%); mp 131?133 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.46?7.45
(m, 1H), 7.39?7.37 (m, 1H), 7.34?7.30 (m, 1H), 7.09?7.06 (m, 1H), 4.63 ( t, J=5.2 Hz, 
1H), 4.47 (t, J=5.2 Hz, 1H), 4.45 (d, J=5.2 Hz, 2H), 4.36 (d, J=5.2 Hz, 2H), 3.81 (s, 2H), 
2.89 (q, J=7.3 Hz, 2H), 1.18 ppm (t, J=7.3 Hz, 3H); Anal. calcd. for C15H17NO2: C 74.05, 
H 7.04, N 5.76, found: C 73.22, H 6.94, N 5.71. 
(2-Hydroxymethyl-3-phenyl-8H-3a-aza–cyclopenta[a]inden-1-yl)methanol (63c). 
Compound 63c was synthesized from 62c (2.08 g, 6 mmol) in anhydrous 
dichloromethane (35 mL) and LiAlH4 (0.568 g, 15 mmol) in anhydrous ether (50 mL); 
yield (1.24 g, 71%); mp 169–171 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.55?7.44 (m, 
6H), 7.12–7.09 (m, 1H), 7.05–7.03 (m, 1H), 6.74–6.73 (m, 1H), 4.80 (t, J=4.8 Hz, 1H), 
4.68 (t, J=4.8 Hz, 1H), 4.55 (d, J=4.8 Hz, 2H), 4.27 (d, J=4.8 Hz, 2H), 3.93 ppm (s, 2H); 
Anal. calcd. for C19H17NO2: C 78.33, H 5.88, N 4.81, found: C 78.50, H 5.98, N 4.72. 
(3-(4-Flourophenyl)-2-hydroxymethyl-8H-3a-aza–cyclopenta[a]inden-1-yl)methanol 
(63d). Compound 63d was synthesized from 62d (2.78 g, 7.6 mmol) in anhydrous 
dichloromethane (26 mL) and LiAlH4 (0.72 g, 19 mmol) in anhydrous ether (40 mL); 
yield (1.69 g, 72%); mp 164?166 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.56–7.54 (m, 
1H), 7.46 (d, J=7.31 Hz, 1H), 7.38–7.34 (m, 2H), 7.12 (t, J=7.31 Hz, 1H), 7.04 (t, J=7.31
Hz, 1H), 6.71 (d, J=8.1 Hz, 1H), 4.79 (t, J=3.9 Hz, 1H), 4.68 (t, J=3.9 Hz, 1H), 4.57 (d, 
J=4.5 Hz, 2H), 4.27 (d, J=4.5 Hz, 2H), 3.92 ppm (s, 2H); Anal. calcd. for C19H16FNO2: C 
73.77, H 5.21, N 4.53, found: C 73.30, H 5.48, N 4.32. 
(3-(4-Chlorophenyl)-2-hydroxymethyl-8H-3a-aza-cyclopenta[a]inden-1-yl)-methanol 
(63e). Compound 63e was synthesized from 62e (1.91 g, 5 mmol) in anhydrous 
dichloromethane (20 mL) and LiAlH4 (0.47 g, 12.5 mmol) in anhydrous ether (35 mL); 
yield (1.16 g, 71%): mp 213–215 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.62–7.45 (m, 
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5H), 7.16–7.13 (m, 1H), 7.08–7.04 (m, 1H), 6.78 (d, J=7.8 Hz, 1H), 4.80 (t, J=5.3 Hz, 
1H), 4.73 (t, J=5.3 Hz, 1H), 4.55 (d, J=5.3 Hz, 2H), 4.26 (d, J=5.3 Hz, 2H), 3.93 ppm (s, 
2H); Anal. calcd for C19H16ClNO2: C 70.05, H 4.95, N 4.30, found: C 69.58, H 5.05, N 
4.20.
[3-(3,4-Diflouro-phenyl)-2-Hydroxymethyl-8H-3a-aza–cyclopenta[a]inden-1-yl)
methanol (63f). Compound 63f was synthesized from 62f (3.83 g, 10 mmol) in 
anhydrous dichloromethane (30 mL) and LiAlH4 (0.95 g, 25 mmol) in anhydrous ether 
(40 mL); yield 2.25 g (68%): mp 146–147 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.62–
7.57 (m, 2H), 7.49 (d, J=4.89 Hz, 1H), 7.36–7.34 (m, 1H), 7.16 (t, J=5.23 Hz, 1H), 7.07 
(t, J=4.92 Hz, 1H), 6.78 (d, J=5.27 Hz, 1H), 4.77 (t, J=3.5 Hz, 1H), 4.73 (t, J=3.5 Hz, 
1H), 4.56 (d, J=3.5 Hz, 2H), 4.26 (d, J=3.5 Hz, 2H), 3.93 ppm (s, 2H); Anal. calcd. for 
C19H15F2NO2: C 69.72, H 4.62, N 4.28, found: C 69.39, H 4.68, N 4.13. 
[3-(4-Methoxyphenyl)-2-Hydroxymethyl-8H-3a-aza–cyclopenta[a]inden-1-yl)-
methanol (63g). Compound 63g was synthesized from 62g (2 g, 8.35 mmol) in 
anhydrous dichloromethane (30 mL) and LiAlH4 (0.76 g, 20 mmol) in anhydrous ether 
(30 mL); yield (1.33 g, 78%): mp 143–144 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.46
(d, J=7.5 Hz, 1H), 7.49–7.42 (m, 2H), 7.11 (t, J=7.5 Hz, 1H), 7.08 (d, J=8.6 Hz, 2H), 
7.04 (t, J=7.4 Hz, 1H), 6.72 (d, J=7.9 Hz, 1H), 4.74 (t, J=5.2 Hz, 1H), 4.60 (t, J=5.2 Hz, 
1H), 4.55 (d, J=5.2 Hz, 2H), 4.25 (d, J=5.2 Hz, 2H), 3.90 (s, 2H), 3.84 ppm (s, 3H); Anal. 
calcd. for C20H19NO3: C 74.75, H 5.96, N 4.36, found: C 74.53, H 6.05, N 4.18. 
[3-(2-methoxyphenyl)-2-Hydroxymethyl-8H-3a-aza–cyclopenta[a]inden-1-
yl)methanol (63h). Compound 63h was synthesized from 62h (2.54 g, 6.73 mmol) in 
anhydrous dichloromethane (25 mL) and LiAlH4 (0.8 g, 21 mmol) in anhydrous ether (40 
mL); yield 1.65 g (76%): mp 132–134 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.50–7.42
(m, 2H), 7.34 (dd, J=7.4, 1.68 Hz, 1H), 7.17–7.15 (d, J=8.1 Hz, 1H), 7.11–7.05 (m, 2H), 
6.99 (t, J=7.4 Hz, 1H),  6.47 (d, J=7.81 Hz, 1H), 4.77 (t, J=5.3 Hz, 1H), 4.57–4.55 (m, 
1H), 4.54 (t, J=5.2 Hz, 1H), 4.33 (d, J=5.2 Hz, 2H), 4.10 (d, J=5.2 Hz, 2H), 3.96–3.81 
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(m, 1H), 3.63 ppm (s, 3H); Anal. calcd. for C20H19NO3: C 74.75, H 5.96, N 4.36. found: 
C 74.45, H 6.01, N 4.34. 
[3-(3,4-Dimethoxyphenyl)-2-Hydroxymethyl-8H-3a-aza-cyclopenta[a]inden-1-
yl)methanol (63i). Compound 63i was synthesized from 62i (3.26 g, 8 mmol) in 
anhydrous dichloromethane (20 mL) and LiAlH4 (1 g, 26.35 mmol) in anhydrous ether 
(40 mL); yield (2.17 g, 77%); mp 160–162 oC; H NMR (400 MHz, DMSO-d6) ?=7.28 (d, 
J=7.2 Hz, 1H), 7.15–7.01 (m, 5H), 6.80 (d, J=8.0 Hz, 1H), 4.73 (t, J=5.2 Hz, 1H), 4.61 (t, 
J=5.2 Hz, 1H), 4.55 (d, J=5.2 Hz, 2H), 4.26 (d, J=5.2 Hz, 2H), 3.91 (s, 2H), 3.84 (s, 3H), 
3.75 ppm (s, 3H); Anal. calcd. for C21H21NO4: C 71.78, H 6.02, N 3.99, found: C 70.65, 
H 6.02, N 3.82. 
[3-(2,6-dimethoxyphenyl)-2-Hydroxymethyl-8H-3a-aza–cyclopenta[a]inden-1-yl]
methanol (63j).  Compound 63j was synthesized from 62j (2.5 g, 6.13 mmol) in 
anhydrous dichloromethane (30 mL) and LiAlH4 (0.83 g, 21.87 mmol) in anhydrous ether 
(50 mL); yield (1.72 g, 80%); mp 146–147 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.46–
7.40 (m, 2H), 7.05 (t, J=7.8 Hz, 1H), 6.97 (t, J=7.7 Hz, 1H), 6.80 (s, 1H), 6.78 (s, 1H), 
6.39–6.37 (m, 1H), 4.81 (t, J=5.3 Hz, 1H), 4.55 (d, J=5.3 Hz, 2H), 4.28 (t, J=4.8 Hz, 1H), 
4.15 (d, J=5.0 Hz, 2H), 3.87 (s, 2H), 3.62 ppm (s, 6H); Anal. calcd. for C21H21NO4: C 
71.78, H 6.02, N 3.99, found: C 71.19, H 6.01, N 3.92. 
(3-(3,4,5-Trimethoxyphenyl)-2-hydroxymethyl-8H-3a-aza–cyclopenta[a]inden-1-yl) 
methanol (63k). Compound 63k  was synthesized from 62k (2.62 g, 6 mmol) in 
anhydrous dichloromethane (35 mL) and LiAlH4 (0.83 g, 21.87 mmol) in anhydrous ether 
(40 mL); yield (1.71 g, 75%); mp 132–134 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.47
(d, J=7.3 Hz, 1H), 7.17 (t, J=7.5 Hz, 1H), 7.05 (t, J=7.2 Hz, 1H), 6.92 (d, J=7.9 Hz, 1H), 
6.79 (s, 2H), 4.73 (t, J=4.7 Hz, 1H), 4.66 (t, J=4.7 Hz, 1H), 4.55 (d, J=4.4 Hz, 2H), 4.30 
(d, J=4.4 Hz, 2H), 3.91 (s, 2H), 3.78 (s, 6H), 3.76 (s, 3H); Anal. calcd. for C22H23NO5: C 
69.28, H 6.08, N 3.67, found: C 68.33, H 6.04, N 3.60. 
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(2-Hydroxymethyl-6-methoxy-3-(4-methoxyphenyl)-8H-3a-aza-cyclopenta[a]inden-
1-yl)methanol (63l). Compound 63l was synthesized from 62l (1.73 g, 3.56 mmol) in 
anhydrous dichloromethane (20 mL) and LiAlH4 (0.45 g, 11.85 mmol) in anhydrous ether 
(40 mL); yield (1.35 g, 91%); mp 186–187 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.40 (d, 
J=8.7 Hz, 2H), 7.10 (d, J=2.3 Hz, 1H), 7.07 (d, J=8.7 Hz, 2H), 6.69 (dd, J=8.7, 2.5 Hz, 
1H), 6.64 (d, J=8.7 Hz, 1H), 4.71 (t, J=4.4 Hz, 1H), 4.56 (t, J=4.4 Hz, 1H), 4.53 (d, J=4.4
Hz, 2H), 4.24 (d, J=4.4 Hz, 2H), 3.87 (s, 2H), 3.84 (s, 3H), 3.71 ppm (s, 3H); Anal. calcd. 
for C21H21NO4: C 71.78, H 6.02, N 3.99, found: C 71.59, H 5.90, N 3.78. 
Methylcarbamic acid 3-methyl-2-methylcarbamoyloxymethyl-8H-3a-aza-cyclopenta 
[a]inden-1-ylmethyl ester (64a). To a solution of 63a (0.80 g, 3.5 mmol) and 
triethylamine (2.5 mL) in anhydrous dichloromethane (10 mL) was added dropwise 
methyl isocyanate (2 mL, 35 mmol) in anhydrous dichloromethane (5 mL). The mixture 
was stirred at room temperature for additional 5 h. The mixture was concentrated under 
reduced pressure to dryness. The residue was triturated with a mixture of ether/methanol 
(15:1), the solid product was collected by filtration, washed with ether (10 mL), and dried 
in vacuo to yield 64a (1.18 g, 98%); mp 86–88 oC; 1H NMR (400 MHz, DMSO-d6)
?=7.52?7.47 (m, 2H), 7.34?7.30 (m, 1H), 7.14?7.10 (m, 1H), 6.86 (brs, 2H), 4.95 (s, 2H), 
4.92 (s, 2H),  3.84 (s, 2H), 2.55 (d, J=2.0 Hz, 3H), 2.54 (d, J=2.0 Hz, 3H), 2.51 ppm (s, 
3H); Anal. calcd. for C18H21N3O4: C 62.96, H 6.16, N 12.24, found: C 62.70, H 6.35, N 
11.99.
By following the same procedure as describe for 64a, the following compounds 64b-l
were synthesized. 
Methylcarbamic acid 3-ethyl-2-methyl carbamoyloxymethyl-8H-3a-aza-cyclo- 
penta[a]inden-1-yl-methyl ester (64b). Compound 14b was synthesized from 63b (0.85
g, 3.5 mmol), triethylamine (2 mL) and methyl isocyanate (2 mL, 35 mmol); yield (1.24 
g, 99%); mp 165–166 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.50?7.48 (m, 1H), 7.45?
7.42 (m, 1H), 7.37?7.33 (m, 1H), 7.15?7.11 (m, 1H), 6.90 (brs, 1H), 6.84 (brs, 1H), 4.96 
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(s, 2H), 4.93 (s, 2H), 3.85 (s, 2H), 2.93 (q, J=7.3 Hz, 2H), 2.55 (d, J=2.8 Hz, 3H), 2.54 (d, 
J=2.8 Hz, 3H), 1.18 ppm (t, J=7.3 Hz, 3H); Anal. calcd. for C19H23N3O4: C 63.85, H 6.49, 
N 11.76, found: C 63.67, H 6.71, N 11.71. 
Methylcarbamic acid 2-methylcarbamoyloxymethyl-3-phenyl-8H-3a-aza-cyclo-penta 
[a]inden-1-yl-methyl ester (64c). Compound 64c was synthesized from 63c (0.73 g, 2.5 
mmol), triethylamine (2.5 mL) and methyl isocyanate (1.47 mL, 25 mmol); yield (0.87 g, 
86%); mp 196–198 oC; 1H NMR (600 MHz, CDCl3) ?=7.48–7.42 (m, 5H), 7.38–7.368 
(m, 1H), 7.05–7.02 (m, 2H), 6.77–6.76 (m, 1H), 5.20 (s, 2H), 5.01 (s, 2H), 4.73 (brs, 1H), 
4.69 (brs, 1H), 3.94 (s, 2H), 2.80 (d, J=4.7 Hz, 3H), 2.78 ppm (t, J=4.7 Hz, 3H); Anal. 
calcd. for C23H23N3O4: C 68.13, H 5.72, N 10.36, found: C 67.69, H 5.75, N 10.31. 
Methylcarbamic acid 3-(4-flourophenyl)-2-methylcarbamoyloxymethyl-8H-3a-aza-
cyclopenta[a]inden-1-yl-methyl ester (64d). Compound 64d was synthesized from 63d
(0.77 g, 2.5 mmol), triethylamine (2.5 mL) and methyl isocyanate (1.47 mL, 25 mmol); 
yield (0.92 g, 87%); mp 199–200 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.55–7.53 (m, 
2H), 7.50 (d, J=7.3 Hz, 1H), 7.38 (t, J=8.7 Hz, 2H), 7.15 (t, J=7.44 Hz, 1H), 7.09 (t, 
J=7.4 Hz, 1H), 6.95 (brs, 1H), 6.92 (brs, 1H), 6.66 (d, J=7.8 Hz, 1H), 5.05 (s, 2H), 4.79 
(s, 2H), 3.96 (s, 2H), 2.58 (d, J=4.5 Hz, 3H), 2.55 ppm (t, J=4.5 Hz, 3H); Anal. calcd. for 
C23H22FN3O4: C 65.24, H 5.24, N 9.92, found: C 65.00, H 5.35, N 9.71. 
Methylcarbamic acid 3-(4-chlorophenyl)-2-methylcarbamoyloxymethyl-8H-3a-aza-
cyclopenta[a]inden-1-ylmethyl ester (64e). Compound 64e was synthesized from 63e
(0.81 g, 2.5 mmol), triethylamine (2.5 mL) and methyl isocyanate (1.47 mL, 25 mmol); 
yield (1.06 g, 96%); mp 204–206 oC; 1H NMR (600 MHz, CDCl3) ?=7.51–7.38 (m, 5H), 
7.08–7.04 (m, 2H), 6.77–6.76 (m, 1H), 5.19 (s, 2H), 4.98 (s, 2H), 4.71 (brs, 1H), 4.67 
(brs, 1H), 3.94 (s, 2H), 2.73 ppm (m, 6H); Anal. calcd. for C23H22ClN3O4: C 62.80, H 
5.04, N 9.55, found: C 62.72, H 5.14, N 9.41. 
Methylcarbamic acid 3-(3,4-diflouro-phenyl)-2-methyl-carbamoyloxymethyl-8H-3a-
aza-cyclopenta[a]inden-1-ylmethyl ester (64f). Compound 64f was synthesized from 
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63f (0.81 g, 2.5 mmol), triethylamine (2.5 mL) and methyl isocyanate (1.47 mL, 25 
mmol); yield (0.93 g, 84%); mp 151–152 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.63–
7.57 (m, 2H), 7.52 (d, J=4.5 Hz, 1H), 7.36 (s, 1H), 7.18 (d, J=5.0 Hz, 1H), 7.12 (d, J=5.1
Hz, 1H), 6.96 (brs, 1H), 6.95 (brs, 1H), 6.73 (d, J=5.2 Hz, 1H), 5.05 (s, 2H), 4.82 (s, 2H), 
3.97 (s, 2H), 2.58 (d, J=4.4 Hz, 3H), 2.55 ppm (t, J=4.4 Hz, 3H); Anal. calcd. for 
C23H21F2N3O4: C 62.58, H 4.80, N 9.52, found: C 62.49, H 4.97, N 9.33. 
Methylcarbamic acid 3-(4-methoxy-phenyl)-2-methyl-carbamoyloxymethyl-8H-3a-
aza-cyclopenta[a]inden-1-ylmethyl ester (64g). Compound 64g was synthesized from 
63g (1 g, 3 mmol), triethylamine (3.5 mL) and methyl isocyanate (1.76 mL, 30 mmol); 
yield (0.73 g, 70%); mp 152–153 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.49 (d, J=7.6
Hz, 1H), 7.40 (d, J=8.5 Hz, 2H), 7.10–7.07 (m, 4H), 6.92 (brs, 1H), 6.90 (brs, 1H), 6.69 
(d, J=7.6 Hz, 1H), 5.04 (s, 2H), 4.78 (s, 2H), 3.95 (s, 2H), 3.85 (s, 3H), 2.58 (d, J=4.8 Hz, 
3H), 2.56 ppm (t, J=4.8 Hz, 3H); Anal. calcd. for C24H25N3O5: C 66.19, H 5.79, N 9.65. 
found: C 66.13, H 5.61, N 9.41. 
Methylcarbamic acid 3-(2-methoxy-phenyl)-2-methyl-carbamoyloxymethyl-8H-3a-
aza-cyclopenta[a]inden-1-ylmethyl ester (64h). Compound 64h was synthesized from 
63h (1.25 g, 3.89 mmol), triethylamine (2.5 mL) and methyl isocyanate (1 mL, 18.12 
mmol)p; yield (1.47 g, 87%); mp 200–203 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.53–
7.46 (m, 2H), 7.32–7.30 (m, 1H), 7.19 (d, J=8.12 Hz, 1H), 7.14–7.04 (m, 3H), 6.95 (brs, 
1H), 6.86 (brs, 1H), 6.47 (d, J=7.7 Hz, 1H), 5.04 (s, 2H), 4.86 (d, J=11.9 Hz, 1H), 4.60 
(d, J=11.9 Hz, 1H), 3.94 (s, 2H), 3.64 (s, 3H), 2.58 (d, J=4.6 Hz, 3H), 2.54 ppm (t, J=4.6
Hz, 3H); Anal. calcd. for C24H25N3O5: C 66.19, H 5.79, N 9.65, found: C 65.71, H 5.87, 
N 9.53. 
Methylcarbamic acid 3-(3,4-dimetoxy-phenyl)-2-methyl-carbamoyloxymethyl-8H-
3a-aza-cyclopenta[a]inden-1-ylmethyl ester (64i). Compound 64i was synthesized from 
63i (1.5 g, 4.27 mmol), triethylamine (2.5 mL) and methyl isocyanate (2.5 mL, 42.60 
mmol); yield (1.80 g, 91%); mp 165–168 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.50–
7.49 (m, 1H), 7.18–7.07 (m, 3H), 7.03–7.00 (m, 2H), 6.92 (brs, 2H), 6.80–6.79 (m, 1H), 
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5.04 (s, 2H), 4.81 (s, 2H), 3.95 (s, 2H), 3.85 (s, 3H), 3.75 (s, 3H), 2.58 (d, J=4.6 Hz, 3H), 
2.55 ppm (t, J=4.6 Hz, 3H); Anal. calcd. for C25H27N3O6: C 64.50, H 5.85, N 9.03, found: 
C 64.28, H 5.86, N 8.95. 
Methylcarbamic acid 3-(2,6-dimethoxyphenyl)-2-methyl-carbamoyloxymethyl-8H-
3a-aza-cyclopenta[a]inden-1-ylmethyl ester (64j). Compound 64j was synthesized from 
63j (0.75 g, 2.13 mmol), triethylamine (1.5 mL) and methyl isocyanate (0.8 mL, 13.56 
mmol); yield (0.89 g, 90%); mp 154–156 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.48–
7.45 (m, 2H), 7.10–7.08 (m, 1H), 7.04–7.01 (m, 1H), 7.00–6.97 (m, 1H), 6.81 (s, 1H), 
6.80 (brs, 1H), 6.79 (brs, 1H), 6.41–6.39 (m, 1H), 5.03 (s, 2H), 4.66 (s, 2H), 3.91 (s, 2H), 
3.62 (s, 6H), 2.59 (d, J=3.6 Hz, 3H), 2.52 ppm (t, J=3.6 Hz, 3H); Anal. calcd. for 
C25H27N3O6: C 64.50, H 5.85, N 9.03, found: C 63.18, H 5.74, N 8.63. 
Methylcarbamic acid 3-(3,4,5-trimethoxyphenyl)-2-methylcarbamoyloxymethyl-8H-
3a-aza-cyclopenta[a]inden-1-ylmethyl ester (64k). Compound 64k was synthesized 
from 63k (1.03 g, 2.7 mmol), triethylamine (1.5 mL) and methyl isocyanate (1 mL, 18.12 
mmol; yield (1.27 g, 95%); mp 204–205 oC; 1H NMR (400 MHz, DMSO-d6) ?=7.52–7.50 
(d, J=7.5 Hz, 2H), 7.22?7.18 (t, J=7.2 Hz, 1H), 7.13?7.10 (t, J=7.2 Hz, 1H), 6.94 (s, 1H), 
6.93 (brs, 1H), 6.91 (brs, 1H), 6.77 (s, 2H), 5.05 (s, 2H), 4.83 (s, 2H), 3.96 (s, 2H), 3.79 
(s, 6H), 3.78 (s, 3H), 2.57 (d, J=4.6 Hz, 3H), 2.55 ppm (t, J=4.6 Hz, 3H); Anal. calcd. for 
C26H29N3O7: C 63.02, H 5.90, N 8.48, found: C 62.74, H 5.92, N 8.42. 
Methylcarbamic acid 6-methoxy-3-(4-methoxyphenyl)-2-methylcarbamoyl-oxy
methyl-8H-3a-aza-cyclopenta[a]inden-1-ylmethyl ester (64l). Compound 64l was 
synthesized from 63l (0.954 g, 2.71 mmol), triethylamine (1.5 mL) and methyl isocyanate 
(0.95 mL, 16.24 mmol); yield (1.17 g, 93%); mp 110–112 oC; 1H NMR (400 MHz, 
DMSO-d6) ?=7.38 (d, J=8.6 Hz, 2H), 7.13 (d, J=2.5 Hz, 1H), 7.08 (d, J=8.6 Hz m, 2H), 
6.92 (brs, 1H), 6.88 (brs, 1H), 6.71 (dd, J=8.7, 2.5 Hz, 2H), 6.60 (d, J=8.7 Hz, 1H), 5.02 
(s, 2H), 4.80 (s, 2H), 3.92 (s, 2H), 3.84 (s, 3H), 3.71 (s, 3H), 2.58 (d, J=4.5 Hz, 3H), 2.55 
ppm (t, J=4.5 Hz, 3H); Anal. calcd. for C25H27N3O6: C 64.50, H 5.85, N 9.03, found: C 
63.41, H 5.80, N 8.84. 
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Biological Experiments 
Tumor and cell lines. Human colon carcinoma HCT-116 cells, human prostate 
adenocarcinoma PC3, ovarian adenocarcinoma SK-OV-3, human lung large cell 
carcinoma H1299 and human glioma cells U87 were obtained from American Type 
Culture Collection (ATCC, Rockville, MD). Human mammary carcinoma (MX-1) tumor 
cells were obtained from MSKCC cell bank. The CCRF-CEM human lymphoblastic 
leukemia cells and their vinblastine resistant subline (CCRF-CEM/VBL, 680-fold 
resistance in vitro) were obtained from Dr. William Beck of the University of Illinois, 
Chicago, and CCRF-CEM/Taxol (330-fold resistance in vitro) resistant cells were 
produced by exposing the parent cells to increasing sublethal concentration (IC50-IC90) of 
paclitaxel for six months. OECM1 (human gingival squamous carcinoma cells) was 
obtained from Dr. T. Y. Liu of the National Yang-Ming Univeristy, Taiwan.
Cytotoxicity assays. The cytotoxic effects of the newly synthesized compounds were 
determined in T-cell acute lymphocytic leukemia (CCRF-CEM) and their resistant subcell 
lines (CCRF-CEM/Taxol and CCRF-CEM/VBL) by the XTT assay51 and human solid 
tumor cells (i.e. breast carcinoma MX-1 and colon carcinoma HCT-116) the SRB assay52
in a 72 h incubation using a microplate spectrophotometer as described previously.53 After
the addition of phenazine methosulfate-XTT solution, incubated  at 37 oC for 6 h and 
absorbance at 450 and 630 nm was detected on a microplate reader (EL 340). The 
cytotoxicity of the newly synthesized compounds against non-small cell lung cancer 
(H1299), human prostate cancer cell line (PC3), human glioma (U87) and oral cancer cell 
line (OECM1) were determined by the WST-1 assay63 in a 72 h incubation using a 
microplate spectrophotometer as described previously. After the addition of WST-1 
solution, it was incubated at 37 oC for 4 h. Absorbance at 460 and 630 nm was detected 
on a microplate reader. IC50 values were determined from dose-effect relationship at six 
or seven concentrations of each drug using the CompuSyn software by Chou and Martin54
based on the median-effect principle and plot.55,56
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In Vivo Studies
Athymic nude mice bearing the nu/nu gene were obtained from NCI, Frederick, MD and 
used for all human tumor xenografts. Male nude mice 6 weeks or older weighing 20-24 g 
or more were used. Compounds were administered via the tail vein for i.v. injection as 
described previously.53 Tumor volume was assessed by measuring length × width × 
height (or width) by using a caliper. Vehicle used was 50 ?L DMSO and 40 ?L Tween 80 
in 160 ?L saline. The maximal tolerate dose of the tested compound was determined and 
applied for the in vivo therapeutic efficacy assay. For tumor-bearing nude mice during the 
course of the experiment, the body weight refers to total weight minus the weight of the 
tumor. All animal studies were conducted in accordance with the guidelines for the 
National Institute of Health Guide for the Care and Use of Animals and the protocol 
approved by the Institutional Animal Care and Use Committee. 
DNA interstrand cross-linking measured using a modified single cell gel 
electrophoresis (comet) assay.
DNA interstrand cross-linking was analysed using a modified comet assay.57,58 All steps 
were carried out under subdued lighting. Briefly, H1299 cells (2 × 105 cells) were plated 
in a 60 mm dish and incubated at 37 oC with 5% CO2 for 32 h. The growing cells were 
treated with alkylating agents (63l, 64l and mitomycin C). After being treated for 1 h, the 
cells were irradiated with 20 Gy of X-ray to induce DNA strand breaks. An aliquot of 5 × 
105 cells were suspended in 50 ?L of phosphate-buffered saline, mixed with a 250 ?L of 
1.2% low melting point agarose, and then processed according to standard comet assay. 
The tail moment of 100 cells were analyzed for each treatment by aid of the COMET 
assay software (Perceptive instruments, Haverhill, UK). The degree of DNA interstrand 
cross-linking present in a drug treated sample was determined by comparing the tail 
moment of the irradiated drug treated samples with irradiated untreated samples and 
unirradiated untreated samples. The level of interstrand cross-linking is proportional to 
the decrease in the tail moment in the irradiated drug treated sample compared to the 
irradiated untreated control. The decrease in tail moment is calculated by the following 
formula: 
% of DNA with interstrand cross-linking
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Where TMdi = mean tail moment of drug treated, irradiated sample, TMcu = mean tail 
moment of unirradiated control sample, TMci = mean tail moment of irradiated control 
sample. 
Alkaline Agarose Gel Shift Assay
Formation of DNA cross-linking was analyzed by alkaline agarose gel electrophoresis.60
In brief, purified pEGFP-N1 plasmid DNA (1500 ng) was mixed with various 
concentrations (0.1–20 μM) of 63l and 64l in 40 μl binding buffer (3 mM sodium 
chloride/1 mM sodium phosphate, pH 7.4, and 1 mM EDTA). The reaction mixture was 
incubated at 37 oC for 2 h. At the end of reaction, the plasmid DNA was linearized by 
digestion with BamHI and followed by precipitation with ethanol. The DNA pellets were 
dissolved in alkaline buffer (0.5 N NaOH- 10 mM EDTA) to denature the DNA. An 
aliquot of 20 μl of DNA solution (1000 ng) was mixed with a 4 ?l of 6×alkaline loading 
dye and then resolved by electrophoresis in 0.8% alkaline agarose gels with NaOH-
EDTA buffer at 4 oC. The electrophoresis was carried out at 18V for 22 h. The DNA was 
then visualized under UV light after staining with ethidium bromide. 
Flow Cytometric Analysis 
The effects of compounds 63l and 64l on cell cycle were analyzed with a flow cytometer 
as described previously.64 Briefly, human non-small cell lung carcinoma H1299 cells 
were treated with these agents at 10 ?M. After the desired length of time the attached 
cells were trypsinized, washed with phosphate buffer saline (PBS), fixed with ice-cold 
70% ethanol for 30 min. The cells were stained with 4 ?g/ml propidium iodide (PI) in 
PBS containing 1% Triton X-100 and 0.1 mg/ml RNase A. The stained cells were then 
analyzed using the FACS SCAN flow cytometer (Becton Dickinson, San Joes, CA, 
USA). The percentage of the cells in each cell cycle phase was determined using the 
ModFit LT 2.0 software based on the DNA histograms. 
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3.1 Introduction
3.1.1 Nitrogen Mustards 
The nitrogen mustards represent the oldest and perhaps most extensively studies 
of the DNA interstrand cross-linking agents.1 Chlorambucil (1), melphalan (2),
cyclophosphamide (3), ifosphamide (4), and istramustine (5) are the example of 
commonly used alkylating agents of N-mustards. N-mustards act through the alkylation 
of DNA and prevent cell division by cross-linking DNA, which leads to DNA breaks or 
abnormal base pairing, and subsequently to cell death2.
Studies on the mechanism of action of N-mustards suggested that these agents 
alkylate DNA in two step sequence. In the first step, one of the chloroethyl side chain, at 
either neutral or alkaline pH, undergoes cyclization, releasing the chloride ion and 
forming an aziridinium cation intermediate 7 (Figure 2A)3. The strained three member 
ring is highly reactive and can undergo nucleophilic addition by DNA nucleophile to 
form a mono alkylation adduct. The second chloroethyl arm can also undergo the same 
reaction to form bi-adduct with DNA Cross-linking. Cross-linking can occur either 
between two complementary strands of DNA (interstrand) or within a strand of DNA 
(intrastrand) (Figure 2B). N-Mustards show preference for the N7 in guanine to give 
interstrand crosslink dG N7–NM–dG N74. Only a few adducts are formed at the N-1 and 
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O-6 position of guanine, the N-1, N-3, and N-7 positions of adenine, the N-3 position f 
cytosine, and the O-4 position of thymidine. 
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Although – DNA alkylating agents, such as N-mustards, possess a broad spectrum of 
antitumor activity and are widely used for treatment of cancer patient, the usefulness of 
these agents, however, is often limited due to their chemical instability. There are several 
drawbacks for using DNA-alkylating agents as chemotherapeutic agents including: 
1. High chemical reactivity5 of  conventional drug. This can result in loss of drug’s 
activity by reacting with other cellular nucleophiles such as proteins and low molecular 
weight thiols. These agents may be also induce cellular resistance mechanisms because of 
increasing high level of glutathione.6, 7
2. Lack of intrinsic DNA binding affinity of the alkylating pharmacophore requiring for 
cross-linking of DNA to reach fully cytotoxic. This can be resulted by formating high 
ratio of genotoxic mono-adducts to cross-links (20:1)8 and produce carcinogenicity9  or 
bone marrow toxicity. 
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3. The major guanine N7 adduct formed by N-mustards is readily repaired and thus, may 
reduce drug efficacy by DNA repair mechanism5
There are several strategies to overcome the drawbacks of N-mustards. One of the 
effective strategies is to synthesize N-mustard prodrug to reduce the reactivity of the 
parent N-mustard pharmacophore. Another strategy is preparing N-mustard-DNA-affinic 
molecule conjugates to increase sequence-specific Drug-DNA binding.
3.1.2 N-Mustards Prodrug Approach 
Prodrug has been widely used to increase oral bioavailability or deliver drug to the 
target site, where the active drug can be released after enzymatic hydrolysis.10 Prodrug 
has been used for cancer therapy. Early work showed that cyclophosphamide (3), a N-
mustards prodrug, is able to be activated by enzymatic oxidation to generate active N-
mustard pharmacophore. This agent is currently widely used for treatment cancer 
patients.11-12 In the last two decades, monoclon antibody and exogenous enzyme have 
been utilized for prodrug antibody therapy.13-15 Enzyme-activating prodrug therapy is a 
two-step approach. In the first step, a drug-activating enzyme is delivered to the targeted 
tumor site. In the second step, a nontoxic prodrug is administrated.13-15 The systemically 
administered prodrug can be converted to active principle in high local concentration at 
the tumor site. Currently, delivery methods for an enzyme/prodrug strategy can be 
divided into two major classes: (a) delivery of genes that encode prodrug-activating 
enzymes into tumor tissues (GDEPT, VDEPT, etc.); and (b) delivery of active enzymes 
onto tumor tissues (ADEPT). 
Springer et al. have synthesized various N-mustard prodrugs, the phenyl N-mustard 
pharmacophore is linked to enzyme’s substrate moiety, L-glutamic acid, via a urea (11
and 12, Z = NH)16 carbamate (11 and 12, Z = O)16 , and carboxamide [13 (CMDA)17,18
and 14 (CJS 1050)19] linkage for antibody-directed enzyme prodrug therapy (ADEPT),20
or gene-directed enzyme prodrug therapy (GDEPT).21 In the presence of their mAB-
CPG2, the prodrug are hydrolyzed to release the active metabolite N-mustard drug. 
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The prodrugs, 15,22 16,23 and 17,24 were also synthesized by linking the aniline N-
mustard to the trigger unit tyramine, 3-hydroxytyramine, or catecholamine, respectively, 
via a urea or carbamate linker for melanocyte-directed enzyme prodrug therapy 
(MDEPT). Upon exposure to tyrosinase, these conjugates can also release the active 
aniline or phenol N-mustard. Since the prodrugs are stable before enzymatic hydrolysis, it 
suggests that the urea or carbamate linker is capable of lowering the reactivity of aniline 
or phenol N-mustard pharmacophore leading to form rather stable N-mustard derivatives. 
Various nitro containing phenyl N-mustard derivatives (Figure 5) were also 
synthesized for antibody-directed or gene-directed enzyme prodrug therapy. These 
prodrugs can be activated by co-treatment of E. coli nitroreductase, which are able to 
concert the electron-withdrawing para-NO2 function to NH2 (electro-donating function) 
via reductive activation.25-29 The E. coli nitroreductase enzyme (NTR) has been widely 
used in suicide gene therapy (GDEPT and ADEPT) applications as an activating enzyme 
for nitroaromatic prodrugs of the dinitrobenzamide class. 
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Another important example is 3,5-dinitrobenzamide nitrogen mustard PR-104 
(20),30 which also can be activated by nitroreductase. This agent is a novel hypoxia-
activated DNA cross-linking agent with potent activity against human tumor xenografts 
(e. g., SiHa cervical, HT29 colon and H460 NSCLC), both as monotherapy and combined 
with radiotherapy and chemotherapy.30 PR-104 has just been entered clinical trial in 2006 
by the Cancer Research Group in New Zealand. 
3.1.3 DNA Directed Alkylating Agents 
Another strategy for overcome the drawbacks of DNA-alkylating agents is to 
construct “DNA-directed alkylating agents”. Many of drawbacks of the “simple” N-
mustards could in principle be ameliorated by attaching them to a DNA-affinic carrier 
molecule. The use of DNA-affinic carriers resulting in improving their sequence 
specificity and regioselectivity of DNA alkylation compared with that of the unmasked 
“simple” N-mustards.31-33
Creech et al.34 first synthesized DNA-directed alkylating agents by using 
substituted quinoline (21, 22) and acridine (23) nuclei as carriers for the N-mustard 
pharmacophore. These conjugates displayed pronounced antitumor activities in tests 
employing mouse ascites tumors. Based on these finding, the same research group have
studies a series of mono- and difunctional alkylating agents linked to various heterocyclic 
chromophores, such as quinoline, isoquinoline, acridine, anthracene, anthraquinone, 
naphthaline (Figure 4). 35-43 It revealed that the these conjugates showed significant in 
vitro activity than the corresponding untargeted N-mustards. Treatment of mice bearing 
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ascites tumors with these compounds caused at least five-fold increase in survival time 
over that of the control mice.  From this effort it becomes clear that initiatives to increase 
drug-DNA-affinity often provide frameworks upon which to design and construct new 
drugs of higher efficacy or altered selectivity. 
Using other carriers for DNA-directed alkylating agents has been then further 
developed. Denny et at. have synthesized a series of compounds in which aniline nitrogen 
mustards was coupled with various quinazoline (32) and 9-aminoacridine (33)
chromophores.32,44,45 These agents were extremely potent and have pronounced antitumor 
activity. Among these agents, N-mustards linked to acridine were more cytotoxicity than 
the corresponding untargeted mustards.32,46 It was shown that compounds having (CH2)n
or (CH2)nO (n was variable from 2 to 5) linker were much more cytotoxic than compound 
having (CH2)nS linker against P388 leukemia cell growth in vitro, whereas, derivatives 
bearing (CH2)nSO2 linker were least potent. The DNA cross-linking studies revealed that 
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the (CH2)n or (CH2)nO containing derivatives were stronger alkylating agents than the 
corresponding (CH2)nS compounds. The in vivo activity of these compound revealed that 
drug bearing (CH2)n or (CH2)nO (n was variable from 2 to 5) were much more potent 
(optimal dose of 20-30 mg/kg) than the control chlorambucil (1) (optimal dose 225 
mg/kg) or any other untethered N-mustards. Similar studies also showed that the thioether 
and sulfoxide congeners of 33 showed weak in vivo activity.  
The 9-anlinoacridine derivatives, Amsacrine (34, Figure 9) [a topoisomerase II 
poison,47,48  DNA intercalating49 and used for treatment of adult leukemia50,51], was used 
as a carrier for constructing DNA-directed alkylating agents. The N-mustard moiety was 
attached to C-4 of the acridine chromophore (e.g., 35) or to C-1’ of the 9-anilino ring 
(e.g., 36, 37).52 At the optimal dose, these analogues achieved  a smaller percentage 
increase of lifespan (%ILS) than the parent m-AMSA (34) in mice bearing murine 
leukemia p388.52 The 4-linked analogue 35 showed to have slightly higher in vivo
antileukemic activity than their corresponding 1’-linked analogues (36), suggesting that 
the active side chain may be better to be linked to the acridine ring rather than to the 
aniline ring. The decrease in potency of compounds 36 is probably due to the long linker 
between the alkylating N-mustard residue and the anilino ring and thus interfere the 
Drug-DNA binding. The DNA alkylation studies revealed that 35 alkylated preferentially 
at N7 of deoxyguanine reside in the major groove, whereas 36 preferentially alkylated at 
the N3 of adenine residue in the minor groove with a smaller portion of alkylation at N7 
of guanine residue.53 The studies provided strong supporting evidence that the 9-
anilinoacridine-4-carboxamide chromophore may be important “DNA-threading agent” 
with high region-specifity, placing the aniline side chain in the minor groove and the 
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carboxamide chain in the major groove. The longer-chain analogue 37 also shows 
adenine-specific alkylation. 54
In order to establish the higher sequence-selectivity of N-mustards, some research 
groups have focused their attention on the synthesis of DNA minor groove binders as 
carriers of N-mustards, because these may offer much higher region- and sequence 
selectivity than intercalator. Utilizing this approach, Gravatt et al.55 have synthesized a 
series of 4-anilinoquinoline-N-mustard conjugates as DNA minor groove binding agents 
(38, 39, Figure 10).  It also showed that these conjugates were at least 10-fold more 
cytotoxic than the unmasked aniline mustard.  
The introduction of nitrogen mustard moiety to bis-benzimidazole analogs, such 
as  Hoechst 33258 (40), a DNA minor groove binding agent, produced a series of 
derivatives with general formula 41.56 These compounds were found to have more 
cytotoxic against human tumor cell line KB than the parent compound Hoechst 33258 
and characterized by an alkylation at adenine residues in the minor groove of DNA.56
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Denny and co-workers57 have synthesized a series of analogues 42, in which the phenyl 
nitrogen mustard moiety was coupled to the benzimidazole ring by an alkyl chain of 
different length. These derivatives showed potent cytotoxicity and proficiently cross-
linked to DNA. Compound 42 with a propyl linker (n=3) was in phase I and II trials. 57 
Another group of DNA minor groove binding agents, distamycin A (44, Figure 12) 
and its four pyrroles homologue (45) were also used as a DNA sequence selective carrier 
for constructing DNA-alkylating agents. Compounds 43, 46 and 47 were synthesized by 
linking the benzoyl N-mustard (BAM) to the C-4 of the pyrrole ring. Similarly, 
compounds 43 were found to be more cytotoxic distamycin A or 45.58,59
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Tallimustine (46, FCE 24517) was selected as an antineoplastic drug candidate 
because this agent has high activity against a wide variety of murine tumors and human 
xenografts. Tallimustine have been evaluated in phase I and II clinical trials.60 However, 
the phas II trials were discontinued becaused this agent showed severe myelotoxicity.61,62
It is interested to note that the cytotoxicity can be increased by increasing the number of 
pyrrole residues from three to four. The resulting derivative, compound 47, was shown to 
be more potent than Tallimistine. 58,59 Bigioni et al. have synthesized compound 48
(MEN-10710), 63 in which the benzoyl N-mustard moiety was replace by benzyl N-
mustard. The results showed that 48 possessed greater in vitro cytotoxicity, higher in vivo 
higher therapeutic efficacy as well as have reduced myelotoxicity when compared with 
tallimustine. 
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Another interesting DNA minor groove binder that has promising antitumor 
activity both in vivo and in vitro is the derivative MS-247 (49) 64 that has three moieties in 
the structure. Two are the pyrrole (a netropsin-like moiety) and the benzoimidazole 
(feature of Hoechst 33342) ring, necessary to acquire DNA minor groove binding 
activity, the third is the BAM residue for DNA alkylation. The MS-247 mode of action 
showed DNA binding activity at the site where Hoechst 33342 bound, inhibited 
topoisomerase I and II, blocked the cell cycle at the G2–M phase and induced apoptosis.64
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3.2 Rational Drug Design 
Recently, Su et al.65-67 reported that alkyl N-mustard residue linked to the DNA-
affinic 9-anilinoacridines either at the anilino ring or/and acridine chromophore of 9-
anilinoacridines (alkyl N-mustard-9-anilinoacridine conjugates) or acridine via a 
methylene or alkoxy (O–C1–4) linker (Figure 15) possessed potent significant cytotoxicity 
in inhibiting various human leukemia or solid tumor cell growth in vitro and potent 
therapeutic effects against human tumor xenografts in animal model.65-67 These agents 
were about >100-fold more cytotoxic than the parent AHMA (50)68, which is a potent 
DNA-intercalating agent and Topoisomerase II inhibitor previously developed in Su’s 
laboratory. The SAR study revealed that the length of the spacer also has influence on 
their potency. Among these conjugates, BO-0742 (53, Fig.15)65,66 and BO-0940 (54)67
were selected for further in vivo antitumor studies. These agent did not exhibit cross-
resistance against vinblastine-resistant (CCRF-CEM/VBL) or taxol-resistant (CCRF-
CEM/taxol) cells. BO-0742 was capable of inducing complete tumor remission human 
breast MX-1 xenograft or significant suppression human T-cell acute lymphoblastic 
leukemia CCRF-CEM, colon carcinoma HCT-116, and ovarian adenocarcinoma SK-OV-
3 tumor xenografts in animal models. In addition, BO-0742 serves as DNA cross-linking 
agent rather than Topoisomerase II inhibitor. The single dose pharmacokinetics of 53 in 
male CD-1(crl.) mouse following intravenous injection displayed very high systemic 
clearance and high volume of distribution with a short terminal half-life of less than 0.4 h, 
thereby has low bioavailability.
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To overcome the poor pharmacokinetics of BO-0742, Naval et al. have recently 
synthesized a series of phenyl N-mustard-9-anilinoacridine conjugates having a urea69
(55, X = NH) and carbamate70 (55, X = O and 56 X = NH) or carbonate70 (56 X = O) 
linker instead of alkyl N-mustard residue and carbon chain spacer, since the urea and 
carbamate spacer may serve as stabilizing function for phenyl N-mustard. The antitumor 
studies revealed that these derivatives possessed significant cytotoxicity with IC50 in 
submicro molar range in inhibiting human lymphoblastic leukemia (CCRF-CEM), breast 
carcinoma (MX-1), colon carcinoma (HCT-116) and human non-small cell lung cancer 
(H-1299) cell growth in vitro. It also revealed that these conjugates exhibited potent 
therapeutic efficacy against human xenografts in vivo and are able to induce DNA 
interstrand cross-linking in tumor cells.  
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Remarkably, BO-1051 (57)69 and BO-1062 (57)70 were much more stable than 
BO-0742 and has long half-life in rat plasma. These agents possessed potent therapeutic 
efficacy against human tumor xenografts in nude mice. Total tumor remission (or 
complete remission, CR) was achieved in nude mice bearing human breast MX-1 
xenograft and showed no relapse over 70 and 129 days respectively.  BO-1051 also 
significantly suppressed human glioma U87 MG in nude mice. Author also reported that 
these agents are capable of inducing DNA interstrand cross-linking.
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These studies clearly suggested that the selection of N-mustard (alkyl or phenyl N-
mustards), DNA-affinic molecules and linker are important since they may affect the 
antitumor activity, DNA-drug interactions and stability of these DNA-directed alkylating 
agents. In general, alkyl N-mustards are very reactive and unstable due to the inductive 
effect of alkyl function leading to rapid generation of the reactive aziridium cation 
intermediate, which readily interacts with DNA forming interstrand cross-inking. While, 
the reactivity of phenyl N-mustards is relatively weaker than alkyl N-mustards due to the 
electron-withdrawing property of the phenyl ring.
To find new DNA-directed alkylating agents with high potential antitumor activity, 
one can use DNA-affinic molecules other than 9-anilinoacridine moiety as carrier. In the 
aspect, we used various substituted quinolines, which are DNA minor groove binders,71
as carrier to deliver the warhead N-mustard to bind more sequence-specifically to the 
target site. We also used urea or hydrazine-carboxamide as linker. The newly synthesized 
DNA-directed alkylating agents are: 
1) Phenyl N-mustard-quinoline conjugates having a urea linker (59, Figure 17);
2) Phenyl N-mustard-quinoline conjugates having a hydrazine-carboximide linker (60,
Figure 17); 
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The newly synthesized conjugates will allow to understand whether using 
quinolines as a carrier has any advantage over 9-anilinoacridines.  It will also allow us to 
realize whether the urea or hydrazine-carboxamide spacers are able to reduce the 
reactivity of the reactive phenyl N-mustard pharmacophore. These conjugates can be 
considered as a single compound or they may be capable of releasing the active form of 
N-mustard and 4-aminoquinoline. The later may be further undergoing enzymatic 
hydrolysis (deamination) to yield the cytotoxic 2-substituted quinolin-4-one. Many 2-
substituted quinolones have been demonstrated to be a potent inhibitor of tubulin 
polymerization and exhibited significant antitumor activity.72-76 Thus, these compounds 
may also exhibit dual mechanism of actions, cross-linked to DNA and inhibit the tubulin 
polymerization. All the newly synthesized derivatives were subjected to antitumor 
evaluation against a variety of human tumor cell growth in vitro, therapeutic efficacy in 
vivo, and their capability of DNA interstrand cross-linking. 
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4.1 Chemistry 
The synthesis of newly designed N-mustards-quinoline conjugates having a urea 
linker were achieved by reacting of the known aniline N-mustard isocynate (65) with the 
corresponding 4-aminoquinolines (68a-m) as shown in scheme 2. The aniline N-mustard 
isocynate (65) was prepared from the known N,N-bis(2-chloroethyl)benzene-1,4-diamine 
dihydrochloride (86), which was prepared according to multi-step literature procedure77
with modification (Scheme 1). The commercially available 4-fluoronitrobenzene (61) was 
reacted with diethanolamine under refluxing to give 4-[N,N-bis(2-
hydroxyethyl)amino]nitrobenzene (62), which was then converted to 4-[N,N-bis(2-
chloroethyl)amino]nitrobenzene (63) by treating with thionyl chloride. Catalytic 
hydrogenation (10% Pd/C, H2) of compound 63 in ethyl acetate afforded N,N-bis(2-
chloroethyl)benzene-1,4-diamine (64), which was immediately treated with 2.5M HCl in 
ethyl acetate to yield aniline N-mustard hydrochloride salt (64). The hydrochloride salt 64
was then converted to isocyanate 6578 by treating with triphosgene in chloroform at –5 
oC. 4-Aminoquinolines (68a-m) used for the synthesis of 69a-m can be synthesized 
starting from quinolin-4-ones (66a-m) as shown in scheme 1. Quinoline-4-one(66a-m)
was synthesized by following the literature methods.72-76  cchlorination of quinolin-4-ones 
(66a-m) using phosphorus oxychloride (POCl3)79 furnished corresponding 4-
chloroquinolines 67a-m. Reaction of 67a-m with ammonia in phenol at 180 oC by 
following literature procedure80 gave corresponding 4-aminoquinolines (68a-m).  4-
aminoquinolines (68a-m) than reacted with the freshly prepared 65 in anhydrous DMF in 
presence of triethylamine afforded N-mustard-quinoline conjugates bearing urea linker 
69a-m in fair to good yield. The yields and physical properties of the newly sinthesized 
N-mustard conjugates are shown in Table 1. 
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Scheme 1. Synthetic route for the aniline N-mustard isocynate 
i ii
Reaction conditions: (i) NH(CH2CH2OH)2, 120 oC; (ii) SOCl2, pyridine, ref lux; (iii) 10% Pd/C, H2, 35 psi, 2 h, 2.5 M HCl in EA;
(iv) triphosgene/Et3N, -10 oC, 30 min.
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Scheme 2. Synthetic route for the N-mustard-quinoline conjugates via a urea linker. 
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Table 1. Yield and physical data table of the compounds 69a-m.
Compd. R1 R2
Yield
(%)
MP (oC)
Chemical 
Formula 
Analysis
69a Me H 85 174–1 75 C21H22Cl2N4O C, H, N 
69b Me 6-MeO 77 251–252 C22H24Cl2N4O2 C, H, N 
69c Me 6,7-(OCH2O) 58 271–272 C22H22Cl2N4O3 C, H, N 
69d Me 6-NMe2 65 267–268 C23H27Cl2N5O C, H, N 
69e Me 6-C4H8N 63 255–256 C25H29Cl2N5O C, H, N 
69f C6H5 H 73 194–195 C26H24Cl2N4O C, H, N 
69g C6H5 6,7-(OCH2O) 65 191–192 C27H24Cl2N4O3 C, H, N 
69h 3-MeO-C6H4 6-Cl 78 >300 C27H25Cl3N4O2 C, H, N 
69i 3-MeO-C6H4 6-MeO 74 255–256 C28H28Cl2N4O3 C, H, N 
69j 3-MeO-C6H4 6,7-(OCH2O) 69 202–203 C28H26Cl2N4O4 C, H, N 
69k 3-MeO-C6H4 6-C4H8N 78 166–167 C31H33Cl2N5O2 C, H, N 
69l 2-F-C6H4 6,7-(OCH2O) 80 188–189 C27H23Cl2FN4O3 C, H, N 
69m 2-F-C6H4 6-C4H8N 70 199–200 C30H30Cl2FN5O C, H, N 
All the synthesized compounds were characterized by using 1H NMR and 
Elemental analysis. For compounds 69a-m, the characteristic protons for methylenic 
proton (i.e., N(CH2CH2Cl) appeared at 3.7 ? ppm. The 1H NMR proton signals for the 
phenyl N-mustards residue appeared as doublet (ortho coupling, J = 8.8–9.0 Hz) at 6.7 
and 7.4 ? ppm. The characteristic peak for the urea linker (NHCONH) appeared at 8.8–
9.5 ? ppm as D2O exchangeable singlet. The elemental analysis of the newly synthesized 
derivatives was within ±0.4% range of the calculated C, H, N data.
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4.2 Biological Results and Discussion 
4.2.1 In vitro cytotoxicity
Table 2 shows the antiproliferative activities of the newly synthesized N-mustard-
quinoline conjugates (69a-m) against human lymphoblastic leukemia (CCRF-CEM) and 
its drug-resistant sublines (resistant to vinblastine and taxol, CCRF-CEM/VBL and 
CCRF-CEM/taxol, respectively). The IC50 value was compared with was compared with 
the aniline N-mustard (64), BO-0742 (53), BO-1051(57) and BO-1062 (58). It was 
revealed that these conjugates possessed significant cytotoxicity with IC50 values in 
submicro molar range and have little or no cross-resistance to either taxol or vinblastine, 
when comparing with the IC50 of the parent cell line. The following discussion of 
structure-activity relationship (SAR) is based on their in vitro cytotoxicity in inhibiting 
CCRF-CEM since this cell line has been used as a comparative standard for our drug 
discovery program. It depicted that the 2-methyl substituted conjugates are more potent 
than the corresponding 2-Ph, 2-(3-MeOPh) or 2-(2-FPh) substituted counter parts with 
exception of C-6 pyrrolidine derivatives 69e, suggesting that the bulky function at C-2 
may interfere the drug/DNA binding capability. In the series of 2-methyl substituted 
compounds the cytotoxicity of 69a is decreased by adding methoxy, methyldioxy or 
pyrolidine function at C-6 or C-6,7 (69b,c). Although addition of the C-6 dimethylamino 
function (69d) slightly increases the cytotoxicity, the C-6-pyrrolidinyl substituent, 
however, greatly decreases the cytotoxicity of 69a. Similar observation can be found in 2-
Ph, 2-(3-MeOPh) or 2-(2-FPh) conjugates.
To explore further, compound 69a, 69b, 69c, 69d, 69h, and 69i were selected to 
study their cell growth inhibitory effect against solid tumor such as breast carcinoma 
(MX-1) and colon carcinoma HCT-116. The cytotoxicity of the targeted compounds is 
summarized in Table 3. It demonstrated that the newly synthesized N-mustard-quinoline 
conjugates possess significant antitumor activity with IC50 in sub-micro molar range.  
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Table 2. The in vitro cytotoxicity of N-mustard-quinoline conjugates having urea 
linker (69a-m) against human lymphoblastic leukemia (CCRF-CEM) and its drug-
resistant sublines (CCRF-CEM/Taxol and CCRF-CEM/VBL).[a]
Compound 
Cell Growth Inhibition IC50 (μM)a
CCRF-CEM CCRF-CEM/Taxolb CCRF-CEM/VBLb
69a 0.193±0.004 0.429±0.009 [2.2×]c 0.664±0.014 [3.4×]
69b 0.309±0.057 0.313±0.006 [1.0×] 0.458±0.003 [1.5×]
69c 0.279±0.025 0.605±0.008 [2.2×] 0.652±0.027 [2.3×]
69d 0.107±0.023 0.308±0.001 [2.9×] 0.242±0.01 [2.3×]
69e 9.02±0.011 16.873±0.792 [1.87×] 12.931±0.018 [1.43×]
69f 1.686±0.024 1.462±0.115 [0.87×] 1.664±0.083 [0.99×]
69g 2.252±0.222 2.229±0.006 [0.99×] 1.837±0.036 [0.82×]
69h 1.88±0.43 1.104±0.066 [0.59×] 1.029±0.02 [0.55×]
69i 0.362±0.004 0.588±0.001 [1.62×] 0.557±0.006 [1.53×]
69j 2.816±0.788 1.961±0.055 [0.70×] 2.224±0.042 [0.79×]
69k 102.15±13.79 2.227±0.013 [0.02×] 774.46±8.625 [7.58×]
69l 3.087±0.508 2.607±0.011 [0.84×] 2.348±0.019 [0.76×]
69m 7.647±0.978 39.896±2.831 [5.22×] 12.423±0.588 [1.62×]
N-mustards (64) 0.0434±0.50 0.0338±0.40 [0.78×] 0.0257±0.10 [0.59×]
BO-0742 (53) 0.007±0.0015 0.034±0.0007[4.9×] 0.0075±0.004 [1.1×]
BO-1051 (57) 0.078±2.3 0.092±15.7 [1.18×] 0.128±2.2 [1.64×]
BO-1062 (58) 0.075±0.016 0.140±0.032 [1.9×]c 0.184±0.028 [2.5×]
Taxol 0.0031±0.0001 0.429±0.042 [330×] 1.274±0.052 [980×]
Vinblastine 0.00073±0.0009 0.078±0.011 [106.2×] 0.496±0.121 [679.5×]
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Table 3. The in vitro cytotoxicity of N-mustard-quinoline conjugates having urea 
linker (69a-m) against human solid tumor (breast carcinoma MX-1 and colon 
carcinoma HCT-116) cell growth in vitro.[a]
Compound 
Cell Growth Inhibition IC50 (μM) 
MX-1 HCT-116 
69a 0.343±0.006 1.423±0.126 
69b 0.645±0.007 0.83±0.033 
69c 0.584±0.008 0.402±0.014 
69d 0.184±0.001 0.3±0.008 
69h 2.246±0.059 4.88±0.007 
69i 1.832±0.036 3.689±0.040 
N-mustards (64) 0.0844±0.0017 0.341±0.0049
BO-0742 (53) 0.035±0.0006 0.0055±0.0012
BO-1051 (57) 0.240±0.0356 0.437±0.0018
BO-1062 (58) 0.099±0.004 0.568±0.037 
Taxol 0.046±0.0007 0.0011±0.0003 
Vinblastine 0.0022±0.0002 0.0011±0.0003 
[a]Cell growth inhibition was measured by the XTT assay[81] for leukemic cells and the SRB 
assay[82] for solid tumor cells after 72-h incubation using a microplate spectrophotometer as 
described previously.[83] IC50 values were determined from dose-effect relationship at six or seven 
concentrations of each drug by using the CompuSyn software by Chou and Martin[84] based on the 
median-effect principle and plot.[85,86] Ranges given for Taxol and Vinblastine were mean ± SE (n 
= 4).
[b] CCRF-CEM/Taxol and CCRF-CEM/VBL are subcell lines of CCRF-CEM cells that are 330-
fold resistant to Taxol, and 680-fold resistant to Vinblastine, respectively, when comparing with 
the IC50 of the parent cell line.  
[c] Numbers in the brackets are fold of cross-resistant determined by comparison with the 
corresponding IC50 of the parent cell line.
111
4.2.2 In Vivo Therapeutic Effect 
Based on the results of the in vitro cytotoxicity, solubility and toxicity to the host, 
compound 69a and 69i was selected for further antitumor evaluation in animal model. 
The administration of agent was carried out at the maximal tolerable dose via either 
intravenous infusion (i.v. infusion) or intravenous injection (i.v. injection) as indicated in 
somewhere else. Figure 18A and 18B showed the therapeutic effect of 69a and 69i in 
nude mice bearing human mammary carcinoma MX-1 xenograft. Under the experimental 
conditions as indicated, 69a and 69i (Figure 18A) achieved complete tumor remission 
(CR) at the dose of 150, and 100 mg/kg (Q2D×5, i.v. injection, n=3), respectively, against 
MX-1 xenograft in nude mice and maintained no relapse over 70 days. Although it 
showed that 69i was more toxic than 69a (Figure 18B), the body-weight of the mice 
recovered after discontinuation of the treatment.   
To understand whether the newly synthesized compounds are effective against 
human glioma xenograft in animal models, we studied the antitumor effect of 69i against 
glioma U87 MG xenograft in nude mice and compared that with cyclophosphamide since 
both are N-mustard derivatives (Figure 19AB).  It showed that 69i is more effective than 
cyclophosphamide at the dose of 150 and 80 mg/kg (Q2D×5, i.v. injection), respectively 
and yet had lower toxicity.
We further investigated the therapeutic efficacy of 69a (BO-1038) against human 
breast MCF-7/Adr xenograft and compared with gemcitamine, cyclophosphamide and 
taxol. As shown in Figures 20AB, it is clear to find that 69a is as potent as gemcitamine, 
but more effective than either Cyclophosphamide or Taxol with relatively lower toxicity 
among compounds tested.  
Compound 69a was also subjected for in vivo study against A549 lung carcinoma 
xenograft and compared with Taxol (Figures 21AB). It revealed that compound 69a is 
somewhat less effective than Taxol against at the dose of 100 and 30 mg/kg, respectively. 
It is noted that compound 69a was less toxic to the host when compare with taxol. 
Figure 22AB shows the antitumor effect of 69a in nude mice (n=4) bearing 
ovarian SK-OV-3 carcinoma xenograft. The therapeutic efficacy was also compared with 
cyclophosphamide and taxol. It is clear to distinguish that 69a is more effective than 
cyclophosphamide but less potent than taxol with relatively lower toxicity. 
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Finally, we chose 69a and N-mustard-AHMA conjugate having a urea linker BO-
1037 (N-mustard-9-anilinoacridine conjugates having a urea linker) for comparing their 
antitumor effects in MX-1 xenograft model (Figure 23AB). It clearly shows that both 
conjugates are able to induce CR at dose of 125 and 100 mg/kg, respectively, via 2 hr i.v. 
infusion.  Although, one out of three mice died from toxicity of BO-1037, during 
treatment, other treated mice recovered soon after the cessation of drug administration.    
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Figure 18. Therapeutic effect of 69a (150 mg/kg, i.v. inj., Q2Dx5, n=3), and 69i (100 
mg/kg, i.v. inj., Q2Dx5, n=3) in nude mice bearing human mammary carcinoma MX-1 
xenograft; average tumor size changes (Figure 18A) and average body weight changes 
(Figure 18B).   
Fig. 18A 
Fig. 18B 
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Figure 19. Therapeutic effect of 69i (150 mg/kg, i.v. inj., Q2Dx5, n=3), and 
cyclophosphamide (100 mg/kg, i.v. inj., Q2Dx5, n=3) in nude mice bearing human 
glioma U87 MG xenograft; average tumor size changes (Figure 19A) and average body 
weight changes (Figure 19B).
Fig. 19A 
Fig. 19B 
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Figure 20. Therapeutic effect of 69a (100 mg/kg, i.v. inj., QDx6, n=3), gemcitabine (40 
mg/kg, i.v. inj., Q2Dx4, n=3), cyclophosphamide (80 mg/kg, i.v. inj., Q2Dx3, n=3), and 
taxol (30 mg/kg, i.v. inj., Q2Dx4, n=3), in nude mice bearing human breast MCF-7/Adr 
xenograft; average tumor size changes (Figure 20A) and average body weight changes 
(Figure 20B).   
Fig. 20A 
Fig. 20B 
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Figure 21. Therapeutic effect of 69a (100 mg/kg, i.v. inj., Q2Dx8, n=4), and taxol (30 
mg/kg, i.v. inj., Q2Dx5, n=4), in nude mice bearing human A549 lung carcinoma 
xenograft; average tumor size changes (Figure 21A) and average body weight changes 
(Figure 21B).  
Fig. 21A 
Fig. 21B 
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Figure 22. Therapeutic effect of 69a (120 mg/kg, i.v. inj., Q2Dx3, n=4), 
cyclophosphamide (80 mg/kg, i.v. inj., Q2Dx3, n=4), and taxol (25 mg/kg, i.v. inj., 
Q2Dx3, n=3), in nude mice bearing human ovarian SK-OV-3 carcinoma xenograft; 
average tumor size changes (Figure 22A) and average body weight changes (Figure 22B).
Fig. 22A 
Fig. 22B 
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Figure 23. Therapeutic effect of 69a (150 mg/kg, i.v. infusion, Q2Dx5, n=3), and BO-
1037 (100 mg/kg, i.v. infusion, Q2Dx5, n=3) in nude mice bearing human mammary 
carcinoma MX-1 xenograft; average tumor size changes (Figure 23A) and average body 
weight changes (Figure 23B).
Fig. 23A 
Fig. 23B 
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4.2.3 Inhibition of Biosynthesis of DNA, RNA and Protein by 69a 
Figure 24 shows the time course of inhibition of biosynthesis of DNA, RNA and 
protein by 69a. [3H]Thymidine (1 μCi), [3H]adenosine (1 μCi) and [3H]leucine (2 μCi)
were used as the tracers for incorporation into DNA, RNA and protein, respectively. Each 
1 mL incubation mixture contained 5.2×105 MX-1 cells, and 10 μM or 10 μM of 69a.
Incubation was terminated at each time points as indicated. For details of the method see 
literature procedure.87 As shown in Figure 24, the degrees of inhibiting biosynthesis of 
DNA and RNA for 69a were maximized at 50-80%. The half-maximal inhibition was 
reached within 15-30 min and persisted for over 6-24 hrs. The protein synthesis inhibition 
by 69a was at similar degree as RNA synthesis inhibition which ranged 40-80% 
inhibition.
Figure 24. Inhibition of biosynthesis of DNA, RNA and protein by 69a at the 
concentration of 10 μM.
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4.2.4 DNA Interstrand Cross-Linking Study 
To understand whether the newly synthesized derivatives are able to cross-link to 
DNA double-strands, compound 69a was selected as the representative compound for 
modified single cell gel electrophoresis assay (modified comet assay).88,89 DNA cross-
linking agent melphalan was chosen as a positive control.  The modified comet assay is 
based on the property of negatively charged DNA fragments migration when electric field 
is applied to the gel after cell lysis.90 Human non-small lung carcinoma H1299 cells were 
treated with 69a and Melphalan at various concentrations breaks. The irradiated cells 
were then subjected to modified comet assay. The results showed that 69a was capable of 
inducing DNA interstrand cross-linking in a dose-dependent manner (Fig. 25). At the 
dose of 10 μM, this agent induced 31.3 % DNA cross-linking, while, melphalan induced 
39.7% DNA cross-linking at the dose of 200 μM under the same experimental conditions. 
The results suggested that DNA interstrand cross-linking may be the main mechanism of 
action of 69a and the related compounds. 
Figure 25.  Induction of DNA interstrand cross-linking in H1299 cells by N-mustard-
quinoline having a urea linker 69a and Melphalan measured by the modified comet assay. 
The experiments were performed in duplicate and repeated three times. Data points 
represent the mean±SE of each test condition. 
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4.2.5 Chemical Stability in Rat Plasma 
Naval et al.69,70 previous reported that urea or carbamate linker  in phenyl N-
mustard-9-anilinoacridine conjugates are able decrease the reactivity of the reactive N-
mustard pharmacophore. Thus these conjugates are stable and have a long half-life. To 
realize whether newly synthesized compounds are chemically stable or not, compound 
69a was selected for its chemical stability in rat plasma. The result showed that 69a is 
also a chemically stable N-mustard derivative in rat plasma with a long half-life (t1/2 =
16.48±3.68 h, n = 3) indicating that the newly prepared N-mustards are chemically and 
metabolically stable derivatives.  
4.3 Conclusion
In conclusion, synthesis and analysis of chemically stable DNA-directed 
alkylating agents, in which the phenyl N-mustard residue is, linked to DNA minor groove 
binder quinolines via a urea spacer. In the light of the discussions made from the results 
obtained for the new N-mustards conjugates 69a-m, it can be concluded that all of them 
have displayed significant anti-tumor activity in vitro and exhibited potent therapeutic 
efficacy in vivo with relatively low toxicity. Among these derivatives, compound 69a and 
69i was revealed to have potent antitumor effect in nude mice bearing human breast MX-
1 xenograft; complete remission was achieved and maintained for over 70 days without 
any relapse. Compound 69i also effectively suppressed human glioma U87 MG xenograft 
in nude mice. Moreover, compound 69a also exhibited significant curative effect against 
human breast MCF-7/Adr xenograft, A549 lung carcinoma xenograft, and ovarian SK-
OV-3 carcinoma xenograft in nude mice.  At their optimum doses, the compounds are 
well-tolerated by the host as reflected from body weight change. Moreover, 69a is able to 
cross-link with DNA and has a long half-life in rat plasma. All the above data support the 
excellent chemotherapeutic efficacy and potential candidature of 69a for further drug 
development.
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4.4 Experimental Section 
Melting points were determined on a Fargo melting point apparatus and are 
uncorrected. Column chromatography was carried out on silica gel G60 (70-230 mesh, 
ASTM; Merck and 230-400 mesh, Silicycle Inc.). Thin-layer chromatography was 
performed on silica gel G60 F254 (Merck) with short-wavelength UV light for 
visualization. Elemental analyses were done on a Heraeus CHN-O Rapid instrument. 
HPLC was performed on Waters Delta Prep4000 using Mightysil RP-18 reverse phase 
column (250×4.6 mm). Compounds were detected by UV at 260 nm. The mobile phase 
was MeCN:H2O (80:20 v/v) with flow rate 1 mL/min. 1H NMR spectra were recorded on 
a 600 MHz, Bruker AVANCE 600 DRX and 400 MHz, Bruker Top-Spin spectrometers. 
The chemical shifts were reported in ppm (δ) relative to TMS. 
Synthesis of Aniline Nitrogen mustard 
2-[(2-Hydroxyethyl)-(4-nitrophenyl)amino]ethanol (62).77 A mixture of p-flouro
nitrobenzene (61, 28.0 g, 198 mmol) and diethanolamine (30.0 g, 285 mmol) was heated 
at 120 oC for 2 h. The reaction mixture was cooled to 60 oC and an aqueous solution of 
0.6 % NaOH (900 mL) was added slowly into the mixture. The separated yellow 
precipitate was collected by filtration, washed well with water, and dried to 62, yield: 
42.6 g (95%); mp 104–105 oC (lit.77 103–104 oC); 1H NMR (CHCl3-d6) δ 3.55–3.62 (8H, 
m, 4×CH2), 4.88 (2H, t, J = 4.4 Hz, exchangeable 2×OH), 6.81 (2H, d, J = 9.5 Hz, 
2×ArH), 8.01 (2H, d, J = 9.5 Hz, 2×ArH).
Bis(2-chloroethyl)-(4-nitrophenyl)amine (63).77 To a mixture of 2-[(2-hdroxyethyl)-(4- 
nitrophenyl)amino]ethanol (62, 16.0 g, 71 mmol) in dry dichloromethane (200 mL) 
containing dry pyridine (10.0 mL) was added dropwise thionylchloride (14.0 mL) at 0 oC. 
The reaction mixture was heated with stirring at refluxed for 3 h and then cooled to room 
temperature.  The mixture was diluted with dichloromethane (100 mL), carefully washed 
with water, 10% KHSO4 solution (100 mL) and brine (100 mL). The organic layer was 
dried over Na2SO4, and evaporated to dryness under reduce pressure to give 63, yield 
16.7 g (89%); mp 91–93 oC (lit.77 92–94 oC) 1H NMR (CHCl3-d6) δ 3.81 (4H, t, J = 6.6 
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Hz, 2×CH2), 3.89 (4H, t, J = 6.6 Hz, 2×CH2), 6.93 (2H, d, J = 9.5 Hz, 2×ArH), 8.07 (2H, 
d, J = 9.5 Hz, 2×ArH).
N,N-Bis(2-chloroethyl)benzene-1,4-diamine hydrochloride (64).77 A mixture bis(2-
chloroethyl)-(4-nitrophenyl)amine (63, 10.0 g, 38 mmol) in ethyl acetate (100 mL) and 10 
% Pd/C (1.0 g) was sonicated for 5 min.  The mixture was then hydrogenated (H2) at 35 
psi for 2 h. and monitored by TLC (SiO2, ethyl acetate/Hexane: 1:1 v/v). After 
completion of reaction, the reaction mixture was filtered through a pad of celite and the 
filtrate was cooled to 0 oC.  A solution of 2.5M HCl in ethyl acetate (20.0 mL) was slowly 
added into the filtrate with stirring. The white solid separated was collected by filtration 
and dried to give 64, yield: 9.18 g (80%), mp 212–214 oC (lit.77 213–215 oC); 1H
NMR(DMSO-d6) δ 3.92 (8H, s, 4×CH2), 6.83 (2H, d, J = 8.8 Hz, 2×ArH), 7.24 (2H, d, J
= 8.8 Hz, 2×ArH), 10.2 (2H, brs, exchangeable, NH2).
Synthesis of 4-chloroquinolines (67b-m)
4-Chloro-2-methyl-6-quinolinyl methyl ether (67b). To a solution of phosphorus 
oxychloride (80 mL) was added portionwise 6-methoxy-2-methyl-4(1H)-quinolinone91
(66b, 17.5 g, 92.49 mmol) at 0 oC. After being stirred for 30 min at room temperature, the 
reaction mixture was heated at 80 °C for 30 min. The excess phosphorus oxychloride was 
removed by vacuum distilation. The residue was poured slowly onto a mixture of crushed 
ice and saturated NaHCO3 solution with vigorous stirring. The pH of the solution was 
adjusted to about 9.0 by addition of ammonium hydroxide. The solid separated out was 
collected by filtration, dried and then recrystallized from CHCl3/hexane to give 67b,
18.15 g (94%); mp 109–111 oC (lit.92 104–106 oC); 1H NMR (DMSO-d6) ? 7.91–7.90 
(1H, m, ArH), 7.62 (1H, s, ArH), 7.47–7.45 (1H, m, ArH), 7.37–7.36 (1H, m, ArH), 3.94 
(3H, s, OMe), 2.61 (3H, s, Me). MS (EI) m/z: 206.9 (M+). 
By following the same procedure, the following compounds were synthesized. 
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8-Chloro-6-methyl[1,3]dioxolo[4,5-g]quinoline (67c). Compound 67c was prepared 
from 6-methyl[1,3]dioxolo[4,5-g]quinolin-8(5H)-one93 (66c, 17.0 g, 83.65 mmol). Yield 
was 17.12 g (92%); mp 130–131 oC (lit.93 129–131 oC); 1H NMR (DMSO-d6) ? 7.45 (1H, 
s, ArH), 7.38 (1H, s, ArH), 7.32 (1H, s, ArH), 6.25 (2H, s, CH2), 2.56 (3H, s, Me). MS 
(EI) m/z: 220.9 (M+). 
N-(4-Chloro-2-methyl-6-quinolinyl)-N,N-dimethylamine (67d). Compound 67d was 
prepared from 6-(dimethylamino)-2-methyl-4(1H)-quinolinone94 (66d, 16.0 g, 79.11 
mmol). Yield was 14.8 g (85%); mp 95–97 oC (lit.94 92–93 oC); 1H NMR (DMSO-d6) ?
7.81–7.80 (1H, m, ArH), 7.49–7.47 (2H, m, 2×ArH), 6.93 (1H, s, ArH), 3.05 (each 3H, s, 
2×Me), 2.56 (3H, s, Me). MS (EI) m/z: 220 (M+). 
4-Chloro-2-methyl-6-(pyrrolidin-1-yl)quinoline (67e). Compound 67e was prepared 
from 2-methyl-6-(pyrrolidin-1-yl)quinolin-4(1H)-one93 (66e, 10.35 g, 45.34 mmol). Yield 
was 9.22 g (82%); mp 125–126 oC; 1H NMR (DMSO-d6) ? 7.74 (1H, d, J = 9.2 Hz, 
ArH),7.29–7.27 (2H, m, 2×ArH), 6.67 (1H, d, J = 2.4 Hz, ArH), 3.40–3.39 (4H, m, 
2×CH2), 2.57 (3H, s, Me), 2.04–2.01 (4H, m, 2×CH2). Anal. Calcld. for (C14H15ClN2): C, 
H, N.  
4-Chloro-2-phenylquinoline (67f). Compound 67f was prepared from 2-phenylquinolin-
4(1H)-one72 (66f, 5.0 g, 2.26 mmol). Yield was 4.89 g (90%); mp 62–63 oC (lit.95 92–93 
oC); 1H NMR (DMSO-d6) ? 8.40 (1H, s, ArH), 8.33–8.31 (2H, m, 2×ArH), 8.21 (1H, d, J
= 8.2 Hz, ArH), 8.16 (1H, d, J = 8.4 Hz, ArH), 7.93–7.89 (1H, m, ArH), 7.78–7.74 (1H, 
m, ArH), 7.60–7.54 (3H, m, 3×ArH). MS (EI) m/z: 239 (M+). 
8-Chloro-6-phenyl-[1,3]dioxolo[4,5-g]quinoline (67g). Compound 67g was prepared 
from 6-phenyl-[1,3]dioxolo[4,5-g]quinolin-8(5H)-one73 (66g, 4.0 g, 15.80 mmol). Yield 
was 3.0 g (70%); mp 136–137 oC; 1H NMR (DMSO-d6) ? 8.20–8.21 (2H, d, J = 6.88 Hz, 
2×ArH), 8.10 (1H, s, ArH), 7.47–7.55 (3H, m, 3×ArH), 7.39–7.40 (2H, d, J = 6.36 Hz, 
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2×ArH), 6.26 (2H, s, CH2). MS (EI) m/z: 283 (M+) Anal. Calcld. for (C16H10ClNO2): C, 
H, N.
4,6-Dichloro-2-(3-methoxyphenyl)quinoline (67h). Compound 67e was prepared from 
6-chloro-2-(3-methoxyphenyl)-4(1H)-quinolinone73 (66f, 6.94 g, 24 mmol). Yield, 7.22 g 
(98%); mp 132–133 oC; 1H NMR (CDCl3) ? 8.20–8.29 (1H, m, ArH), 8.13–8.12 (1H, s, 
ArH), 7.97 (1H, s, ArH), 7.72–7.65 (3H, m, 3×ArH), 7.45–7.42 (1H, m, ArH), 7.05–7.03 
(1H, m, ArH), 3.93 (3H, s, OMe). Anal. Calcd. for (C16H11Cl2NO): C, H, N. 
4-Chloro-6-methoxy-2-(3-methoxyphenyl)quinoline (67i). Compound 67i was prepared 
from 6-methoxy-2-(3-methoxyphenyl)-4(1H)-quinolinone73 (66i, 5.63 g, 20 mmol). 
Yield, 5.94 g (99%); mp 106–107 oC; 1H NMR (CDCl3) ? 8.07 (1H, d, J = 8.8 Hz, ArH), 
7.92 (1H, s, ArH), 7.71 (1H, t, J = 1.5 Hz, ArH), 7.64 (1H, d, J = 8.1 Hz, ArH), 7.45–7.40 
(3H, m, 3×ArH), 7.00 (1H, m, ArH), 3.93 and 3.99 (each 3H, s, 2×OMe). Anal. Calcd. for 
(C17H14ClNO2): C, H, N. 
8-Chloro-6-(3-methoxyphenyl)-[1,3]dioxolo[4,5-g]quinoline (67j). Compound 67j was
prepared from 6-(3-methoxy phenyl)-6,7-dihydro-[1,3]dioxolo[4,5-g]quinolin-8(5H)-
one73 (66j, 8.5 g, 28.78 mmol). Yield 7.5 g (83%); mp 145–146 oC; 1H NMR (DMSO-d6)
? 8.17 (1H, s, ArH), 7.80–7.77 (2H, t, J = 10.0 Hz, 2×ArH), 7.45–7.44 (3H, t, J = 12.0 
Hz, 3×ArH), 7.06–7.05 (1H, d, J = 6.64 Hz, ArH), 6.28 (2H, s, CH2), 3.87 (3H, s, OMe). 
MS (EI) m/z: 313 (M+). Anal. Calcld. for (C17H12ClNO3): C, H, N. 
4-Chloro-2-(3-methoxyphenyl)-6-(pyrrolidin-1-yl)quinoline (67k). Compound 67k
was prepared from 2-(3-methoxyphenyl)-6-(pyrrolidin-1-yl)quinolin-4(1H)-one75 (66k,
8.2 g, 25.59 mmol). Yield 4.16 g (70%); mp 131–132 oC; 1H NMR (DMSO-d6) ? 8.16 
(1H, s, ArH), 7.91 (1H, d, J = 9.2 Hz, ArH), 7.79–7.77 (2H, m, ArH), 7.2 (1H, t, J = 8.0 
Hz, ArH), 7.30–7.27 (1H, m, ArH), 7.03–7.00 (1H, m, ArH), 6.74 (1H, s, ArH), 3.87 (3H, 
s, OMe), 3.36 (4H, s, 2×CH2), 1.99 (4H, s, 2×CH2). MS (EI) m/z: 338 (M+) Anal. Calcld. 
for (C16H9ClNO2): C, H, N. 
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8-Chloro-6-(2-fluorophenyl)-[1,3]dioxolo[4,5-g]quinoline (67l). Compound 67l was 
prepared from 6-(2-fluorophenyl)-6,7-dihydro-[1,3]dioxolo[4,5-g]quinolin-8(5H)-one73
(66l, 6.4 g, 22.43 mmol). Yield 5.09 g (73%); mp 146–147 oC; 1H NMR (DMSO-d6) ?
8.03–7.99 (1H, m, ArH), 7.88–7.87 (1H, d, J = 1.4 Hz, ArH), 7.57–7.52 (1H, m, ArH), 
7.47–7.46 (2H, d, J = 1.9 Hz, 2×ArH), 7.40–7.36 (2H, m, 2×ArH), 6.30 (2H, s, CH2). MS 
(EI) m/z: 301 (M+). Anal. Calcld. for (C16H9ClNO2): C, H, N. 
4-Chloro-2-(2-fluorophenyl)-6-(pyrrolidin-1-yl)quinoline (67m). Compound 67m was 
prepared from 2-(2-fluorophenyl)-6-(pyrrolidin-1-yl)quinolin-4(1H)-one76 (66m, 6.2 g, 
20.1 mmol). Yield was 5.76 g (88%); mp 131–132 oC; 1H NMR (DMSO-d6) ? 8.10–7.99 
(1H, m, ArH), 7.99 (1H, d, J = 9.2 Hz, ArH), 7.88 (1H, d, J = 2.1 Hz, ArH), 7.38–7.34 
(1H, m, ArH), 7.30–7.28 (1H, m, ArH), 7.26–7.22 (1H, m, ArH), 7.19–7.14 (1H, m, 
ArH), 6.92 (1H, d, J = 2.6 Hz, ArH), 3.48–3.45 (4H, m, 2×CH2), 2.10–2.07 (4H, m, 
2×CH2). Anal. Calcld. for (C19H9ClFN2): C, H, N. 
Synthesis of 4-aminoquinolines (68b-f) 
6-Methoxy-2-methyl-4-quinolinamine (68b). A mixture of 4-chloro-2-methyl- 6-
quinolinyl methyl ether (67b, 10.35 g, 49.8 mmol) and phenol (40 g) was heated at 180 
oC for 1h. A slow stream of ammonia was passed through the reaction mixture at 180 oC
for 5 h. After cooling to room temperature, the mixture was poured into 10% NaOH 
aqueous solution. The solid separated was collected by filtration, washed with water and 
dried to give 68d; 5.66 g (82%); mp 215–216 oC (lit.95 207–208 oC); 1H NMR (DMSO-d6)
? 7.59 (d, J = 9.1 Hz, 1H, ArH), 7.46 (d, J = 2.7 Hz, 1H, ArH), 7.20 (dd, J = 2.7 and 9.1 
Hz, 1H, ArH), 6.47 (brs, 2H, NH2, exchangeable), 6.40 (s, 1H, ArH), 3.85 (s, 3H, OMe), 
2.38 (s, 3H, Me). 
By following the same reaction procedure, the following compounds were synthesized. 
6-Methyl[1,3]dioxolo[4,5-g]quinolin-8-amine (68c). Compound 68c was prepared from 
8-chloro-6-methyl[1,3]dioxolo[4,5-g]quinoline (67c, 4.44 g, 20 mmol). Yield, 3.34 g 
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(83%); mp 277–279 oC; 1H NMR (DMSO-d6) ? 7.45 (s, 1H, ArH), 7.03 (s, 1H, ArH), 
6.32 (s, 1H, ArH), 6.30 (brs, 2H, NH2, exchangeable), 6.09 (s, 2H, CH2), 2.33 (s, 3H, 
Me). Anal. Calcd. for (C11H10N2O2): C, H, N. 
N6,N6,2-Trimethyl-4,6-quinolinediamine (68d). Compound 68d was prepared from N-
(4-chloro-2-methyl-6-quinolinyl)-N,N-dimethylamine (67d, 6.63 g, 30 mmol). Yield, 5.84 
g (95%); mp 198–200 oC (lit.94 201–203 oC); 1H NMR (DMSO-d6) ? 7.52 (d, J = 9.2 Hz, 
1H, ArH), 7.23 (dd, J = 2.6 and 9.2 Hz, 1H, ArH), 7.03 (d, J = 2.5 Hz, 1H, ArH), 6.33 (s, 
1H, ArH), 6.30 (brs, 2H, NH2, exchangeable), 2.96 (s, 6H, N-Me2), 2.34 (s, 3H, Me). 
2-Methyl-6-(pyrrolidin-1-yl)quinolin-4-amine (68e). Compound 68e was prepared 
from 4-chloro-2-methyl-6-(pyrrolidin-1-yl)quinoline (67e, 6.63 g, 30 mmol). Yield, 5.84 
g (95%); mp 235–2236 oC (lit94 265 oC); 1H NMR (DMSO-d6) ? 7.67 (d, J = 9.2 Hz, 1H, 
ArH), 7.35–7.33 (m, 2H, ArH), 6.69 (d, J = 2.4 Hz, 1H, ArH), 6.37 (brs, 2H, NH2,
exchangeable), 3.49–3.47 (m, 4H, 2×CH2), 2.57 (s, 3H, Me), 2.10–2.08 (m, 4H, 2×CH2).
2-Phenylquinolin-4-amine (68f). Compound 68f was prepared from 4-chloro-2-
phenylquinoline (67f, 4.794 g, 20 mmol). Yield was 4.32 g (98%); mp 172–174 (lit. mp 
166–168);96 1H NMR (DMSO-d6) δ 8.16 (d, J = 8.0 Hz, 1H, ArH), 8.09 (d, J = 7.2 Hz, 
1H, ArH), 7.84 (d, J = 8.4 Hz, 1H, ArH), 7.64–7.60 (m, 1H, ArH), 7.53–7.49 (m, 2H, 
ArH), 7.46–7.40 (m, 1H, ArH), 7.39–7.37 (m, 1H, ArH), 7.13 (s, 1H, ArH), 6.83 (s, 2H, 
NH2, exchangeable).  
6-Phenyl-[1,3]dioxolo[4,5-g]quinolin-8-amine (68g). Compound 68g was prepared from 
8-chloro-6-phenyl-[1,3]dioxolo[4,5-g]quinoline (67g, 2.83 g, 10 mmol). Yield was 1.98 g 
(75%); mp 198–199 oC; 1H NMR (DMSO-d6) δ 8.02 (d, J = 7.6 Hz, 2H, ArH), 7.57 (s, 
1H, ArH), 7.47 (t, J = 7.2 Hz, 2H, ArH), 7.42–7.38 (m, 1H, ArH), 7.19 (s, 1H, ArH), 7.02 
(s, 1H, ArH), 6.52 (s, 2H, NH2, exchangeable), 6.15 (s, 2H, CH2). Anal. Calcld. for 
(C16H12N2O2): C, H, N. 
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6-Chloro-2-(3-methoxyphenyl)-4-quinolinamine (68h). Compound 68h was prepared 
from 4,6-dichloro-2-(3-methoxyphenyl)quinoline (67h, 6.5 g, 21 mmol). Yield 5.66 g 
(93%); mp 174–176 oC; 1H NMR (DMSO-d6) ? 8.30 (d, J = 1.9 Hz, 1H, ArH), 7.86 (d, J
= 8.9 Hz, 1H, ArH), 7.66–7.62 (m, 3H, ArH), 7.43 (t, J = 7.9 Hz, 1H, ArH), 7.16 (s, 1H, 
ArH), 7.03 (dd, J = 2.4 and 8.1 Hz, 1H, ArH), 6.97 (2H, brs, NH2, exchangeable), 3.86 (s, 
3H, OMe). Anal. Calcd. for (C16H13ClN2O): C, H, N. 
6-Methoxy-2-(3-methoxyphenyl)-4-quinolinamine (68i). Compound 68i was prepared 
from 4-chloro-6-methoxy-2-(3-methoxyphenyl)quinoline (67i, 5.90 g, 19.6 mmol). Yield 
5.31 g (96%); mp 148–149 oC; 1H NMR (DMSO-d6) ? 7.77 (d, J = 8.8 Hz, 1H, ArH), 
7.64 (t, J = 2.2 Hz, 1H, ArH), 7.61 (d, J = 8.1 Hz, 1H, ArH), 7.53 (d, J = 2.9 Hz, 1H, 
ArH), 7.40 (t, J = 8.1 Hz, 1H, ArH), 7.28 (dd, J = 2.9 and 8.8 Hz, 1H, ArH), 7.10 (s, 1H, 
ArH), 7.00 (dd, J = 2.9 and 8.1 Hz, 1H, ArH), 6.67 (s, 2H, NH2, exchangeable), 3.90 (s, 
3H, OMe), 3.85 (s, 3H, OMe). Anal. Calcd. for (C17H16N2O2): C, H, N. 
6-(3-Methoxyphenyl)-[1,3]dioxolo[4,5-g]quinolin-8-amine (68j). Compound 68j was 
prepared from 8-chloro-6-(3-methoxyphenyl)-[1,3]dioxolo[4,5-g]quinoline (67j, 6.27 g, 
20 mmol). Yield was  5.263 g (89%); mp 219–221 oC; 1H NMR (DMSO-d6) δ 7.65–7.60 
(m, 3H, ArH), 7.40–7.37 (m, 1H, ArH), 7.19 (s, 1H, ArH), 7.01–6.97 (m, 2H, ArH), 6.52 
(s, 2H, NH2, exchangeable), 6.14 (s, 2H, CH2), 3.84 (s, 1H, OMe). Anal. Calcld. for 
(C17H14N2O3): C, H, N. 
2-(3-Methoxyphenyl)-6-(pyrrolidin-1-yl)quinolin-4-amine (68m). Compound 68k was 
prepared from 4-chloro-2-(3-methoxyphenyl)-6-(pyrrolidin-1-yl)quinoline (67k, 3.39 g, 
10 mmol). Yield was 2.69 g (84%); mp 152–153 oC; 1H NMR (DMSO-d6) δ 7.70 (d, J = 
7.2 Hz, 1H, ArH), 7.99–7.94 (m, 2H, ArH), 7.37 (t, J = 6.4 Hz, 1H, ArH), 7.02 (s, 1H, 
ArH), 6.94 (d, J = 6.4 Hz, 1H, ArH), 6.88 (s, 1H, ArH), 6.75 (d, J = 5.2 Hz, 1H, ArH), 
6.43 (s, 2H, NH2, exchangeable), 3.84 (s, 3H, OMe), 3.36 (m, 4H, 2×CH2), 2.01 (m, 4H, 
2×CH2). Anal. Calcld. for (C20H21N3O): C, H, N. 
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6-(2-Flourophenyl)-[1,3]dioxolo[4,5-g]quinolin-8-amine (68l). Compound 68l was 
prepared from 8-chloro-6-(2-fluorophenyl)-[1,3]dioxolo[4,5-g]quinoline (67l, 6.21 g, 20 
mmol). Yield was  4.91 g (87%); mp 213–214 oC; 1H NMR (DMSO-d6) δ 7.98–7.94 (m, 
1H, ArH), 7.58 (s, 1H, ArH), 7.45–7.42 (m, 1H, ArH), 7.32–7.27 (m, 2H, ArH), 7.18 (s, 
1H, ArH), 6.92–6.91 (m, 1H, ArH), 6.59 (s, 2H, NH2, exchangeable), 6.15 (s, 2H, CH2). 
Anal. Calcld. for (C16H11FN2O2): C, H, N. 
2-(2-Fluorophenyl)-6-(pyrrolidin-1-yl)quinolin-4-amine (68m). Compound 68m was 
prepared from 4-chloro-2-(2-fluorophenyl)-6-(pyrrolidin-1-yl)quinoline (67m, 4.90 g, 15 
mmol). Yield was 4.27 g (92%); mp 141–142 oC; 1H NMR (DMSO-d6) δ 7.99–7.94 (m, 
1H, ArH), 7.68 (d, J = 9.2 Hz, 1H, ArH), 7.42–7.39 (m, 1H, ArH), 7.31–7.25 (m, 2H, 
ArH), 7.18–7.12 (m, 1H, ArH), 6.91–6.88 (m, 2H, ArH), 6.47 (s, 2H, NH2,
exchangeable), 3.39–3.34 (m, 4H, 2×CH2), 2.03–2.00 (m, 4H, 2×CH2). Anal. Calcld. for 
(C19H18FN3): C, H, N. 
General procedure for the preparation of 69a-m
A solution of known 4-[N,N-bis(2-chloroethyl)amino]phenylisocyanate (65)78 [freshly 
prepared from N,N-bis(2-chloroethyl)benzene-1,4-diamine hydrochloride (64,77 1.7
equivalent) by treating with triphosgene (0.5 equivalent) in presence of TEA at –10 oC.]
in dry DMF was added dropwise to a solution of appropriate 4-aminoquinoline (68a-m,
1.0 equivalent) in dry DMF containing Et3N (1.5 to 4 equivalent) at room temperature. 
The reaction was monitered by thin-layer chromatography (SiO2, solvent: CHCl3/MeOH,
about 10:1 v/v). After the completion of the reaction (1.5–5 h), the reaction mixture was 
evaporated to dryness in vacuo. The desired product 69a-m was purified either by liquid 
column chromatography (SiO2, solvent: CHCl3) or recrystallization. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-(2-methyl-4-quinolinyl)urea (69a).  
Compound 69a was prepared from 4-aminoquinoline (68a, 0.47 g, 3 mmol) and 
isocyanate (65) [freshly prepared from N,N-bis(2-chloroethyl)benzene-1,4-diamine 
hydrochloride (64,77 1.68 g, 5.4 mmol). Yield, 1.06 g (85%); mp 174–175 oC; 1H NMR 
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(CHCl3-d6) δ 8.40 (brs, 1H, exchangeable, NH), 8.14 (s, 1H, ArH), 7.92 (d, J = 8.5 Hz, 
2H, ArH), 7.44–7.56 (m, 2H, ArH), 7.26 (s, 1H, ArH), 7.21 (d, J = 8.8 Hz, 2H, ArH), 
7.12–7.14 (m, 1H, ArH), 6.56 (d, J = 7.9 Hz, 2H, ArH), 3.66 (t, J = 6.6 Hz, 4H, 2×CH2), 
3.57 (t, J = 6.6 Hz, 4H, 2×CH2,), 2.63 (s, 3H, Me). Anal. Calcd. for (C21H22Cl2N4O): C, 
H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-(6-methoxy-2-methyl-4-quinolinyl)urea 
(69b). Compound 69b was prepared from 6-methoxy-2-methyl-4-quinolinamine (68b,
1.07 g, 5.31 mmol) and isocyanate 65 (freshly prepared from 64, 2.81 g, 9 mmol). Yield 
was 1.78 g (77%); mp 251–252 oC; 1H NMR (DMSO-d6) δ 9.31 (brs, 1H, NH, 
exchangeable), 9.21 (brs, 1H, NH, exchangeable), 8.17 (s, 1H, ArH), 7.82 (d, J = 9.1 Hz, 
1H, ArH), 7.63 (s, 1H, ArH), 7.44 (dd, J = 2.3 and 9.1 Hz, 1H, ArH), 7.38 (d, J = 8.9 Hz, 
2H, ArH), 6.76 (d, J = 8.9 Hz, 2H, ArH), 3.98 (s, 3H, OMe), 3.72–3.73 (m, 8H, 4×CH2),
2.58 (s, 3H, Me). Anal. (C22H24Cl2N4O2): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-(6-methyl[1,3]dioxolo[4,5-g]quinolin-8-
yl)urea (69c).  Compound 69c was prepared from 6-methyl[1,3]dioxolo[4,5-g]-quinolin-
8-amine (68c, 1.01 g, 5 mmol) and isocyanate 65 (freshly prepared from 64, 2.81 g, 9 
mmol). Yield, 1.35 g (58%); mp 271–272 oC; 1H NMR (DMSO-d6) δ 2.54 (s, 3H, Me), 
3.71 (m, 8H, 4×CH2), 6.23 (s, 2H, CH2), 6.76 (d, J = 8.9 Hz, 2H,  ArH), 7.25 (s, 1H, 
ArH), 7.35 (d, J = 8.9 Hz, 2H, ArH), 7.71 (s, 1H, ArH), 8.08 (s, 1H, ArH), 9.15. Anal. 
(C22H22Cl2N4O3): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-[6-(dimethylamino)-2-methyl-4-
quinolinyl]urea (69d).  Compound 69d was prepared from N6,N6,2-trimethyl-4,6- 
quinolinediamine (68d, 1.03 g, 5 mmol) and isocyanate 65 (freshly prepared from 64,
2.89 g, 9 mmol). Yield, 1.53 g (65%); mp 267–268 oC; 1H NMR (DMSO-d6) δ 10.27 (1H, 
brs, NH, exchangeable), 9.98 (1H, brs, NH, exchangeable), 8.33 (s, 1H, ArH), 7.82 (d, J =
9.4 Hz, 1H, ArH), 7.55–7.58 (m, 1H, ArH), 7.44 (s, 1H, ArH), 7.40 (d, J = 8.9 Hz, 2H, 
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ArH), 6.77 (d, J = 8.9 Hz, 2H, ArH), 3.72–3.73 (m, 8H, 4×CH2), 3.14 (s, 6H, 2×Me), 2.66 
(s, 3H, Me). Anal. (C23H27Cl2N5O): C, H, N.  
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-[2-methyl-6-(1-pyrrolidinyl)-4-quinolinyl] 
urea (69e). Compound 69e was prepared from 2-methyl-6-(pyrrolidin-1-yl)quinolin-4-
amine (68c, 0.46 g, 2 mmol) and isocyanate 65 (freshly prepared from 64, 1.21 g, 3.6 
mmol). Yield, 0.61 g (63%); mp 255–256 oC; 1H NMR (DMSO-d6) δ 11.83 (s, 1H, NH, 
exchangeable), 9.56 (s, 1H, NH, exchangeable), 7.70 (d, J = 8.8 Hz, 1H, ArH), 7.47 (d, J
= 8.4 Hz, 2H, ArH), 7.16–7.05 (m, 1H, ArH), 7.05 (s, 1H, ArH), 6.76 (d, J = 8.8 Hz, 2H, 
ArH), 6.67 (s, 1H, ArH), 3.72 (m, 8H, 4×CH2), 3.34 (m, 4H, 2×CH2), 2.56 (s, 3H, Me), 
2.00 (m, 4H, 2×CH2). Anal. Calcld. for (C25H29Cl2N5O): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-(2-phenyl-4-quinolinyl)urea (69f).
Compound 69f was prepared from 2-phenylquinolin-4-amine (68f, 0.55 g, 2.5 mmol) and 
isocyanate 65 (freshly prepared from 64, 1.40 g, 4.5 mmol). Yield, 0.87 g (73%); mp 
194–195 oC; 1H NMR (DMSO-d6) δ 9.22 (s, 1H, NH, exchangeable), 9.07 (s, 1H, NH, 
exchangeable), 8.87 (s, 1H, ArH), 8.21 (d, J = 8.4 Hz, 1H, ArH), 8.15 (d, J = 7.6 Hz, 2H, 
ArH), 8.04 (d, J = 8.4 Hz, 1H, ArH), 7.79 (t, J = 7.6 Hz, 1H, ArH), 7.66 (t, J = 7.6 Hz, 
1H, ArH), 7.58–7.55 (m, 2H, ArH), 7.52–7.50 (m, 1H, ArH), 7.29 (d, J = 8.8 Hz, 2H, 
ArH), 6.77 (d, J = 8.8 Hz, 2H, ArH), 3.72–3.69 (m, 8H, 4×CH2). Anal. Calcld. for 
(C26H24Cl2N4O): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-(6-phenyl[1,3]dioxolo[4,5-g]quinolin-8-
yl)urea (69g). Compound 69g was prepared from 6-phenyl-[1,3]dioxolo[4,5-g]quinolin-
8-amine (68g, 0.66 g, 2.5 mmol) and isocyanate 65 (freshly prepared from 64, 1.40 g, 4.5 
mmol). Yield, 0.85 g (65%); mp 191–192 oC; 1H NMR (DMSO-d6) δ 8.92 (s, 1H, NH, 
exchangeable), 8.91 (s, 1H, NH, exchangeable), 8.71 (s, 1H, ArH), 8.08 (d, J = 7.2 Hz, 
2H, ArH), 7.58 (s, 1H, ArH), 7.55–7.51 (m, 2H, ArH), 7.48–7.44 (m, 1H, ArH), 7.38–
7.36 (m, 3H, ArH), 6.77 (d, J = 9.2 Hz, 2H, ArH), 6.25 (s, 2H, CH2), 3.73–3.71 (m, 8H, 
4×CH2). Anal. Calcld. for (C27H24Cl2N4O3): C, H, N. 
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N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-[6-chloro-2-(3-methoxyphenyl)-4-
quinolinyl] urea (69h).  Compound 69h was prepared from 6-chloro-2-(3-
methoxyphenyl)-4-quinolinamine (68h, 1.01 g, 3.5 mmol) and isocyanate 65 (freshly 
prepared from 64, 1.71 g, 5.6 mmol). Yield, 1.50 g (78 %); mp >300 oC; 1H NMR 
(DMSO-d6) δ 9.21 (1H, s, NH, exchangeable), 8.98 (1H, s, NH, exchangeable), 8.88 (s, 
1H, ArH), 8.30 (d, J = 1.8 Hz, 1H,  ArH), 8.05 (d, J = 8.9 Hz, 1H, ArH), 7.78 (dd, J = 1.9 
and 8.9 Hz, 1H, ArH), 7.71 (s, 1H, ArH), 7.67 (d, J = 7.8 Hz, 1H, ArH), 7.48 (t, J = 7.9 
Hz, 1H, ArH), 7.38 (d, J = 8.9 Hz, 2H, ArH), 7.09 (dd, J = 2.3 and 8.2 Hz, 1H, ArH), 
6.77 (d, J = 9.0 Hz, 2H, ArH), 3.87 (s, 3H, CH3), 3.70–3.73 (m, 8H, 4×CH2). Anal. 
Calcld. for (C27H25Cl3N4O2): C, H, N.
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-[6-methoxy-2-(3-methoxyphenyl)-4-
quinolinyl] urea (69i).  Compound 69i was prepared from 6-methoxy-2-(3-
methoxyphenyl)-4-quinolinamine (68i, 0.56 mg, 2 mmol) and isocyanate 65 (freshly 
prepared from 64, 1.21 g, 3.6 mmol). Yield, 0.80 g (74 %); mp 255–256 oC; 1H NMR 
(DMSO-d6) δ 9.25 (brs, 2H, exchangeable, 2×NH), 8.80 (d, J = 8.8 Hz, 1H, ArH), 7.99 
(d, J = 10.3 Hz, 2H, ArH), 7.65 (m, 3H, ArH), 7.47 (m, 2H, 2×ArH), 7.41 (d, J = 8.8 Hz, 
2H, ArH), 7.07 (dd, J = 2.2 and 8.1 Hz, 1H, ArH), 6.72 (d, J = 8.8 Hz, 2H, ArH), 4.01 (s, 
3H, OMe), 3.87 (s, 3H, OMe), 3.72 (m, 8H, 4×CH2). Anal. Calcd. for (C28H28Cl2N4O3):
C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-[6-(3-methoxyphenyl)[1,3]dioxolo[4,5-
g]quinolin -8-yl]urea (69i). Compound 69f was prepared from 6-(3-methoxyphenyl)-
[1,3]dioxolo[4,5-g]quinolin-8-amine (68f, 0.75 g, 2.5 mmol) and isocyanate 65 (freshly 
prepared from 64, 1.40 g, 4.5 mmol). Yield, 0.95 g (69%); mp 202–203 oC; 1H NMR 
(DMSO-d6) δ 8.91 (s, 1H, NH, exchangeable), 8.89 (s, 1H, NH, exchangeable), 8.68 (s, 
1H, ArH), 7.65–7.61 (m, 2H, ArH), 7.57 (s, 1H, ArH), 7.44 (t, J = 7.8 Hz, 1H, ArH), 
7.38–7.36 (m, 3H, ArH), 7.04 (dd, J = 8 and 2.4 Hz, 1H, ArH), 6.76 (d, J = 8.8 Hz, 2H, 
ArH), 6.25 (s, 2H, CH2), 3.86 (s, 3H, OMe), 3.73–3.72 (m, 8H, 4×CH2). Anal. Calcld. for 
(C28H28Cl2N4O3): C, H, N. 
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N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-[2-(3-methoxyphenyl)-6-(1-pyrrolidinyl)-
4-quinolinyl]urea (69j). Compound 69f was prepared from 2-(3-methoxyphenyl)-6-
(pyrrolidin-1-yl)quinolin-4-amine (68f, 0.64 g, 2 mmol) and isocyanate 65 (freshly 
prepared from 64, 1.21 g, 3.6 mmol). Yield, 0.90 g (78%); mp 166–167 oC; 1H NMR 
(DMSO-d6) δ 9.17 (s, 1H, NH, exchangeable), 8.86 (s, 1H, NH, exchangeable), 8.70 (s, 
1H, ArH), 7.88 (d, J =  9.2 Hz, 1H, ArH), 7.65–7.60 (m, 2H, ArH), 7.46–7.39 (m, 3H, 
ArH), 7.28 (d, J =  9.2 Hz, 1H, ArH), 7.02 (d, J = 8 Hz, 1H, ArH), 6.87 (s, 1H, ArH), 6.77 
(d, J = 8.8 Hz, 2H, ArH), 3.86 (s, 3H, OMe), 3.73 (m, 8H, 4×CH2), 3.46 (m, 4H, 2×CH2),
2.07–2.05 (m, 4H, 2×CH2). Anal. Calcld. for (C28H26Cl2N4O4): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-[6-(2-fluorophenyl)[1,3]dioxolo[4,5-
g]quinolin-8-yl]urea (69k). Compound 69f was prepared from 6-(2-flourophenyl)-
[1,3]dioxolo[4,5-g]quinolin-8-amine (68f, 0.71 g, 2.5 mmol) and isocyanate 65 (freshly 
prepared from 64, 1.40 g, 4.5 mmol). Yield, 1.09 g (80%); mp 188–189 oC; 1H NMR 
(DMSO-d6) δ 8.92 (s, 1H, NH, exchangeable), 8.89 (s, 1H, NH, exchangeable), 8.59–8.58 
(m, 1H, ArH), 7.99–7.94 (m, 1H, ArH), 7.59 (s, 1H, ArH), 7.53–7.48 (m, 1H, ArH), 
7.38–7.32 (m, 5H, ArH), 6.76 (d, J = 9.2 Hz, 2H, ArH), 6.26 (s, 2H, CH2), 3.72–3.71 (m, 
8H, 4×CH2). Anal. Calcld. for (C31H33Cl2N5O2): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N'-[2-(2-fluorophenyl)-6-(1-pyrrolidinyl)-4-
quinolinyl]urea (69l). Compound 69f was prepared from 2-(2-fluorophenyl)-6-
(pyrrolidin-1-yl)quinolin-4-amine (68f, 0.85 g, 2.75 mmol) and isocyanate 65 (freshly 
prepared from 64, 1.56 g, 5 mmol). Yield, 1.09 g (70%); mp 199–200 oC; 1H NMR 
(DMSO-d6) δ 9.03 (s, 1H, NH, exchangeable), 8.74 (s, 1H, NH, exchangeable), 8.58 (s, 
1H, ArH), 7.99–7.96 (m, 1H, ArH), 7.87 (d, J = 9.6 Hz, 1H, ArH), 7.48–7.46 (m, 1H, 
ArH), 7.39–7.27 (m, 5H, ArH), 6.86 (s, 1H, ArH), 6.77 (d, J = 8.8 Hz, 2H, ArH), 3.72 (m, 
8H, 4×CH2), 3.46 (m, 4H, 2×CH2), 2.08–2.06 (m, 4H, 2×CH2). Anal. Calcld. for 
(C27H23Cl2FN4O3): C, H, N. 
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Cytotoxicity assays
The cytotoxic effects of the newly synthesized compounds were determined in T-
cell acute lymphocytic leukemia (CCRF-CEM) and their resistant subcell lines (CCRF-
CEM/Taxol and CCRF-CEM/VBL) by the XTT assay81 and human solid tumor cells (i.e. 
breast carcinoma MX-1 and colon carcinoma HCT-116) by the SRB assay82 in a 72 h 
incubation using a microplate spectrophotometer as described previously.83 After the 
addition of phenazine methosulfate-XTT solution, incubated at 37 oC for 6 h and 
absorbance at 450 and 630 nm was detected on a microplate reader (EL 340). IC50 values 
were determined from dose-effect relationship at six or seven concentrations of each drug 
using the CompuSyn software by Chou and Martin84 based on the median-effect principle 
and plot.85,86 Ranges given for Taxol, Vinblastine and Cisplatin were mean ± SE (n = 4). 
In Vivo Studies 
Athymic nude mice bearing the nu/nu gene were obtained from NCI, Frederick, 
MD and used for all human tumor xenografts. Male nude mice 6 weeks or older weighing 
20-24 g or more were used. Compounds were administered via the tail vein for i.v. 
injection as described previously.83 Tumor volume was assessed by measuring length × 
width × height (or width) by using a caliper. Vehicle used was 50 μL DMSO and 40 μL
Tween 80 in 160 μL saline. The maximal tolerate dose of the tested compound was 
determined and applied for the in vivo therapeutic efficacy assay. For tumor-bearing nude 
mice during the course of the experiment, the body weight refers to total weight minus the 
weight of the tumor. All animal studies were conducted in accordance with the guidelines 
for the National Institute of Health Guide for the Care and Use of Animals and the 
protocol approved by the Institutional Animal Care and Use Committee. 
Determination of DNA Interstrand Cross-Linking 
The level of DNA interstrand cross-linking was determined using a modified 
comet assay.93,94 All steps were carried out under subdued lighting. Briefly, H1299 cells 
(2×105 cells) were plated in a 60 mm dish and incubated at 37 oC with 5% CO2 for 32 h. 
The growing cells were treated with alkylating agent (69a or mephalan). After being 
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treated with 1 h, the cells were exposed to 20 Gy X-ray to induce DNA strand breaks. An 
aliquot of 5×105 cells were suspended in 50 μl of phosphate-buffered saline, mixed with a 
250 μl of 1.2% low melting point agarose, and subjected to comet assay. The tail moment 
of 100 cells were analyzed for each treatment by aid of the COMET assay software. The 
degree of DNA interstrand cross-linking presented at a drug-treated sample was 
determined by comparing the tail moment of the irradiated control, which was calculated 
by the following formula; 
% of DNA with interstrand cross-linking
Where TMdi = mean tail moment of drug treated, irradiated sample, TMcu = mean tail 
moment of unirradiated control sample, TMci = mean tail moment of irradiated control 
sample. 
Determination of Half-life of 69a in Rat Plasma 
 The chromatographic system consisted of a photodiode-array system, 
chromatographic pump, an auto-sampler equipped with a 40 μL sample loop. Compound 
69a was separated from rat plasma using a revise phase column (30×150 mm, particle 
size 5 μm) maintained at an ambient temperature (25±1 oC) to perform the ideal 
chromatographic system. The detector wavelength was set at 266 nm. The mobile phase 
comprised methanol:10mM NaH2PO4 (60:40, v/v), which was adjusted to pH 3.0 with 
85% of H3PO4. Analysis was run at a flow rate of 0.5 mL/min and the samples were 
quantified using peak area. An aliquot of plasma sample (40 μL, with 69a 5 μg/mL) was 
vortex-mixed with acetonitrile (1:2, v/v) for protein precipitation and centrifuged at 
10,000×g for 10 min. The supernatant was passed through a 0.45 μm filter for injected 
into the HPLC. 
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Synthesis and biological activity of 
Phenyl N-mustard-quinoline conjugates 
having a hydrazine-carboxamide linker 
Chapter? 5
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5.1 Chemistry  
The general synthetic route of the newly N-mustard-quinoline conjugates via 
hydrazine-carboxamide is summarized in Scheme 3. Substituted 4-chloroquinolines (67a-
m) was prepared according to method describe in part I. The 4-hydrazinoquinolines (70a-
m) used for preparing 71a-m were obtained by treatment of the appropriate 4-
chloroquinolines (67a-m) with hydrazine hydrate as previously described97,98 or by 
reaction with phenol followed by treatment with hydrazine hydrates. 4-[N,N-bis(2-
chloroethyl)amino]phenylisocyanate (65),78 was synthesized as describe previously. 
Condensation of 4-hydrazinoquinolines (70a-m) with 4-[N,N-bis(2-
chloroethyl)amino]phenylisocyanate (65) in anhydrous DMF in presence of triethylamine 
afforded N-mustard-quinoline conjugates bearing hydrazine-carboxamide linker 71a-m in 
fair to good yield. The yields and physical properties of the new N-mustard conjugates 
are shown in Table 1. 
N
Cl
N
NHNH2
R2 R2
R1R3R3 R1
N R1
R2
R3
HN
H
N
H
N
O
N
Cl
Cl
N(CH2CH2Cl)2O=C=N
N(CH2CH2Cl)2HCl - H2Ni
ii
iii
64
65
67 (a-m) 70 (a-m)
71 (a-m)
a: R1 =Me, R2 = H
b: R1 =Me, R2 = OMe
c: R1 =Me, R2 = R3 = O-CH2-O
d: R1 =Me, R2 = NMe2
e: R1 =Me, R2 = N(C4H8)
f : R1 =Ph, R2 = H
g: R1 =Ph, R2 = R3 = O-CH2-O
h: R1 =3'-OMe-Ph, R2 = Cl
i: R1 =3'-OMe-Ph, R2 = OMe
j: R1 =3'-OMe-Ph, R2 = R3 = O-CH2-O
k: R1 =3'-OMe-Ph, R2 = N(C4H8)
l: R1 =2'-F-Ph, R2 = R3 = O-CH2-O
m: R1 =2'-F-Ph, R2 = N(C4H8)
Scheme 3
Reaction condition: i) NH2NH2/ethanol, ref lux or phenol/180 oC, NH2NH2/130 oC; ii) triphosgene, CHCl3/Et3N,
-10 oC; iii) Et3N, DMF, room temperature.
150
Table 1. Analytical data and yields of new N-mustard conjugates (71a-m)
Compd. R1 R2
Yield
(%)
MP (oC)
Chemical 
Formula 
Analysis
71a Me H 94 263–264 C21H23Cl2N5O C, H, N 
71b Me 6-MeO 60 255–256 C22H25Cl2N5O2 C, H, N 
71c Me 6,7-(OCH2O) 80 253–254 C22H23Cl2N5O3 C, H, N 
71d Me 6-NMe2 68 260–261 C23H28Cl2N6O C, H, N 
71f C6H5 H 60 235–236 C26H25Cl2N5O C, H, N 
71g C6H5 6,7-(OCH2O) 64 289–291 C27H25Cl2N5O3 C, H, N 
71h 3-MeO-C6H4 6-Cl 61 237–238 C27H26Cl3N5O2 C, H, N 
71i 3-MeO-C6H4 6-MeO 71 215–216 C28H29Cl2N5O3 C, H, N 
71j 3-MeO-C6H4 6,7-(OCH2O) 73 279–280 C28H27Cl2N5O4 C, H, N 
71k 3-MeO-C6H4 6-C4H8N 68 190–191 C31H34Cl2N6O2 C, H, N 
71l 2-F-C6H4 6,7-(OCH2O) 78 211–212 C27H24Cl2FN5O3 C, H, N 
71m 2-F-C6H4 6-C4H8N 62 270–271 C30H31Cl2FN6O C, H, N 
All of the synthesized compounds were characterized by using 1H NMR and 
Elemental analysis. For compounds 71a-m, the characteristic signal for methylenic proton 
(i.e., N(CH2CH2Cl) appeared at 3.7 ? ppm. The 1H NMR signals for the phenyl N-
mustards residue appeared as doublet (ortho coupling, J = 8.8–9.0 Hz) at 6.7 and 7.3 ?
ppm. The characteristic proton values for the hydrazinecarboxamide linker 
(NHNHCONH) appeared at 8.8–11.2 ? ppm as D2O exchangeable singlet. The elemental 
analysis of the newly synthesized derivatives was within ±0.4% range of the calculated C, 
H, N data.
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5.2 Biological Results and Discussion 
5.2.1 In Vitro Cytotoxicity
Table 2 shows the cytotoxic activities of the newly synthesized N-mustard-
quinoline conjugates hydrazine-carboxamide linker (71a-m) against human 
lymphoblastic leukemia (CCRF-CEM) and its subcell lines resistant to vinblastine and 
taxol and was compared with untargeted N-mustard (64), BO-0742 (53), BO-1051(57)
and BO-1062 (58). IC50 value revealed that all compounds exhibited potent in vitro 
cytotoxicity against tested cell lines. Moreover, tested compounds have little or no cross-
resistance to either taxol or vinblastine with one exception, compound 71c, which has 
certain degree of cross-resistance to both cell lines. Studies on structure-activity 
relationships of these N-mustards showed that their antitumor activity was slightly 
affected by the size of C-2 substituent. In general, 2-methyl substituted conjugates are 
more potent than the corresponding 2-Ph, 2-(3-MeOPh) or 2-(2-FPh) substituted counter 
parts suggesting the bulky function at C-2 may interfere the drug/DNA binding 
capability. In the series of 2-methyl substituted compounds the cytotoxicity of 71a is 
increased by adding methyldioxy or dimethylamino function at C-6,7 or C-6 (71c,d).
Although additions the C-6 methoxy function (71b) slightly decreases the potency of 71a.
Similar observation can be found in 2-Ph, 2-(3-OMePh) or 2-(2-FPh) conjugates. In the 
series of C-2 phenyl ring, addition of methelenedioxy substitution at C-6,7 position 
increase the activity of parent compound 71f. The order of cytotoxic effects for the series 
of C-2 OMe substituted phenyl derivatives is as follows: C-6,7 methylenedioxy (71j) > C-
6 pyrrolidine (71k) > C-6 methoxy (71i) > C-6 chloro (71h). In contrast, C-2 F 
substituted phenyl derivatives, C-6 pyrrolidine (71m) derivatives was more potent than 
that of C-6,7 methylenedioxy (71l) derivative. From above discussion, it can be 
concluded that addition of methylenedioxy or pyrrolidine functions at C-6,7 or C-6 
position , respectively, increase the potency of parent compound. 
To explore further, C-2 methyl substituted derivatives 71a, 71b, 71c, and 71d
were selected to study their cell growth inhibitory effect against solid tumor such as 
breast carcinoma (MX-1), colon carcinoma HCT-116, non-small cell lung cancer 
(H1299), human prostate cancer (PC3), human lung adenocarcinoma (CL1-0 and CL1-5) 
and human breast adenocarcinoma (MCF-7) cell growth in vitro. The cytotoxicity of the 
targeted compounds are summarized in Table 3. It demonstrated that the newly 
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synthesized N-mustard-quinoline conjugates possess significant antitumor activity with 
IC50 in micro molar range. The SAR study revealed that the cytotoxicity of 71a is 
increased by adding methyldioxy or dimethylamino function at C-6,7 or C-6 (71c,d). This 
result is consistent with the SAR study of these compounds as describe previously.
Table 2. The in vitro cytotoxicity of N-mustard-quinoline conjugates having 
hydrazinecarboxamide linker (71a-m) against human lymphoblastic leukemia 
(CCRF-CEM) and its drug-resistant sublines (CCRF-CEM/Taxol and CCRF-
CEM/VBL).[a]
Compd. 
Cell Growth Inhibition IC50 (μM)[a] 
CCRF-CEM CCRF-CEM/Taxol[b] CCRF-CEM/VBL[b]
71a 0.118±0.053 1.83±0.8 [15.5×][c] 0.85±0.05 [7.2×][c]
71b 0.196±0.019 1.535±0.385 [7.8×] 2.015±0.181 [10.3×]
71c 0.042±0.02 2.26±0.65 [53.8×] 1.725±0.39 [41.1×]
71d 0.058±0.026 4.193±0.651 [72.3×] 6.95±5.86 [120×]
71f 0.578±0.002 0.908±0.0025 [1.57×] 1.217±0.012 [2.11×]
71g 0.258±0.044 0.574±0.0021 [2.22×] 0.495±0.0057 [1.92×]
71h 0.732±0.22 2.253±0.042 [3.08×] 2.133±0.051 [2.91×]
71i 0.552±0.064 2.154±0.193 [3.90×] 1.623±0.088 [2.94×]
71j 0.209±0.045 0.734±0.013 [3.51×] 1.134±0.02 [5.43×]
71k 0.354±0.031 0.568±0.006 [1.60×] 0.833±0.044 [2.35×]
71l 1.423±0.270 2.979±0.024 [2.09×] 3.174±0.205 [2.23×]
71m 0.152±0.02 0.261±0.030 [1.72×] 0.312±0.057 [2.05×]
N-mustards (64) 0.0434±0.50 0.0338±0.40 [0.78×] 0.0257±0.10 [0.59×]
BO-0742 (53) 0.007±0.0015 0.034±0.0007[4.9×] 0.0075±0.004 [1.1×]
BO-1051 (57) 0.078±2.3 0.092±0.0157 [1.18×] 0.128±0.0022 [1.64×]
BO-1062 (58) 0.075±0.016 0.140±0.032 [1.9×]c 0.184±0.028 [2.5×]
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Taxol 0.0031±0.0001 0.429±0.042 [330×] 1.274±0.052 [980×]
Vinblastine 0.00073±0.0009 0.078±0.011 [106.2×] 0.496±0.121 [679.5×]
Table 3. The in vitro cytotoxicity of N-mustard-quinoline conjugates having 
hydrazinecarboxamide linker (71a-m) against human solid tumor (breast carcinoma MX-
1 and colon carcinoma HCT-116, non-small cell lung cancer H1299, human prostate 
cancer PC3, human lung adenocarcinoma CL1-0 and CL1-5 and human breast 
adenocarcinoma MCF-7) cell growth in vitro.[a]
[a]Cell growth inhibition was measured by the XTT assay[81] for leukemic cells and the SRB 
assay[82] for solid tumor cells after 72-h incubation using a microplate spectrophotometer as 
described previously.[83] IC50 values were determined from dose-effect relationship at six or seven 
concentrations of each drug by using the CompuSyn software by Chou and Martin[84] based on the 
median-effect principle and plot.[85,86] Ranges given for Taxol and Vinblastine were mean ± SE (n 
= 4).
[b] CCRF-CEM/Taxol and CCRF-CEM/VBL are subcell lines of CCRF-CEM cells that are 330-
fold resistant to Taxol, and 680-fold resistant to Vinblastine, respectively, when comparing with 
the IC50 of the parent cell line.  
[c] Numbers in the brackets are fold of cross-resistant determined by comparison with the 
corresponding IC50 of the parent cell line.
Compd.  71a 71b 71c 71d Cis-pt
C
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 (μ
M
)[a
]
MX-1 0.36±0.072 0.264±0.005 0.127±0.002 0.278±0.013 N. D. 
HCT-116 0.382±0.029 0.257±0.002 0.123±0.003 0.145±0.002 N. D. 
H1299 0.784±0.056 N. D. 0.812±0.136 0.289±0.112 4.707±0.574 
PC3 5.963±0.572 N. D. 2.322±0.579 1.289±0.387 11.803±5.775 
CL1-0 9.441±2.915 N. D. 1.115±0.921 1.832±0.536 56.917±16.984
CL1-5 8.869±2.38 N. D. 2.712±0.905 4.326±0.963 27.741±3.913 
MCF7 5.549±1.357 N. D. 2.534±1.071 3.487±0.444 19.872±1.885 
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5.2.2 In Vivo Therapeutic Effect 
The newly synthesized conjugates were selected for evaluating their antitumor 
effects against human tumor xenografts in animal model based on their in vitro 
cytotoxicity, toxicity to the host and solubility. The administration of agent was carried 
out at the maximal tolerable dose via either intravenous infusion (i. v. infusion) or 
intravenous injection (i. v. injection) as indicated in somewhere else. Figure 26AB 
showed the therapeutic effect of N-mustard-quinoline conjugate having hydrazine-
carboxamide linker 71a in nude mice bearing human mammary carcinoma MX-1 
xenograft. At low dose [10 mg/kg, Q2D×7, 2 hr intravenous (i.v.) infusion], tumor was 
significantly suppressed, but tumor relapse on D30 (Fig. 26A). However, at the dose of 15 
mg/kg (Q2D×7, 2 hr i.v. infusion), tumor remission was observed (4/4 remission on D26, 
D26, D32, and D38), but only one mouse out of four showed tumor relapse on D42. At 
this maximal tolerate dose, about 8% average body-weight loss (Fig. 26B) was found 
indicating that 71a had litter toxicity to the host. 
Figure 27AB shows the antitumor effect of N-mustard-quinoline conjugate having 
a hydrazinecarboxamide linker 71c and 71d in nude mice (n=4) bearing human mammary 
carcinoma MX-1 xenograft. At the maximal dose of 40 and 40 mg/kg, respectively, 
Q2D×6, i.v. injection, complete tumor remission (CR) induced by 71c and 71d (for 71c:
on D19, D21, D21, and D23; for 71d: D17, D19, D19, and D21) was seen although about 
15% body-weight loss was observed.
The therapeutic effect of 71g was also compared with its 3’-MeOPh substituted 
derivative 71j against MX-1 xenograft in nude mice. As shown in Figure 28A, it revealed 
that 71j is somewhat more potent than 71g at the dose of 20 and 20 mg/kg, respectively, 
as one can see that CR was observed in all mice (4/4) treated with 71j. It is noted that the 
maximal tolerate dose, these two agents were less toxic to the host when compare with 
71c,d.
Conjugates 71c and 71d were also selected for evaluating their therapeutic 
efficacy against human colon HCT-116 xenograft in nude mice. As shown in Figure 
29AB, it revealed that 60 and 78% tumor suppression against HCT-116 by 71c and 71d,
respectively, at the maximum tolerable dose (30 and 50 mg/kg, respectively) with 
acceptable toxicity (about 15% body-weight loss). 
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The above studies demonstrated that N-mustard-quinoline conjugates having a 
hydrazinecarboxamide linker, in general, are potent than the corresponding derivatives 
bearing a urea linker regarding the dose used. However, the later conjugates possess 
lower toxicity.  
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Figure 26. Therapeutic effect of 71a (10 mg/kg, i.v. infusion, Q2Dx7, n=4), and 71a (15 
mg/kg, i.v. infusion, Q2Dx7, n=4), in nude mice bearing human mammary carcinoma 
MX-1 xenograft; average tumor size changes (Figure 26A) and average body weight 
changes (Figure 26B). 
Fig. 26A 
Fig. 26B 
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Figure 27. Therapeutic effect of 71c (40 mg/kg, i.v. inj., Q2Dx6, n=4), and 71d (40 
mg/kg, i.v. inj., Q2Dx6, n=4), in nude mice bearing human mammary carcinoma MX-1 
xenograft; average tumor size changes (Figure 27A) and average body weight changes 
(Figure 27B).   
Fig. 27A 
Fig. 27B 
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Figure 28. Therapeutic effect of 71g (25 mg/kg, i.v. inj., Q2Dx6, n=5), and 71j (25
mg/kg, i.v. inj., Q2Dx6, n=5), in nude mice bearing human mammary carcinoma MX-1 
xenograft; average tumor size changes (Figure 28A) and average body weight changes 
(Figure 28B).   
Fig. 28A 
Fig. 28B 
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Figure 29. Therapeutic effect of 71c (30 mg/kg, i.v. inj., Q2Dx6, n=4), and 71d (50 
mg/kg, i.v. inj., Q2Dx6, n=4), in nude mice bearing human colon HCT-116 xenograft; 
average tumor size changes (Figure 29A) and average body weight changes (Figure 29B).
Fig. 29A 
Fig. 29B 
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5.3 Conclusion 
In the present study, I have synthesized a series of potent DNA-directed alkylating 
agents by linking the phenyl N-mustard pharmacophore with quinoline via a 
hydrazinecarboxamide linker (71a-k). The present studies demonstrated that these newly 
synthesized compounds exhibited potent cytotoxicity against human leukemia and 
various solid tumor cell growths in vitro and potent antitumor efficacy in vivo with a 
relatively low toxicity. The current studies also suggest that the newly synthesized 
compounds may have superior antitumor efficacy against multi-drug resistant tumor since 
these conjugates have no or little multi-drug resistance as described previously. Detailed 
SAR studies demonstrated that the size of the substituent at C-2 substituent affected the 
cytotoxicity of these agents. Among these compounds, 71a,c,d,g,j were found to have 
potent therapeutic efficacy against human breast MX-1 xenograft in animal model. 
Complete tumor remission was achieved in nude mice bearing human breast carcinoma 
MX-1 xenograft by these derivatives. Moreover, compound 71c and 71d were able to 
significantly suppress human colon HCT-116 xenograft in nude mice. Thus one can 
anticipate that all the newly synthesized N-mustards-quinoline conjugates will have 
potent antitumor activity.   
5.4 Experimental Section 
Melting points were determined on a Fargo melting point apparatus and are 
uncorrected. Column chromatography was carried out on silica gel G60 (70-230 mesh, 
ASTM; Merck and 230-400 mesh, Silicycle Inc.). Thin-layer chromatography was 
performed on silica gel G60 F254 (Merck) with short-wavelength UV light for 
visualization. Elemental analyses were done on a Heraeus CHN-O Rapid instrument. 
HPLC was performed on Waters Delta Prep4000 using Mightysil RP-18 reverse phase 
column (250×4.6 mm). Compounds were detected by UV at 260 nm. The mobile phase 
was MeCN:H2O (80:20 v/v) with flow rate 1 mL/min. 1H NMR spectra were recorded on 
a 600 MHz, Brucker AVANCE 600 DRX and 400 MHz, Brucker Top-Spin 
spectrometers. The chemical shifts were reported in ppm (δ) relative to TMS. 
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General process for the preparation of 4-hydrazinoquinolines (70a-x) 
Method A: 
A solution of 4-chloroquinolines (67a-m) and 80 % hydrazine hydrate in anhydrous 
ethanol were refluxed for 8h. The corresponding hydrazinoquinoline hydrochloride 
precipitated already in the course of refluxing and completed after cooling. The obtained 
precipitate was collected by filtration. The product was purified by recrystalization from 
ethanol to give corresponding 4-hydrazinoquinolines (70a-m) in good yield. 
Method B: 
A solution of 4-chloroquinolines (67a-m) and phenol was heated at 180 oC for 1h. 80 % 
hydrazine hydrate was added dropwise to the reaction mixture and heated continuously at 
140 for 1.5 h.  After cooling to room temperature, the mixture was poured into 10% 
NaOH aqueous solution. The solid separated was collected by filtration, washed with 
water and dried to give corresponding 4-hydrazinoquinolines (70a-m) in good yield, 
which was purified by crystlization from ethanol. 
4-Hydrazino-2-methylquinoline (70a). Methoc A. Compound 70a was prepared from 
4-chloroquinoline (67a, 5.01 g, 28.2 mmol) and 80 % hydrazine hydrate (8 mL). Yield, 
4.71 g (80%): mp 195–197 oC (lit.97 200 oC); 1H NMR (DMSO-d6) ? 10.64 (1H, s, 
exchangeable, NH), 8.42 (d, J = 8.2 Hz, 1H, ArH), 7.85 (d, J = 8.4 Hz, 1H, 1H, ArH), 
7.86 (t, J = 7.6 Hz, 1H, ArH), 7.58 (t, J = 7.6 Hz, 1H, ArH), 6.99 (s, 1H, ArH), 5.15 (brs, 
2H, NH2, exchangeable), 2.64 (3H, s, CH3).
4-Hydrazino-6-methoxy-2-methylquinoline (70b). Methoc A. Compound 70b was 
prepared from 4-chloro-2-methyl-6-quinolinyl methyl ether (67b, 2.07 g, 10 mmol) and 
80%  hydrazine hydrate (3 mL). Yie ld, 1.80 g (75%): mp 199–201 oC (lit.99 208 oC); 1H
NMR (DMSO-d6) ? 10.44 (s, 1H, NH, exchangeable), 7.89 (d, J = 9.2 Hz, 1H, ArH), 7.87 
(d, J = 2.3 Hz, 1H, ArH), 7.50 (dd, J = 2.5 and 9.2 Hz, 1H, ArH), 6.95 (s, 1H, ArH), 5.10 
(brs, 2H, NH2, exchangeable), 3.89 (s, 3H, OCH3), 2.61 (s, 3H, CH3).
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8-Hydrazino-6-methyl[1,3]dioxolo[4,5-g]quinoline (70c). Methoc A. Compound 70c
was prepared from 8-chloro-6-methyl[1,3]dioxolo[4,5-g]quinoline (67c, 2.22 g, 10 mmol) 
and 80% hydrazine hydrate (4 mL). Yield, 1.52 g (60 %): mp 235–237 oC (lit.93 240–242
oC); 1H NMR (DMSO-d6) ? 10.64 (s, 1H, NH, exchangeable), 7.86 (s, 1H, ArH), 7.44 (s, 
1H, ArH), 6.78 (s, 1H, ArH), 6.32 (s, 2H, CH2), 5.15 (brs, 2H, NH2, exchangeable), 2.64 
(s, 3H, CH3).
4-Hydrazino-N,N,2-trimethyl-6-quinolinamine (70d). Methoc A. Compound 70d was 
prepared from 4-chloro-N,N,2-trimethyl-6-quinolinamine (67d, 2.207 g, 10 mmol) and 
80% hydrazine hydrate (4 mL). Yield, 1.83 g (72 %): mp 215–217 oC; 1H NMR (DMSO-
d6) ? 10.44 (s, 1H, NH, exchangeable), 7.89 (d, J = 9.2 Hz, 1H, ArH), 7.78 (d, J = 2.3 Hz, 
1H, ArH), 7.45 (dd, J = 2.5 and 9.2 Hz, 1H, ArH), 6.97 (s, 1H, ArH), 5.12 (brs, 2H, NH2, 
exchangeable), 3.07 (s, 6H, 2×CH3), 2.61 (s, 3H, CH3). Anal. Calcd. for (C12H16N4): C, 
H, N. 
4-Hydrazinyl-2-phenylquinoline (70f). Methoc A. Compound 70f was prepared from 4-
chloro-2-phenylquinoline (67f, 4.79 g, 20 mmol) and 80% hydrazine hydrate (6 mL). 
Yield, 3.42 g (73%): mp 145–146 oC; 1H NMR (DMSO-d6) δ 8.49 (s, 1H, NH, 
exchangeable), 8.20–8.14 (m, 3H, ArH), 7.86 (d, J = 8.4 Hz, 1H, ArH), 7.61 (t, J = 7.2 
Hz, 1H, ArH), 7.54–7.50 (m, 2H, ArH), 7.46–7.43 (m, 2H, ArH), 7.37 (t, J = 7.6 Hz, 1H, 
ArH), 4.50 (brs, 2H, NH2, exchangeable). Anal. Calcld. for (C15H13N3): C, H, N. 
8-Hydrazinyl-6-phenyl-[1,3]dioxolo[4,5-g]quinoline (70g). Methoc B.  Compound 70g
was prepared from 8-chloro-6-phenyl-[1,3]dioxolo[4,5-g]quinoline (67g, 2.13 g, 7.5 
mmol) and 80% hydrazine hydrate (2 mL). Yield, 1.82 g (87%): mp 199–201 oC; 1H
NMR (DMSO-d6) δ 8.14–8.12 (m, 2H, ArH), 8.11 (s, 1H, NH, exchangeable), 7.56 (s, 
1H, ArH), 7.50–7.43 (m, 2H, ArH), 7.43–7.40 (m, 1H, ArH), 7.39–7.38 (m, 1H, ArH), 
7.21 (s, 1H, ArH), 6.14 (s, 2H, CH2), 4.41 (brs, 2H, NH2, exchangeable). Anal. Calcld. for 
(C16H13N3O2): C, H, N. 
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6-Chloro-4-hydrazinyl-2-(3-methoxyphenyl)quinoline (70h). Methoc A. Compound 
70h was prepared from 4,6-dichloro-2-(3-methoxyphenyl)quinoline (67h, 3.04 g, 10 
mmol) and 80% hydrazine hydrate (5 mL). Yield, 2.61 g (87%): mp 170–171 oC; 1H
NMR (DMSO-d6) δ 8.57 (s, 1H, NH, exchangeable), 8.29 (s, 1H, ArH), 7.86 (d, J = 8.8 
Hz, 1H), 7.74–7.73 (m, 2H, ArH), 7.62–7.59 (m, 1H, ArH), 7.46–7.41 (m, 2H, ArH), 
7.05–7.02 (m, 1H, ArH), 4.53 (brs, 2H, NH2, exchangeable), 3.86 (s, 3H, OMe). Anal. 
Calcld. for (C16H14ClN3O): C, H, N. 
4-Hydrazinyl-6-methoxy-2-(3-methoxyphenyl)quinoline (70i). Methoc B. Compound 
70i was prepared from 4-chloro-6-methoxy-2-(3-methoxyphenyl)quinoline (67i, 2.99 g, 
10 mmol) and 80% hydrazine hydrate (3 mL). Yield, 2.81 g (95%): mp 127–128 oC; 1H
NMR (DMSO-d6) δ 8.32 (s, 1H, NH, exchangeable), 7.79 (d, J = 9.2 Hz, 1H), 7.74–7.72 
(m, 2H, ArH), 7.55–7.54 (m, 1H, ArH), 7.43–7.39 (m, 2H, ArH), 7.28–7.26 (m, 1H, 
ArH), 7.01–6.99 (m, 1H, ArH),  4.47 (brs, 2H, NH2, exchangeable), 3.88 (s, 3H, OMe), 
3.85 (s, 3H, OMe). Anal. Calcld. for (C17H17N3O2): C, H, N. 
8-Hydrazinyl-6-(3-methoxyphenyl)-[1,3]dioxolo[4,5-g]quinoline (70j). Methoc B. 
Compound 70j was prepared from 8-chloro-6-(3-methoxyphenyl)-[1,3]dioxolo[4,5-
g]quinoline (67j, 2.35 g, 7.5 mmol) and 80% hydrazine hydrate (3 mL). Yield, 2.16 g 
(93%): mp 152–154 oC; 1H NMR (DMSO-d6) δ 9.33 (s, 1H, NH, exchangeable),7.68 (s, 
2H, ArH), 7.59 (s, 1H, ArH), 7.42 (t, J =  6.2 Hz, 1H, ArH), 7.35 (s, 1H, ArH), 7.25 (s, 
1H, ArH), 7.01 (d, J = 6.4 Hz, 1H, ArH), 6.16 (s, 2H, CH2), 4.50 (brs, 2H, NH2,
exchangeable), 3.85 (s, 3H, OMe). Anal. Calcld. for (C17H15N3O3): C, H, N. 
4-Hydrazinyl-2-(3-methoxyphenyl)-6-(pyrrolidin-1-yl)quinoline (70k). Methoc B. 
Compound 70k was prepared from 4-chloro-2-(3-methoxyphenyl)-6-(pyrrolidin-1-
yl)quinoline (67k, 2.54 g, 7.5 mmol) and 80% hydrazine hydrate (3 mL). Yield, 2.08 g 
(80%): mp 206–207 oC; 1H NMR (DMSO-d6) δ 8.04 (s, 1H, NH, exchangeable), 7.72–
7.69 (m, 3H, ArH), 7.38 (t, J = 7.8 Hz, 1H, ArH), 7.32 (s, 1H, ArH), 7.11–7.09 (m, 1H, 
ArH), 6.97–6.94 (m, 1H, ArH), 6.89–6.88 (m, 1H, ArH), 4.36 (brs, 2H, NH2,
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exchangeable), 3.85 (s, 3H, OMe), 3.35–3.34 (m, 4H, 2×CH2), 2.02–1.99 (m, 4H, 
2×CH2). Anal. Calcld. for (C20H22N4O): C, H, N. 
6-(2-Fluorophenyl)-8-hydrazinyl-[1,3]dioxolo[4,5-g]quinoline (70l). Methoc A.
Compound 70l was prepared from 8-chloro-6-(2-fluorophenyl)-[1,3]dioxolo[4,5-
g]quinoline (67l, 3.01 g, 10 mmol) and 80% hydrazine hydrate (15 mL). Yield, 2.21 g 
(64%): mp 212–213 oC; 1H NMR (DMSO-d6) δ 8.16 (s, 1H, NH, exchangeable), 7.94–
7.90 (m, 1H, ArH), 7.56 (s, 1H, ArH), 7.48–7.42 (m, 1H, ArH), 7.33–7.26 (m, 3H, ArH), 
7.19 (s, 1H, ArH), 6.15 (s, 2H, CH2), 4.38 (brs, 2H, NH2, exchangeable). Anal. Calcld. for 
(C16H12FN3O3): C, H, N. 
2-(2-Fluorophenyl)-4-hydrazinyl-6-(pyrrolidin-1-yl)quinoline (70m). Methoc B.
Compound 70m was prepared from 4-chloro-2-(2-fluorophenyl)-6-(pyrrolidin-1-
yl)quinoline (67m, 4.09 g, 20 mmol) and 80% hydrazine hydrate (5 mL). Yield, 3.38 g 
(84%): mp 168–169 oC; 1H NMR (DMSO-d6) δ 8.10 (s, 1H, NH, exchangeable), 7.95 (t, J
= 7.4 Hz, 1H, ArH), 7.70 (d, J = 9.2 Hz, 1H, ArH), 7.43–7.41 (m, 1H, ArH), 7.31–7.23 
(m, 3H, ArH), 7.10 (d, J = 8.4 Hz, 1H, ArH), 6.68 (s, 1H, ArH), 4.33 (brs, 2H, NH2,
exchangeable), 3.35(s, 4H, 2×CH2), 2.01 (s, 4H, 2×CH2). Anal. Calcld. for (C19H19FN4):
C, H, N. 
General procedure for the preparation of 71a-m
A solution of known 4-[N,N-bis(2-chloroethyl)amino]phenylisocyanate (65)78 [freshly 
prepared from N,N-bis(2-chloroethyl)benzene-1,4-diamine hydrochloride (64,77 1.5
equivalent) by treating with triphosgene (0.5 equivalent) in presence of TEA at –10 oC.]
in dry DMF was added dropwise to a solution of appropriate 4-hydrazinoquinoline (71a-
m, 1.0 equivalent) in dry DMF containing Et3N (1.5 to 4 equivalent) at room temperature. 
The reaction was monitered by thin-layer chromatography (SiO2, solvent: CHCl3/MeOH,
about 10:1 v/v). After the completion of the reaction (1.5–5 h), the reaction mixture was 
evaporated to dryness in vacuo. The desired product 71a-m was purified either by liquid 
column chromatography (SiO2, solvent: CHCl3) or recrystallization. 
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N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-(2-methyl-4-quinolinyl)hydrazine-
carboxamide (71a).  Compound 71a was prepared from 4-hydrazino-2-methylquinoline
(70a, 1.05 g, 5 mmol) and isocyanate 65 (freshly prepared from 64, 2.60 g, 8 mmol). 
Yield, 2.05 g (94%); mp 263–264 oC; 1H NMR (DMSO-d6) δ 10.84 (brs, 1H, NH, 
exchangeable), 9.12 (each 1H, s, NH, exchangeable), 9.04 (1H, s, NH, exchangeable), 
8.49 (d, J = 8.5 Hz, 1H, ArH), 8.03 (d, J = 8.5 Hz, 1H, ArH), 7.97 (t, J = 7.1 Hz, 1H, ArH 
), 7.72 (t, J = 7.7 Hz, 1H, ArH), 6.89 (s, 1H, ArH), 6.70 (d, J = 9.0 Hz, 2H, ArH), 3.68–
3.71 (m, 8H, 4×CH2), 2.71 (s, 3H, CH3). Anal. Calcld. for (C21H23Cl2N4O): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-(6-methoxy-2-methyl-4-quinolinyl)-
hydrazine carboxamide (71b). Compound 71b was prepared from 4-hydrazino-6-
methoxy-2-methylquinoline (70b, 0.36 g, 1.5 mmol) and isocyanate 65 (freshly prepared 
from 64, 0.84 g, 2.7 mmol).  Yield, 0.413 g (60%); mp 255–256 oC; 1H NMR (DMSO-d6)
δ 10.65 (brs, 1H, NH, exchangeable), 9.11 (1H, s, NH, exchangeable), 9.01 (1H, s, NH, 
exchangeable), 7.96 (d, J = 9.2 Hz, 1H,  ArH), 7.91 (d, J = 2.2 Hz, 1H, ArH), 7.61 (dd, J
= 2.2 and 9.2 Hz, 1H, ArH), 7.31 (d, J = 9.0 Hz, 2H,  ArH), 6.84 (s, 1H, ArH), 6.70 (d, J
= 9.0 Hz, 2H,  ArH), 3.94 (s, 3H, OMe), 3.68–3.70 (m, 8H, 4×CH2), 2.68 (s, 3H, Me). 
Anal. Calcld. for (C22H25Cl2N5O2): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-(6-methyl[1,3]dioxolo[4,5-g]quinolin-8-yl)
hydrazine-carboxamide (71c).  Compound 71d was prepared from 8-hydrazino-6-
methyl[1,3]dioxolo[4,5-g]quinoline  (70c, 0.51 g, 2 mmol) and isocyanate 65 (freshly 
prepared from 64, 1.21 g, 3.6 mmol). Yield, 0.76 g (80%); mp 253–254 oC; 1H NMR 
(DMSO-d6) δ 10.42 (brs, 1H, NH, exchangeable), 9.06 (1H, s, NH, exchangeable), 9.06 
(1H, s, NH, exchangeable),  7.44 (s, 1H, ArH), 7.86 (s, 1H, ArH), 6.78 (s, 1H, ArH), 7.29 
(d, J = 8.1 Hz, 2H, ArH), 6.69 (d, J = 8.1 Hz, 2H, ArH), 6.32 (s, 2H, CH2), 3.68–3.70 (m, 
8H, 4×CH2), 2.63 (s, 3H, Me). Anal. Calcld. for (C22H23Cl2N5O3): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-[6-(dimethylamino)-2-methyl-4-quinolinyl] 
hydrazine-carboxamide (71d).  Compound 71d was prepared from 4-hydrazino-N,N,2-
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trimethyl-6-quinolinamine (70d, 1.26 g, 5 mmol) and isocyanate 65 (freshly prepared 
from 64, 2.60 g, 8 mmol). Yield, 1.61 g (68%); mp 260–261 oC; 1H NMR (DMSO-d6) δ
10.42 (brs, 1H, NH, exchangeable),  9.10 (1H, s, NH, exchangeable), 8.94 (1H, s, NH, 
exchangeable), 7.85 (d, J = 9.3 Hz, 1H, ArH), 7.57 (dd, J = 9.4 and 2.1 Hz, 1H,  ArH), 
7.30–7.32 (m, 3H, ArH), 6.69–6.74 (m, 3H, ArH), 3.68–3.70 (m, 8H, 4×CH2), 3.07 (s, 
6H, 2×CH3), 2.64 (s, 3H, CH3).  Anal. Calcld. for (C23H28Cl2N6O): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-(2-phenyl-4-quinolinyl)hydrazine-
carboxamide (71f). Compound 71f was prepared from 4-hydrazinyl-2-phenylquinoline
(70f, 1.4 g, 5 mmol) and isocyanate 65 (freshly prepared from 64, 2.60 g, 8 mmol). Yield, 
1.48 g (60%); mp 235–236 oC; 1H NMR (DMSO-d6) δ 11.13 (s, 1H, NH, exchangeable), 
9.31 (s, 1H, NH, exchangeable), 9.28 (s, 1H, NH, exchangeable), 8.59 (d, J = 8.4 Hz, 1H, 
ArH), 8.34 (d, J = 8.4 Hz, 1H, ArH), 8.06–8.02 (m, 3H, ArH), 7.77 (t, J = 7.6 Hz, 1H, 
ArH), 7.72–7.66 (m, 3H, ArH), 7.31–7.29 (d, J = 8.8 Hz, 2H, ArH), 7.19 (s, 1H, ArH), 
6.70 (d, J = 8.8 Hz, 2H, ArH), 3.71–3.67 (m, 8H, 4×CH2). Anal. Calcld. for 
(C26H25Cl2N5O): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-(6-phenyl[1,3]dioxolo[4,5-g]quinolin-8-yl) 
hydrazine-carboxamide (71g). Compound 71g was prepared from 8-hydrazinyl-6-
phenyl-[1,3]dioxolo[4,5-g]quinoline (70g, 0.77 g, 2.75 mmol) and isocyanate 65 (freshly 
prepared from 64, 1.56 g, 5 mmol). Yield, 0.95 g (64%); mp 289–291 oC; 1H NMR 
(DMSO-d6) δ 10.59 (s, 1H, NH, exchangeable), 9.19 (s, 1H, NH, exchangeable), 9.15 (s, 
1H, NH, exchangeable), 7.97–7.95 (m, 3H, ArH), 7.77 (s, 1H, ArH), 7.66–7.65 (m, 3H, 
ArH), 7.29 (d, J = 8.8 Hz, 2H, ArH), 7.10 (s, 1H, ArH), 6.69 (d, J = 8.8 Hz, 2H, ArH), 
6.37 (s, 2H, CH2), 3.70–3.68 (m, 8H, 4×CH2). Anal. Calcld. for (C27H25Cl2N5O3): C, H, 
N.
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-[6-chloro-2-(3-methoxyphenyl)-4-
quinolinyl] hydrazine-carboxamide (71h). Compound 71h was prepared from 6-chloro-
4-hydrazinyl-2-(3-methoxyphenyl)quinoline (70h, 0.75 g, 4 mmol) and isocyanate 65
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(freshly prepared from 64, 2.24 g, 7.2 mmol). Yield, 0.86 g (61%); mp 237–238 oC; 1H
NMR (DMSO-d6) δ 11.22 (s, 1H, NH, exchangeable), 9.36 (s, 1H, NH, exchangeable), 
9.25 (s, 1H, NH, exchangeable), 8.77 (d, J = 2 Hz, 1H, ArH), 8.47 (d, J = 9.2 Hz, 1H, 
ArH), 8.12–8.08 (dd, J = 2.2 and 9.0 Hz, 1H, ArH), 7.63–7.54 (m, 3H, ArH), 7.31–7.23 
(m, 4H, ArH), 6.70 (d, J = Hz, 2H, ArH), 3.90 (s, 3H, OMe), 3.69–3.68 (m, 8H, 4×CH2).
Anal. Calcld. for (C27H26Cl3N5O2): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-[6-methoxy-2-(3-methoxyphenyl)-4-
quinolinyl] hydrazine-carboxamide (71i). Compound 71i was prepared from 4-
hydrazinyl-6-methoxy-2-(3-methoxyphenyl)quinoline (70i, 0.59 g, 2 mmol) and 
isocyanate 65 (freshly prepared from 64, 1.21 g, 2.7 mmol).  Yield, 0.79 g (71%); mp 
215–216 oC; 1H NMR (DMSO-d6) δ 10.89 (s, 1H, NH, exchangeable), 9.23 (s, 2H, 
2×NH, exchangeable), 8.29 (d, J = 9.2 Hz, 1H, ArH), 7.99 (s, 1H, ArH), 7.67 (d, J = 8.8 
Hz, 1H, ArH), 7.57–7.50 (m, 3H, ArH), 7.31–7.23 (m, 3H, ArH), 7.16 (s, 1H, ArH), 6.69 
(d, J = 8.4 Hz, 2H, ArH), 3.97 (s, 3H, OMe), 3.89 (s, 3H, OMe), 3.68 (m, 8H, 4×CH2).
Anal. Calcld. for (C28H29Cl2N5O3): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-[6-(3-methoxyphenyl)[1,3]dioxolo[4,5-
g]quinolin-8-yl]hydrazine-carboxamide (71j). Compound 71j was prepared from 8-
hydrazinyl-6-(3-methoxyphenyl)-[1,3]dioxolo[4,5-g]quinoline (70j, 0.62 g, 2 mmol) and 
isocyanate 65 (freshly prepared from 64, 1.21 g, 3.6 mmol). Yield, 0.83 g (73%); mp 
279–280 oC; 10.60 (s, 1H, NH, exchangeable), 9.26 (s, 1H, NH, exchangeable), 9.22 (s, 
1H, NH, exchangeable), 7.99 (s, 1H, ArH), 7.89 (s, 1H, ArH), 7.57–7.49 (m, 3H, ArH), 
7.29 (d, J = 8.4 Hz, 2H, ArH), 7.21 (d, J = 7.6 Hz, 1H, ArH), 7.10 (s. 1H, ArH), 6.69 (d, J
= 8.4 Hz, 2H, ArH), 6.35 (s, 2H, CH2), 3.89 (s, 3H, OMe), 3.69–3.67 (m, 8H, 4×CH2).
Anal. Calcld. for (C28H27Cl2N5O4): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-[2-(3-methoxyphenyl)-6-(1-pyrrolidinyl)-4-
quinolinyl] hydrazine-carboxamide (71k). Compound 71k was prepared from 4-
hydrazinyl-2-(3-methoxyphenyl)-6-(pyrrolidin-1-yl)quinoline (70k, 1.17 g, 3.5 mmol) 
and isocyanate 65 (freshly prepared from 64, 1.6 g, 5.4 mmol). Yield, 1.41 g (68%); mp 
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190–191 oC; 10.60 (s, 1H, NH, exchangeable), 9.26 (s, 1H, NH, exchangeable), 9.20 (s, 
1H, NH, exchangeable), 8.19 (d, J = 8.8 Hz, 1H, ArH), 7.55–7.53 (m, 2H, ArH), 7.49–
7.43 (m, 2H, ArH), 7.30 (d, J = 8 Hz, 2H, ArH), 7.23–7.21 (m, 2H, ArH), 7.06 (s, 1H, 
ArH), 6.69 (d, J = 8.4 Hz, 2H, ArH), 3.89 (s, 3H, OMe), 3.69–3.68 (m, 8H, 4×CH2), 3.40 
(m, 4H, 2×CH2), 2.04 (m, 4H, 2×CH2). Anal. Calcld. for (C31H34Cl2N6O2): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-[6-(2-fluorophenyl)[1,3]dioxolo[4,5-
g]quinolin-8-yl]hydrazine-carboxamide (71l). Compound 71l was prepared from 6-(2-
fluorophenyl)-8-hydrazinyl-[1,3]dioxolo[4,5-g]quinoline (70l, 0.56 g, 2 mmol) and 
isocyanate 65 (freshly prepared from 64, 1.21 g, 3.6 mmol). Yield, 0.87 g (78%); mp 
211–212 oC; 10.70 (s, 1H, NH, exchangeable), 9.19 (s, 1H, NH, exchangeable), 9.16 (s, 
1H, NH, exchangeable), 7.95 (s, 1H, ArH), 7.84 (t, J = 6.8 Hz, 1H, ArH), 7.72–7.68 (m, 
1H, ArH), 7.65 (s, 1H, ArH), 7.53–7.45 (m, 2H, ArH), 7.28 (d, J = 8.8 Hz, 1H, ArH),  
7.03 (s, 1H, ArH), 6.69 (d, J  =8.8  Hz, 2H, ArH), 6.37 (s, 1H, ArH), 6.37 (s, 2H, CH2),
3.69–3.67 (m, 8H, 4×CH2). Anal. Calcld. for (C27H24Cl2FN5O3): C, H, N. 
N-{4-[Bis(2-chloroethyl)amino]phenyl}-2-[2-(2-fluorophenyl)-6-(1-pyrrolidinyl)-4-
quinolinyl]hydrazine-carboxamide (71m). Compound 71m was prepared from 2-(2-
fluorophenyl)-4-hydrazinyl-6-(pyrrolidin-1-yl)quinoline (70m, 1.29 g, 4 mmol) and 
isocyanate 65 (freshly prepared from 64, 2.24 g, 7.2 mmol). Yield, 1.44 g (62%); mp 
270–271 oC; 1H NMR (DMSO-d6) δ 10.67 (s, 1H, NH, exchangeable), 9.26 (s, 1H, NH, 
exchangeable), 9.20 (s, 1H, NH, exchangeable), 8.06 (d, J = 9.2 Hz, 1H, ArH), 7.83 (t, J
= 7.6 Hz, 1H, ArH), 7.72–7.67 (m, 1H, ArH), 7.52–7.45 (m, 3H, ArH), 7.30–7.28 (m, 3H, 
ArH), 6.96 (s, 1H, ArH), 6.69 (d, J = 8.8 Hz, 2H, ArH), 3.69–3.68 (m, 8H, 4×CH2), 3.42 
(m, 4H, 2×CH2), 2.05 (m, 4H, 2×CH2). Anal. Calcld. for (C30H31Cl2FN6O): C, H, N. 
Cytotoxicity Assays 
The cytotoxic effects of the newly synthesized compounds were determined in T-
cell acute lymphocytic leukemia (CCRF-CEM) and their resistant subcell lines (CCRF-
CEM/Taxol and CCRF-CEM/VBL) by the XTT assay81 and human solid tumor cells (i.e. 
breast carcinoma MX-1 and colon carcinoma HCT-116) by the SRB assay82 in a 72 h 
incubation using a microplate spectrophotometer as described previously.83 After the 
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addition of phenazine methosulfate-XTT solution, incubated at 37 oC for 6 h and 
absorbance at 450 and 630 nm was detected on a microplate reader (EL 340). The 
cytotoxicity of the newly synthesized compounds against non-small cell lung cancer 
H1299, human prostate cancer PC3, human lung adenocarcinoma CL1-0 and CL1-5 and 
human breast adenocarcinoma MCF-7 were determined by the WST-1 assay100 in a 72 h 
incubation using a microplate spectrophotometer as described previously. After the 
addition of WST-1 solution, it was incubated at 37 oC for 4 h. Absorbance at 460 and 630 
nm was detected on a microplate reader. IC50 values were determined from dose-effect 
relationship at six or seven concentrations of each drug using the CompuSyn software by 
Chou and Martin84 based on the median-effect principle and plot.85,86 Ranges given for 
Taxol, Vinblastine and Cisplatin were mean ± SE (n = 4). 
In Vivo Studies
Athymic nude mice bearing the nu/nu gene were obtained from NCI, Frederick, 
MD and used for all human tumor xenografts. Male nude mice 6 weeks or older weighing 
20-24 g or more were used. Compounds were administered via the tail vein for i.v. 
injection as described previously.83 Tumor volume was assessed by measuring length × 
width × height (or width) by using a caliper. Vehicle used was 50 μL DMSO and 40 μL
Tween 80 in 160 μL saline. The maximal tolerate dose of the tested compound was 
determined and applied for the in vivo therapeutic efficacy assay. For tumor-bearing nude 
mice during the course of the experiment, the body weight refers to total weight minus the 
weight of the tumor. All animal studies were conducted in accordance with the guidelines 
for the National Institute of Health Guide for the Care and Use of Animals and the 
protocol approved by the Institutional Animal Care and Use Committee. 
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Summary 
Cancer is still the most lethal illnesses known worldwide after heart disease. 
Although significant research has done to date to cancer diseases, there is still a lack of 
effective chemotherapeutic treatment to cure it completely. The aim of the thesis is to 
establish research platforms for a better discovery and development of anticancer agents 
with high therapeutic efficacy, low toxicity, good bioavailability, and effective against 
various multi-drug resistant tumor cells. The following classes of DNA alkylating agents 
have been designed and synthesized to treat cancer. 
To search more potent DNA bi-functional alkylating agents, a series of 
bis(hydroxymethyl)-8H-3a-azacyclopenta[a]indene-1-yl derivatives and their 
bis(carbamate) derivatives, were designed and synthesized. All of them have displayed 
excellent and reproducible anti-tumor activity against human leukemia (CCRF-CEM) and 
its drug resistant sublines (CCRF-CEM/Taxol and CCRF-CEM/VBL) and various solid 
tumors (breast carcinoma MX-1, colon carcinoma HCT-116, lung carcinoma H1299, oral 
carcinoma OECM1, prostate carcinoma PC3, and human glioma U87) cell growths in 
vitro. The present studies also demonstrated that these derivatives exhibited significant 
‘curative’ antitumor efficacy in vivo with a relatively low toxicity. Detailed SAR studies 
demonstrated that the size and electron properties of the substituent at C3 affected the 
cytotoxicity of these agents. Among these agents, BO-1090 (63a), BO-1099 (63b), BO-
1012 (64g), and BO-1124 (64h) were found to have potent therapeutic efficacy against 
human breast MX-1 xenograft in animal model. Complete tumor remission was achieved 
in nude mice bearing human breast carcinoma MX-1 xenograft by these derivatives. It is 
also interesting to note that compound BO-1099 (63b) was able to significantly suppress 
human prostate adenocarcinoma PC3 xenograft in nude mice. Studies on the DNA 
interstrand cross-linking suggested that the newly synthesized derivatives are potent bi-
functional DNA cross-linking agents. Furthermore, these agents induced substantial 
G2/M phase arrested of the cell cycle.  
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Previously, Su et al. have reported a series of alkyl N-mustards-9-anilinoacridines 
conjugates via a O-alkyl spacer. Among these agents, BO-0742 exhibited potent 
therapeutic efficacy against human breast and ovarian tumor xenografts in vivo.  
However, this agent is chemically unstable and has short half-life (t1/2 < 25 min) in rat. To 
search for more stable and potent DNA-directed alkylating agents endowed with potent 
antitumor activity, several new phenyl N-mustard-quinoline conjugates having urea and 
hydrazine-carboxamide spacer were synthesized for antitumor evaluation. All of the new 
N-mustards conjugates found to have potent antiproliferative activity against human 
leukemia (CCRF-CEM) and its drug resistant sublines (CCRF-CEM/Taxol and CCRF-
CEM/VBL) and various solid tumors (breast carcinoma MX-1, colon carcinoma HCT-
116, non-small cell lung cancer H-1129, human prostate cancer PC-3, human lung 
adenocarcinoma CL1-0 and human breast adenocarcinoma MCF-7) cell growths in vitro. 
Among these derivatives, compound BO-1038 (69a), BO-1049 (69i), BO-1233 (71a), 
BO-1242 (71d), BO-1243 (71c), BO-1391 (71g), and BO-1397 (71j) were found to have 
potent therapeutic efficacy against human breast MX-1 xenograft in animal model. 
Complete tumor remission was achieved in nude mice bearing human breast carcinoma 
MX-1 xenograft by these derivatives. Compound BO-1049 (69i) also effectively 
suppressed human glioma U87 MG xenograft in nude mice. Moreover, compound BO-
1038 (69a) also exhibited significant curative effect against human breast MCF-7/Adr 
xenograft, A549 lung carcinoma xenograft, and ovarian SK-OV-3 carcinoma xenograft in 
nude mice. Compound BO-1242 (71d) and BO-1243 (71c) were able to significantly 
suppress human colon HCT-116 xenograft in nude mice. At their optimum doses, all the 
tested the compounds are well-tolerated by the host as reflected from body weight 
change. Moreover, BO-1038 (69a) is able to cross-link with DNA and has a long half-life 
in rat plasma. All the above data support the excellent chemotherapeutic efficacy and 
potential candidature of BO-1038 (69a) for further drug development. Thus one can 
anticipate that all the newly synthesized DNA-alkylating agents will have excellent 
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chemotherapeutic efficacy. All the above data support the potential candidature of the 
newly synthesized derivatives for further drug developments. 
 
In all 131 derivatives have been synthesized in current work which are 
characterized by spectral data. All the final compounds were tested for preliminary 
antitumor activity and advanced study. Other mechanistic studies like DNA interstrand 
cross-linking, cell cycle inhibition and rat plasma stability was also performed in the 
current work. 
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A series of 9-anilinoacridines having an alkylating N-mustard pharmacophore on both anilino (C-30 or C-
40) and acridine (C-4) rings with O-ethyl (O-C2) or O-butyl (O-C4) spacer were synthesized to evaluate
their cytotoxicity against human lymphoblastic leukemia (CCRF-CEM) cell growth in vitro. It was
revealed that these conjugates exhibited signiﬁcant in vitro cytotoxicity. Among these agents, compound
13 was the most cytotoxic with IC50 value of 1.3 nM and is as potent as taxol (IC50¼1.1 nM). The
structure–activity relationship study showed that the length of the spacer and the position of the
substituent do affect their cytotoxicity.
 2008 Elsevier Masson SAS. All rights reserved.1. Introduction
Nitrogen mustards (chlorambucil, melphalan) are bifunctional
DNA-alkylating agents and are widely used in the treatment of
a variety ofmalignant diseases [1–3]. These agents are able to cross-
link cellular DNA and thereby interfere with the DNA replication.
However, because of their high reactivity, they are chemically
unstable and produce many unwanted side effects including bone
marrow toxicity and genotoxicity [4,5]. To improve the drawbacks
of nitrogen mustards, one effective strategy is to design and
synthesize DNA-directed alkylating agents by linking the N-
mustard residue to DNA-afﬁnic molecules such as DNA-inter-
calators [e.g., anthraquinone [6], cyclopentanthraquinone [7]
quinoline [8,9], 9-aminoacridine [10,11], 9-anilinoacridine [11–14]
(1–5, Chart 1)] and DNA minor groove binders (e.g., distamycin A
and its analogues [15–21] such as tallimustine [21]). In general,
these conjugates are more potent than their corresponding
unmasked nitrogen mustards and yet have higher sequence spec-
iﬁcity for DNA interaction.
Recently, we have synthesized a series of 9-anilinoacridines
bearing a N-mustard pharmacophore on the C-3 or C-4 of ani-
lino ring via a linker with various lengths such as methyl, O-
ethyl (O-C2) or O-butyl (O-C4) spacer [13]. We demonstrated that
these agents were about 100-fold more cytotoxic than thex: þ886 2 27827685.
son SAS. All rights reserved.
et al., Synthesis and in vitro
l of Medicinal Chemistry (200parent 3-(9-acridinylamino)-5-hydroxymethylaniline (AHMA, 6)
[22]. Of these compounds, BO-0742 (3) exhibited potent cyto-
toxicity against various human leukemia and solid tumor cell
growth in vitro [13]. Furthermore, BO-0742 exhibited a broad
spectrum of antitumor activity against various human solid
tumor xenografts in vivo [13]. Total tumor remission was ach-
ieved in nude mice bearing human breast carcinoma MX-1
xenograft. We have also synthesized a series of 9-anilinoacridines
having N-mustard residue on the C-4 of the acridine chromophore
[14]. Among these derivatives, compounds 4 and 5 were shown
to have potent antitumor activity in nude mice bearing MX-1
xenograft. The therapeutic efﬁcacies of BO-0742, 4 and 5 are
comparable to those of taxol. The topoisomerase II-mediated DNA
cleavage by these agents has been studied and suggested that
they are DNA cross-linking agents rather than topoisomerase II
poisons [13,14]. Our unpublished results showed that BO-0742
was about 10-fold less toxic to human normal hemopoietic stem
cells (CFU-E, BFU-E and CFU-GM) than leukemic CCRF-CEM
suggesting that this agent has low toxicity to human bone
marrow.
As a part of our ongoing research on searching new potent DNA-
directed alkylating agents, we have synthesized 9-anilinoacridine
analogues bearing the N-mustard residue on both anilino and
acridine rings for antitumor evaluation. The results revealed that
the newly synthesized derivatives exhibited signiﬁcant in vitro
cytotoxicity. Herein, we describe the synthesis and biological
evaluation of the new N-mustard conjugates.cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both
8), doi:10.1016/j.ejmech.2008.07.016
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The synthetic route for the 9-anilinoacridines bearing an alky-
lating N-mustard residue on both anilino and acridine rings with O-
ethyl (O-C2) and O-butyl (O-C4) linkers is shown in Scheme 1.
Intermediates, 9-chloroacridines (7) and aniline-N-mustard
conjugates (8), were prepared by following the procedure
previously developed in our laboratory [13,14]. Synthesis of
conjugates 9–13 having N-mustard residues on both anilino and
acridine rings was achieved by the reaction of freshly prepared 9-
chloroacridines (7a,b) with anilines (8a, 8b, 8c and 8d) in ethanol at
5 C. After completion of the reaction, the desired products were
puriﬁed by column chromatography.
The cytotoxic effects of the newly synthesized derivatives
against human T-cell acute lymphocytic leukemia CCRF-CEM cell
growth were determined by XTT-tetrazolium assay [23] and
compared with N-mustards linked to either anilino ring or acridine
chromophore of the 9-anilinoacridines [13,14], AHMA (6) and taxol.N
Cl
O(CH2)mN(CH2CH2Cl)27a m = 27b m = 4
O(CH2)nN(CH
R
CHCl3/EtOH, Con. HCl (1-2 drops)
8
8a  R = 3-NH
2
  n = 2,
8b  R = 3-NH
2
  n = 4,
8c  R = 4-NH
2
  n = 2,
8d  R = 4-NH
2
  n = 4
Scheme 1. Synthesis of 9-anilinoacridine analogues (9–13) bearin
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compoundswere about 30- to 580-foldmore potent thanAHMA (6).
Of these agents, compound 13 was the most cytotoxic with IC50
value of 1.3 nM and was as potent as taxol (IC50¼1.1 mM). The
cytotoxicity of compounds bearingN-mustard pharmacophore at C-
4 on the acridine ring having –O–(CH2)2– linker revealed that
derivatives bearing N-mustard residue at C-30 were as potent as or
more potent than the corresponding derivatives having this residue
on C-40 (9 vs 11 and 10 vs 12). Compounds having –O–(CH2)n– linker
at C-30 yielded higher in vitro activity when n¼ 4 than n¼ 2 (9was
3-fold more potent than 10). In contrast, the conjugates bearing
linker at C-40 position afforded higher cytotoxicity when n¼ 2 than
n¼ 4.
Previously, we have demonstrated that N-mustards linked to 9-
anilinoacridines on the anilino ring with –O–(CH2)n– spacer
between mustard residue and the anilino ring (i.e., 14–17, Table 1)
yielded higher in vitro activity when n¼ 2 than n¼ 4 [13]. While in
contrast, 9-anilinoacridine derivatives bearing N-mustard residueN
HN
O(CH2)mN(CH2CH2Cl)2
O(CH2)nN(CH2CH2Cl)2
2CH2Cl)2
9-13
g the N-mustard residue on both anilino and acridine rings.
cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both
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Table 1
Analytical data and cytotoxicity of N-mustard derivatives against human lympho-
blastic leukemic cell (CCRF-CEM) growth in vitro
N
HN
R4
R1
R2
R3
1
2
3
4
5
6
Compound R1 R2 R3 R4 Mp (C) Yield (%) Anal. Calcd IC50 (nM)
9 A H H A 108–109 39.5 C, H, N 17.0
10 B H H A 98–99 40 C, H, N 6.0
11 H A H A 105–106 62 C, H, N 14.2
12 H B H A 95–96 24 C, H, N 21.0
13 H A H B 101–102 63 C, H, N 1.3
14 [13] A H H H 86.0
15 [13] B H H H 392.0
16 [13] H A H H 20.0
17 [13] H B H H 56.0
4 [14] NH2 H OMe A 6.7
5 [14] NH2 H OMe B 4.2
AHMA [22] NH2 H CH2OH H 753.0
Taxol 1.1
A¼O(CH2)2N(CH2CH2Cl)2. B¼O(CH2)4N(CH2CH2Cl)2.
Cell growth inhibition was measured by the XTT assay for leukemic cells after 72 h
incubation using a micro-plate spectrophotometer as described previously [23]. IC50
values were determined from dose–effect relationship at six or seven concentrations
of each drug by using the CompuSyn software based on the median–effect principle
and plot [24,25].
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yielded higher in vitro activity when n¼ 4 than n¼ 2 (4 vs 5) [14].
Based on the present structure–activity relationship study and the
previous results, it suggested that introducing a –O–(CH2)4– spacer
on the acridine ring can enhance the cytotoxicity of this series of
compounds. The new N-mustard conjugates were subjected to in
vivo antitumor evaluation, however, we found that these agents
have poor solubility in intravenous injection vehicle (DMSO/Tween
80/normal saline) and are very toxic to mice; mice died at the dose
of 2 mg/kg, QD 3, via intravenous injection demonstrating that
these agents were more toxic than BO-0742.3. Conclusion
We have synthesized a series of 9-anilinoacridines bearing an
alkylating N-mustard residue on both anilino and acridine rings. It
was revealed that these agents exhibited signiﬁcant cytotoxicity
against human lymphoblastic leukemia CCRF-CEM cell growth in
vitro. The length of the spacer used to connect theN-mustard residue
and DNA-afﬁnic carrier signiﬁcantly affected the cytotoxicity of these
agents. Among these agents, compound 13was found to be the most
potent being equivalent to taxol. Although these derivatives
possessed signiﬁcant in vitro cytotoxicity, they have poor solubility
and are more toxic than BO-0742 when the antitumor experiments
were carried out in animal model. So far, all N-mustard derivatives
linked to 9-anilinoacridines synthesized from our laboratory can be
considered as alkyl N-mustard analogues. The inductive effect of the
alkyl function may enhance the formation of the active aziridium
cation intermediate, which is able to react rapidly with nucleophile,
such as the deoxyguanosine (dG) residue of DNA, resulting in high in
vitro cytotoxicity, but possess low stability. While the phenyl N-Please cite this article in press as: C.-H. Chen et al., Synthesis and in vitro
anilino and acridine rings, European Journal of Medicinal Chemistry (200mustards, they are less reactive probably due to the electron-
withdrawing property of the phenyl ring. To ﬁnd stable N-mustard
analogueswith potent antitumor activity, we have recently designed
and synthesized a series of new phenyl N-mustards linked to DNA-
afﬁnic molecules (9-anilinoacridines and 4-aminoquinolines) via
a urea spacer [26]. These derivatives were quiet stable and yet
exhibited potent therapeutic efﬁcacy in inhibiting various human
tumor xenografts in nude mice. The results will be reported
separately.
4. Experimental
Melting points were determined on Fargo melting point
apparatus and are uncorrected. Column chromatography was
carried out on silica gel G60 (70–230 mesh). Thin-layer chroma-
tography was performed on silica gel G60 F254 (Merck) with short-
wavelength UV light for visualization. Elemental analyses were
done on a Heraeus CHN-O Rapid instrument. 1H NMR spectra were
recorded in DMSO-d6 solution on a 400 MHz Bruker AVANCE 400
DRX spectrometer. Chemical shifts (d) are reported in parts per
million, relatively to TMS.
4.1. General procedure for the synthesis of compounds 9–13
A solution of freshly prepared 9-chloroacridines (7) [14] in
CHCl3 was added into a suspension of freshly prepared anilines (8)
[13] in ethanol at 5 C for 1 h and then stirred at room tempera-
ture for 5–7 h. The reaction mixture was evaporated to dryness
under vacuum and the desired products were obtained after
chromatography (silica gel column, solvent: CHCl3/MeOH,10:1 v/v).
The detailed synthetic procedure for representative compound 9 is
described below.
4.1.1. (4-{2-[Bis(2-chloroethyl)amino]ethoxy}acridin-9-yl)-
(3-{2-[bis(2-chloroethyl)amino]ethoxy}phenyl)amine (9)
A solution of freshly prepared 9-chloroacridine (7a, 193 mg,
0.5 mmol) in CHCl3 (25 mL) was added into a solution of freshly
prepared aniline (8a) in EtOH (10 mL) containing two drops of
concd HCl at 5 C. After being stirred for 1 h, the solution was
allowed to stir at room temperature for additional 6 h. The solution
was concentrated in vacuo and the residue was chromatographed
on a silica gel column using CHCl3/MeOH (10:1 v/v) as an eluent.
The fractions containing the main product were combined and
concentrated in vacuo and the residue was dissolved in 4.2 N HCl in
ethyl acetate solution and concentrated again in vacuo. The residue
was triturated well with EtOAc (20 mL) and the precipitates were
collected by ﬁltration and dried to give 9 as hydrochloride salt,
252 mg (39.5%); mp 108–109 C; 1H NMR (DMSO-d6) d 3.60 (4H, br
s, 2 CH2), 3.78 (6H, m, 3 CH2), 3.96 (2H, m, CH2), 4.07 (4H, m,
2 CH2), 4.20 (4H, m, 2 CH2), 4.46 (2H, br s, OCH2), 4.72 (2H, br s,
OCH2), 7.13 (2H, d, J¼ 8.3 Hz, 2ArH), 7.40–7.45 (4H, m, 4ArH),
7.57 (1H, m, ArH), 7.89 (1H, m, ArH), 7.98 (1H, m, ArH), 8.26 (1H, m,
ArH), 8.89 (1H, m, ArH), 11.90 (1H, br s, exchangeable, NH). Anal.
Calcd for C31H36N4O2Cl4$3HCl$4.01H2O: C, 45.33; H, 5.77; N, 6.82.
Found: C, 45.32; H, 5.72; N, 6.50.
By following the same procedure as that for 9, the following
compounds (10–13) were synthesized.
4.1.2. (4-{2-[Bis(2-chloroethyl)amino]ethoxy}acridin-9-yl)-
(3-{2-[bis(2-chloroethyl)amino]butoxy}phenyl)amine (10)
Compound 10 was prepared from 4-{2-[bis(2-chloroethyl)-
amino]ethoxy}-9-chloro acridine (7a, 193 mg, 0.5 mmol) and bis(2-
chloroethyl)-[2-(3-nitro-phenoxy)butyl]amine (8b, 335 mg,
1 mmol). Yield: 242 mg (40%); mp 98–99 C; 1H NMR (DMSO-d6)
d 1.75 (2H, m, CH2), 1.85 (2H, m, CH2), 3.56 (4H, m, 2NCH2), 3.81
(4H, m, 2NCH2), 3.99 (4H, m, 3 CH2), 4.09 (6H, m, 3 CH2), 4.22
cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both
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(1H, m, ArH), 7.37–7.48 (3H, m, 3ArH), 7.58 (1H, m, ArH), 7.99
(2H, m, 2ArH), 8.37 (1H, m, ArH), 8.97 (1H, m, ArH), 12.0 (1H, br s,
exchangeable, NH). Anal. Calcd for C33H40N4O2Cl4$5HCl$0.3H2O: C,
50.43; H, 5.71; N, 6.81. Found: C, 50.43; H, 5.30; N, 6.35.
4.1.3. (4-{2-[Bis(2-chloroethyl)amino]ethoxy}acridin-9-yl)-
(4-{2-[bis(2-chloroethyl)amino]ethoxy}phenyl)amine (11)
Compound 11 was prepared from 4-{2-[bis(2-chloroethyl)-
amino]ethoxy}-9-chloro acridine (7a, 569 mg, 1.5 mmol) and bis(2-
chloroethyl)-[2-(4-nitro-phenoxy)ethyl]amine (8c, 617 mg,
1.8 mmol). Yield: 595 mg (62%); mp 105–106 C; 1H NMR (DMSO-
d6) d 3.38 (4H, br s, 3 CH2), 3.73 (6H, br s, 3 CH2), 3.90 (2H, br s,
CH2), 4.01 (4H, m, 2 CH2), 4.15 (4H, m, 2 CH2), 4.43 (2H, br s,
OCH2), 4.69 (2H, br s, OCH2), 7.14 (2H, d, J¼ 8.5 Hz, 2ArH), 7.38–
7.45 (4H, m, 4ArH), 7.57–7.59 (1H, m, ArH), 7.85–7.87 (1H, m,
ArH), 7.97–8.01 (1H, m, ArH), 8.21–8.23 (1H, m, ArH), 8.84–8.86
(1H, m, ArH), 11.80 (1H, exchangeable, NH). Anal. Calcd for
C31H36Cl4N4O2$6HCl$3H2O: C, 40.85; H, 5.31; N, 6.14. Found: C,
40.87; H, 5.09; N, 6.03.
4.1.4. (4-{2-[Bis(2-chloroethyl)amino]ethoxy}acridin-9-yl)-
(4-{2-[bis(2-chloroethyl)amino]butoxy}phenyl)amine (12)
Compound 12 was prepared from 4-{2-[bis(2-chloroethyl)-
amino]ethoxy}-9-chloro acridine (7a, 455 mg, 1.2 mmol) and bis(2-
chloroethyl)-[2-(4-nitro-phenoxy)butyl]amine (8d, 588 mg,
1.5 mmol). Yield: 115 mg (24%); mp 95–96 C; 1H NMR (DMSO-d6)
d 1.88 (2H, br s, CH2), 1.97 (2H, br s, CH2), 3.36 (2H, br s, CH2), 3.63
(4H, br s, 2 CH2), 3.84 (4H, br s, 2 CH2), 4.01 (4H, br s, 2 CH2),
4.16 (4H, br s, 2 CH2C), 4.25 (4H, br s, 2 CH2Cl), 4.77 (2H, br s,
OCH2), 7.12 (2H, m, 2ArH), 7.45–7.47 (5H, m, 5ArH), 7.61 (1H,
m, ArH), 8.02 (1H, m, ArH), 8.40 (1H, m, ArH), 8.99 (1H, br s, NH),
11.90 (1H, exchangeable, NH). Anal. Calcd for
C33H40Cl4N4O2$7HCl$4H2O: C, 42.9; H, 6.00; N, 6.07. Found: C,
43.63; H, 6.10; N, 6.02.
4.1.5. (4-{2-[Bis(2-chloroethyl)amino]butoxy}acridin-9-yl)-
(4-{2-[bis(2-chloroethyl)amino]ethoxy}phenyl)amine (13)
Compound 13 was prepared from 4-{2-[bis(2-chloroethyl)-
amino]butoxy}-9-chloro acridine (7b, 407 mg,1.0 mmol) and bis(2-
chloroethyl)-[2-(4-nitro-phenoxy)ethyl]amine (8c, 412 mg,
1.2 mmol). Yield: 375 mg (63%); mp 101–102 C; 1H NMR (DMSO-
d6) d 1.64–1.72 (2H, m, CH2), 1.94–2.01 (2H, m, CH2), 2.65–2.69 (2H,
t, J¼ 7.0 Hz, CH2), 2.90 (4H, t, J¼ 8.9 Hz, 2 CH2), 3.02–3.05 (6H, m,
3 CH2), 3.51–3.78 (8H, m, 8 CH2), 4.03 (2H, t, J¼ 5.6 Hz, OCH2),
4.16 (2H, t, J¼ 6.4 Hz, OCH2), 7.17 (2H, m, 2ArH), 7.32–7.37 (2H, m,
2ArH), 7.40–7.42 (3H, m, 3ArH), 7.52 (1H, m, ArH), 7.87 (1H, m,
ArH), 7.95 (1H, m, ArH), 8.31 (1H, m, ArH), 8.78 (1H, m, ArH), 11.71
(1H, br s, exchangeable, NH). Anal. Calcd for
C33H40Cl4N4O2$8HCl$6H2O: C, 39.81; H, 6.75; N, 5.63. Found: C,
39.63; H, 6.14; N, 5.66.Please cite this article in press as: C.-H. Chen et al., Synthesis and in vitro
anilino and acridine rings, European Journal of Medicinal Chemistry (2004.2. Cytotoxicity assays
The effects of the compounds on cell growth were determined
in T-cell acute lymphocytic leukemia CCRF-CEM, in a 72 h incuba-
tion, by XTT-tetrazolium assay, as described by Scudiero et al. [23].
After the addition of phenazine methosulfate–XTT solution at 37 C
for 6 h, absorbance at 450 and 630 nm was detected on a micro-
plate reader (EL 340; Bio-Tek Instruments Inc., Winooski, VT). Six to
seven concentrations of each compound were used. The IC50 and
dose–effect relationships of the compounds for antitumor activity
were calculated by a median–effect plot [24] using a computer
program on an IBM-PC workstation [25].
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Abstract—To improve the chemical stability and therapeutic eﬃcacy of N-mustard, a series of phenyl N-mustard linked to DNA-
aﬃnic 9-anilinoacridines and acridine via a urea linker were synthesized and evaluated for antitumor studies. The new N-mustard
derivatives were prepared by the reaction of 4-bis(2-chloroethyl)aminophenyl isocyanate with a variety of 9-anilinoacridines or 9-
aminoacridine. The antitumor studies revealed that these agents exhibited potent cytotoxicity in vitro without cross-resistance to
taxol or vinblastine and showed potent antitumor therapeutic eﬃcacy in nude mice against human tumor xenografts. It also showed
that 24d was capable of inducing marked dose-dependent levels of DNA cross-linking by comet assay and has long half-life in rat
plasma.
 2008 Elsevier Ltd. All rights reserved.
1. Introduction
Bifunctional alkylating agents particularly N-mustards
have played an important role in anticancer drug devel-
opment.1,2 However, they are highly reactive species
resulting in loss of drug’s therapeutic activity against
malignancy by reacting with other cellular components
such as proteins, thiols, or genes3 and producing many
unwanted side-eﬀects including bone marrow toxicity.4
In addition, the N,N-bis(2-chloroethyl)amine pharma-
cophore required for bifunctional cross-linking of
DNA generally lacks intrinsic DNA-binding aﬃnity.
Consequently, DNA alkylation by N-mustards forms
higher ratio for genotoxic mono-adducts than the bi-ad-
ducts, the latter was found to be essential for their full
cytotoxicity.5
An eﬀective strategy to overcome the drawback of using
N-mustards is to design and synthesize DNA-directed
alkylating agents by linking the N-mustard residue to
DNA-aﬃnic molecules. These conjugates were found
to have higher cytotoxicity and therapeutic eﬃcacy than
the corresponding untargeted N-mustard derivatives.6–10
Another strategy to minimize the side-eﬀects caused by
the drug is to prepare N-mustard prodrugs, which can
be activated selectively at tumor site after enzymatic
hydrolysis. Among N-mustard prodrugs, Springer et
al. have synthesized a series of N-mustard prodrugs by
attaching the aniline mustards to L-glutamic acid moiety
through a urea, carbamate (1, Chart 1)11 or carboxam-
ide (2, CMDA)12,13 linker for antibody-directed enzyme
prodrug therapy (ADEPT). After enzymatic cleavage by
bacterial enzyme carboxypeptidase G2 (CPG2), they can
be transformed into their corresponding active metabo-
lite phenol or aniline N-mustard drugs. The prodrugs,
3,14 4,15 and 5,16 were also synthesized by linking the
aniline N-mustard to the trigger unit tyramine, 3-
hydroxytyramine, or catecholamine, respectively, via a
0968-0896/$ - see front matter  2008 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2008.04.024
Keywords: Cytotoxic; Aniline nitrogen mustards; 9-Anilinoacridines;
DNA alkylating agents.
* Corresponding author. Tel.: +886 2 27899045; fax: +886 2
27827685; e-mail: tlsu@ibms.sinica.edu.tw
Available online at www.sciencedirect.com
Bioorganic & Medicinal Chemistry 16 (2008) 5413–5423
Author's personal copy
urea or carbamate linker for melanocyte-directed en-
zyme prodrug therapy (MDEPT).16 Upon exposure to
tyrosinase, these conjugates can also release the active
aniline or phenol N-mustard. Since the prodrugs are sta-
ble before enzymatic hydrolysis, it suggests that the urea
or carbamate linker is capable of lowering the reactivity
of aniline or phenol N-mustard pharmacophore leading
to form rather stable N-mustard derivatives.
Recently, we have reported a series of DNA-directed
alkylating agents in which the alkyl N-mustard was
linked to the anilino ring or acridine chromophore of
9-anilinoacridines, such as BO-0742 (6, Chart 1)9 and
BO-0944 (7).10 These agents were about >100-fold more
cytotoxic than AHMA (8)17,18 in inhibiting human acute
lymphoblastic leukemia (CCRF-CEM) in vitro.
Remarkably, BO-0742 exhibited a broad spectrum of
antitumor activity against various human solid tumor
xenografts in vivo. Total tumor remission was achieved
in nude mice bearing human breast MX-1 xenograft.
Our unpublished results showed that BO-0742 is chem-
ically unstable and has a short half-life (< 25 min.) in
mice. The chemical instability of BO-0742 and the re-
lated compounds can be explained by the fact that these
agents are considered as alkyl N-mustard derivatives.
The inductive eﬀect of the alkyl function is thought to
be able to enhance the formation of the reactive aziridi-
um cation intermediate, which reacts rapidly with nucle-
ophile, such as the deoxyguanosine (dG) residue of
DNA. While in the case of phenyl N-mustards, they
are rather stable due to the electron-withdrawing prop-
erty of phenyl ring. Therefore, in our continual develop-
ment eﬀorts on new potent DNA-targeted alkylating
agents having an improved pharmacokinetics, it is of
great interest to design and synthesize phenyl N-mus-
tards linked to DNA-aﬃnic molecule such as 9-anilino-
acridines through a urea linker instead of alkyl
N-mustard residue and carbon-chain spacer, since
phenyl N-mustards having a urea linker at para-position
are chemically less reactive than phenol or aniline
N-mustards.11,14,15 We found that the newly synthesized
compounds were much more stable than BO-0742 and
displayed potent therapeutic eﬃcacy against several
human xenografts in animal model. Herein, we describe
the synthesis and antitumor activity of the new
conjugates.
2. Chemistry
The newly synthesized compounds are phenyl N-mus-
tards linked to 9-anilinoacridines via a urea spacer. In
general, the urea linker can be prepared by reacting an
amine derivative with either substituted carbamoyl chlo-
rides or isocyanate derivatives (Scheme 1). We found
that the desired compounds (24a–n and 26) can be
synthesized in better yields by treating 4-bis(2-chloroeth-
yl)aminophenyl isocyanate 10 with a variety 9-anilinoac-
ridines (8, 11–23). Following the reported procedure
with modiﬁcation14,15 aniline N-mustard 9 was synthe-
sized, which was further converted into isocyanate 1021
by treating with triphosgene. The freshly prepared 10
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Chart 1. Chemical structures of N-mustard derivatives.
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was then reacted with various 9-anilinoacridines (8, 11–
23), prepared by following the method previously devel-
oped in our laboratory,17,19,20 in dry DMF in the pres-
ence of triethylamine or pyridine at room temperature
to furnish the desired phenyl N-mustards linked to 9-
anilinoacridine conjugates via a urea linker (24a–n). In
a similar manner treatment of 10 with 9-aminoacridine
(25) aﬀorded acridine-N-mustard conjugate 26 in good
yield. The yields and physical properties of the new N-
mustard conjugates are shown in Table 1.
3. Biological results and discussion
3.1. In vitro cytotoxicity
We have previously demonstrated that antitumor
9-anilinoacridines including 3-(9-acridinylamino)-5-
hydroxymethylanilines (AHMAs),17 5-(9-acridinylami-
no)toluidines,19 and 5-(9-acridinylamino)anisidines20
are potent inhibitors of topoisomerase II and capable
of intercalating into DNA doubled strands. Hence,
they are suitable as a carrier for constructing the
new DNA-targeted compounds. Table 2 showed the
cytotoxicity of the newly synthesized N-mustards
(24a–n and 26) against human lymphoblastic leukemia
(CCRF-CEM), breast carcinoma (MX-1), and colon
carcinoma HCT-116 and was compared with BO-
0742 (6) and the untargeted N-mustard 9. It was
revealed that these conjugates possessed signiﬁcant
cytotoxicity with IC50 values in submicro molar range
and did not exhibit cross-resistance to either vinblas-
tine or taxol. The structure–activity relationships stud-
ies of the newly synthesized derivatives showed that
the C4 0-OMe and C5 0-OMe substituted compounds
were more cytotoxic than the corresponding C4 0-Me
and C5 0-Me derivatives (24h vs 24c, 24i vs 24d, 24j
vs 24e) against CCRF-CEM cell growth in vitro. In
contrast, the C4 0-Me and C5 0-Me substituted com-
pounds were more potent than the corresponding
C4 0-OMe and C5 0-OMe derivatives (24c vs 24h, 24d
vs 24i, 24e vs 24j) in inhibiting MX-1 cell growth.
Although, the C6 0-Me substituted compounds were
more cytotoxic than the corresponding C6 0-OMe
derivatives (24f vs 24m and 24g vs 24n) against
CCRF-CEM cell growth, they (24f vs 24m) were
equally potent against MX-1 cell growth. The cytotox-
icity of the series of OMe substituted compounds
against CCRF-CEM showed that the C4 0-OMe deriv-
atives (24h and 24i) were about 2- to 5-fold more po-
tent than the corresponding C5 0-OMe (24j and 24k)
and C6 0-OMe (24m and 24n) conjugates. As for the
inhibitory eﬀect of these conjugates against HCT-116
cell growth in culture, it showed that C4 0-Me and
C4 0-OMe derivatives were more cytotoxic than the
10
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Scheme 1. Synthesis of N-mustard linked to 9-anilinoacridines and 9-aminoacridine via a urea linkage. Reagents and conditions: (a) triphosgene/
Et3N/CHCl3, 0 C; (b) Et3N or pyridine/DMF, room temperature.
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C5 0-Me and C5 0-OMe conjugates (24c vs 24e, 24h vs
24j 24i vs 24k). It is of great interest to note that
the cytotoxicity of these agents can be increased by
addition of Me group at C4 (24b, 24f, 24k, and
24n), or CONHCH2CH2NMe2 and Me at C4 and
C5 (24h and 24l), respectively (except for compounds
Table 1. Analytical data and yields of N-mustard linked to 9-anilinoacridines (24a–n and 26)
N
HN
HN
O
N
H
N(CH2CH2Cl2)2
R
3
R
2
1'
2'
3'
4'
5'
6'
45
R
1
Compound R1 R2 R3 Mp (C) Yield (%) Analysis
24a 50-CH2OH H H 174–175 53.8 C, H, N
24b 50-CH2OH H Me 251–252 55.2 C, H, N
24c 40-Me H H 271–272 57.1 C, H, N
24d 40-Me H Me 267–268 83.8 C, H, N
24e 50-Me H H >280 39.0 C, H, N
24f 60-Me H Me 255–256 44.0 C, H, N
24g 60-Me Me CONH(CH2)2NMe2 >280 32.0 C, H, N
24h 40-OMe H H 263–264 70.2 C, H, N
24i 40-OMe H Me 255–256 60.2 C, H, N
24j 50-OMe H H 260–261 64.5 C, H, N
24k 50-OMe H Me 253–254 63.7 C, H, N
24l 50-OMe H CONH(CH2)2NMe2 188–190 61.8 C, H, N
24m 60-OMe H H 268–269 80.4 C, H, N
24n 60-OMe H Me 270–272 48.8 C, H, N
26 184–186 60 C, H, N
Table 2. Cytotoxicity of new N-mustards against human lymphoblastic leukemia (CCRF-CEM) and its drug-resistant sublines (CCRF-CEM/Taxol
and CCRF-CEM/VBL) and solid tumors (MX-1 and HCT-116) cell growth in vitroa
Compound IC50 (nM)
CCRF-CEM CCRF-CEM/Taxolb CCRF-CEM/VBLb MX-1 HCT-116
24a 56.2 ± 1.1 17180 ± 142[304·] c 64140 ± 2000[1141·] 369.0 ± 11 216.0 ± 19
24b 31.1 ± 0.08 393.5 ± 6.6[12.7·] 1789 ± 331[57.5·] 124.7 ± 4.5 262.6 ± 6.0
24c 16.7 ± 0.60 34.7 ± 0.80[2.08·] 33.4 ± 1.0[2.00·] 583.6 ± 26.4 264.5 ± 4.7
24d 77.8 ± 2.3 91.8 ± 15.7[1.18·] 127.9 ± 2.2[1.64·] 239.7 ± 35.6 437.4 ± 1.8
24e 141.0 ± 3.3 384.2 ± 2.0[2.72·] 593.2 ± 2.0[4.20·] 529.0 ± 21.9 815.5 ± 10.1
24f 11.4 ± 0.46 23.0 ± 0.5[2.02·] 24.5 ± 1.1[2.15·] 588.6 ± 52.3 158.1 ± 3.2
24g 11.9 ± 0.30 175.7 ± 5.6[14.7·] 303.1 ± 0.30[25.4·] 60.1 ± 1.1 60.0 ± 2.8
24h 7.7 ± 0.14 33.8 ± 1.4[4.39·] 54.9 ± 1.8[7.13·] 1203 ± 40.6 256.3 ± 8.1
24i 9.2 ± 0.24 11.5 ± 0.50[1.25·] 24.6 ± 0.07[2.76·] 367.3 ± 12.5 74.9 ± 2.7
24j 37.5 ± 1.2 50.4 ± 0.80[1.34·] 54.8 ± 0.10[1.46·] 1109 ± 61.7 495.6 ± 0.53
24k 29.6 ± 0.60 49.8 ± 1.1[1.68·] 43.3 ± 0.50 [1.46·] 868.0 ± 47.8 242.0 ± 1.6
24l 13.2 ± 0.43 30.2 ± 0.20[2.29·] 951.4 ± 3.0[72.0·] 638.0 ± 2.0 110.2 ± 5.3
24m 44.2 ± 0.32 58.8 ± 0.20[1.33·] 54.8 ± 3.7[1.24·] 590.6 ± 4.2 187.8 ± 6.1
24n 29.7 ± 0.30 57.4 ± 0.10[1.93·] 30.6 ± 2.8[1.30·] 1810.4 ± 100 571.2 ± 18.5
26 228.9 ± 23.9 385.4 ± 21.3[1.68·] 378.1 ± 17.8[1.65·] 810.1 ± 19.3 899.8 ± 23.6
9 43.4 ± 0.50 33.8 ± 0.40[0.78·] 25.7 ± 0.10[0.59·] 84.4 ± 1.7 340.8 ± 4.9
6 3.33 ± 1.5 3.20 ± 0.40[0.96·] 12.8 ± 0.70[3.84·] 3.5 ± 0.60 6.5 ± 1.2
Taxol 1.3 ± 0.36 429.0 ± 112.6[330·] 1.274 ± 468[980·] 35.0 ± 0.51 1.3 ± 0.45
Vinblastine 0.73 ± 0.12 78.0 ± 14.8[106.2·] 496.0 ± 280.9[679.5·] 2.9 ± 0.083 1.8 ± 0.37
a Cell growth inhibition was measured by the XTT assay22 for leukemic cells and the SRB assay23 for solid tumor cells after 72-h incubation using a
microplate spectrophotometer as described previously.24 IC50 values were determined in duplicate or triplicate from dose–eﬀect relationship at six
or seven concentrations of each drug by using the CompuSyn software by Chou and Martin25 based on the median-eﬀect principle and plot26,27 and
serial deletion analysis. Ranges given for taxol and vinblastine were mean ± SE (n = 4).
b CCRF-CEM/Taxol and CCRF-CEM/VBL are subcell lines of CCRF-CEM cells that are 330-fold resistant to taxol, and 680-fold resistant to
vinblastine, respectively, when comparing with the IC50 of the parent cell line.
c Numbers in the brackets are fold of cross-resistant determined by comparison with the corresponding IC50 of the parent cell line.
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24a and 24d against HCT-116 cell growth where the
cytotoxicity of 24a > 24b and 24c > 24d). These results
conﬁrm our previous studies17,19,20 and clearly demon-
strated that the changes in the cytotoxicity proﬁle by
modifying substituent(s) in the anilino or acridine ring
may attribute to the appropriate increasing lipophilic-
ity and DNA-binding aﬃnity. Of these derivatives,
compound 24h was the most cytotoxic with IC50 value
of 7.7 nM. As for the in vitro cytotoxicity of N-mus-
tard linked to acridine, it showed that compound 26
was less cytotoxic than compounds having 9-anilinoac-
ridines as a carrier. It is worthwhile to note that most
compounds linking to 9-anilinoacridines were equally
potent or in some cases more cytotoxic than the un-
masked N-mustard 9, but this ﬁnding was not ob-
served in compound 26. This suggested that the 9-
anilinoacridines were more favorable for using as a
DNA-aﬃnic carrier than acridine.
3.2. In vivo therapeutic activity
The therapeutic eﬀects of the representative new N-mus-
tards (24a, 24b, 24d, 24e) against human breast carci-
noma MX-1 and human Glioma U87 MG xenografts
in nude mice were evaluated. Under the experimental
conditions as indicated, 24b and 24d (Fig. 1) achieved
complete tumor remission (CR) in nude mice bearing
MX-1 xenograft at the doses of 30 and 100 mg/kg, intra-
venous injection (iv), Q2D · 5 (n = 3). Remarkably,
both compounds (24b and 24d) with only one cycle 5-
dose-treatments, complete remission was achieved and
maintained for over 70 days without any relapse in 3
out of 3 mice (Fig. 1A). Compound 24a also led to com-
plete tumor suppression but not complete tumor remis-
sion at the dose of 50 mg/kg, Q2D · 8 (n = 3). The
maximal toxicity of these agents as shown in Figure
1B by body weight decrease was about 10% drop from
the initial pretreatment body weight (on day 8), after
four treatments. However, the body weight showed
recovery after cession of treatment. Similar result was
found for 24e, which also resulted in tumor complete
remission at the dose of 75 mg/kg (QD · 8, iv injection)
in nude mouse bearing MX-1 xenograft (ﬁgure not
shown). Compound 24d was further selected to evaluate
its therapeutic eﬀect in nude mice bearing human glioma
U87 MG xenograft (Fig. 2). The results showed that 24d
was more potent than cyclophosphamide with low tox-
icity to the host (15% body-weight drop). These studies
Figure 1. The therapeutic eﬀects of 24a (50 mg/kg, Q2D · 8, iv
injection), 24b (30 mg/kg, Q2D · 5, iv injection), and 24d (100 mg/kg,
Q2D · 5, iv injection) in nude mice bearing MX-1 xenograft (n = 3);
control (d), 24a (m), 24b (), and 24d (·); average tumor size changes
(A); and average body weight changes (B). The values for the treated
versus the untreated group from day 16 to day 24 are <0.0006, <0.0003
and <0.0003 for 24a, 24b, and 24d, respectively.
Figure 2. The therapeutic eﬀects of 24d (100 mg/kg) and cyclophos-
phamide (80 mg/kg) in nude mice bearing human glioma U87 MG
xenograft (iv inj., Q2D · 5, n = 3); control (d), 24d () and
cyclophosphamide (); average tumor size changes (A); and body
weight changes (B). The values for the treated versus the untreated
group from day 18 to day 30 are <0.0001 and <0.0012 for
cyclophosphamide and 24d, respectively.
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demonstrated that the newly synthesized compounds
possess potent antitumor therapeutic eﬃcacy with a rel-
atively mild toxicity. Interestingly, we found that the
complete tumor suppression was observed in mice on
day-16 (last dose) and remained continuously for over
70 days without relapse.
3.3. Chemical stability
To realize whether the new conjugates are more stable
than BO-0742, we further investigated the comparative
chemical stability of the 24a, 24b, 24d, and BO-0742 in
intravenous injection vehicle (1 mg of compound in
DMSO/Tween 80/normal saline: 0.5:0.4:1.6 v/v/v) by
thin-layer chromatography (SiO2, solvent: CHCl3/
MeOH, 10:1 v/v) and parallel conﬁrmed by HPLC
(Mightysil RP-18; mobile phase: acetonitril/H2O 80:20,
elution rate: 1 mL/min). It revealed that the half-life
(t 1/2, time required for 50% decomposition of com-
pound) of 24a, 24b, and 24d were 55, 59, and 36 days,
respectively. We could not detect the t1/2 value for BO-
0742 by HPLC analysis, since this agent decomposed
during eluation from column. However, TLC analysis
showed that BO-0742 had a t1/2 value of 2 h demonstrat-
ing that the newly synthesized compounds were signiﬁ-
cantly more stable than BO-0742 although they were
less cytotoxic than the latter.
Compound 24d was further selected to study its chemi-
cal stability in rat plasma. The degradation of this agent
was detected by HPLC. The detection limit is 20 ng/mL
for the authentic 24d in the rat plasma. It revealed that
24d is a very stable N-mustard derivative in rat plasma
with a long half-life (t1/2 = 54.18 ± 0.96 h, n = 4). These
results demonstrate that the newly prepared N-mustards
are chemically and metabolically stable derivatives.
3.4. DNA interstrand cross-linking study
Compound 24d was found to be cytotoxic to human
non-small lung cancer H1299 cell line with IC50 value
of 0.51 lM. This agent was selected and subjected to
DNA cross-linking studies in human non-small lung
cancer H1299 cells by modiﬁed comet assay.28 The
DNA cross-linking caused by 24d was compared with
that of mephalan and cisplatin. It revealed that 24d
was capable of inducing DNA cross-linking in a dose-
dependent manner (Fig. 3). At the dose of 10 lM, this
agent induced 39.2% DNA cross-linking, while, mepha-
lan and cisplatin induced 47.3% and 47.4% DNA
cross-linking at the dose of 200 and 100 lM, respec-
tively, under the same experimental conditions. The
results suggested that DNA interstrand cross-linking
may be the main mechanism of action of 24d and the
related compounds.
4. Conclusion
In this study, we have synthesized a series of chemically
stable DNA-directed alkylating agents, in which the
phenyl N-mustard residue is linked to DNA-intercalat-
ing 9-anilinoacridines via a urea spacer, demonstrating
that these agents exhibited potent antitumor eﬃcacy in
vivo with a relatively low toxicity. Among these deriva-
tives, compound 24d was revealed to have potent antitu-
mor eﬀect in nude mice bearing human breast MX-1
xenograft; complete remission was achieved and main-
tained for over 70 days without any relapse with only
one cycle of treatments. Compound 24d also eﬀectively
suppressed human glioma U87 MG xenograft in nude
mice. Moreover, we also found that this agent is able
to cross-link with DNA and has a long half-life in rat
plasma suggesting that this agent is a promising candi-
date for preclinical studies.
5. Experimental
Melting points were determined on a Fargo melting
point apparatus and are uncorrected. Column chroma-
tography was carried out on silica gel G60 (70–230
mesh, ASTM; Merck and 230–400 mesh, Silicycle
Inc.). Thin-layer chromatography was performed on sil-
ica gel G60 F254 (Merck) with short-wavelength UV
light for visualization. Elemental analyses were done
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Figure 3. DNA interstrand cross-linking study. H1299 cells were used to determine the DNA cross-linking study by a modiﬁed comet assay.
Mephalan and cisplatin were used as positive controls. Data represents the means of three individual experiments (mean ± SD).
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on a Heraeus CHN-O Rapid instrument. HPLC was
performed on Waters Delta Prep4000 using Mightysil
RP-18 reverse phase column (250 · 4.6 mm). Com-
pounds were detected by UV at 260 nm. The mobile
phase was MeCN/H2O (80:20 v/v) with ﬂow rate of
1 mL/min. 1H NMR spectra were recorded on a
600 MHz, Brucker AVANCE 600 DRX and 400 MHz,
Brucker Top-Spin spectrometers. The chemical shifts
were reported in ppm (d) relative to TMS.
5.1. General procedure for the preparation of new N-
mustards
N,N-Bis(2-chloroethyl)benzene-1,4-diamine hydrochlo-
ride (9) was prepared by following the procedure devel-
oped by Jordan et al.14 Compound 9 was converted into
isocyanate 10, which was then condensed with appropri-
ate 9-anilinoacridines (8, 11–23) previously synthesized
from our laboratory17,19,20 and the commercially avail-
able 9-aminoacridine hydrochloride (13) in dry DMF in
the presence of triethylamine or pyridine to give 24a–n
and 26. The ﬁnal products were puriﬁed either by recrys-
tallization from an appropriate solvent or by column
chromatography using (SiO2, CHCl3/MeOH, v/v 100:2).
The detailed procedure was described as follows:
5.1.1. 4-[N,N -Bis(2-chloroethyl)amino]phenylisocyanate
(10). To a suspension of N,N-bis(2-chloroethyl)benzene-
1,4-diamine hydrochloride (9)14 (1.683 g, 5.4 mmol) in
dry chloroform (30 mL) was added triethylamine
(2.5 mL) at 0 C. The clear solution obtained was then
added dropwise into a solution of triphosgene (0.623 g,
2.1 mmol) in dry chloroform (10 mL) at 10 C. The
reaction mixture was allowed to stand at room temper-
ature. After being stirred for 30 min, the reaction mix-
ture was evaporated to dryness under reduced
pressure. The solid residue was triturated with dry
THF (100 mL), ﬁltered, and washed with small amount
of THF. The combined ﬁltrate and washings was evap-
orated to dryness to give the crude isocyanate 1021
which was used directly for the next reaction without
further puriﬁcation.
5.1.2. 1-[3-(Acridin-9-ylamino)-5-hydroxymethyl-phenyl]-
3-{4-[bis(2-chloroethyl)amino]phenyl}urea (24a). A solu-
tion of isocyanate 10 (freshly prepared from 9, 0.672
g, 2.2 mmol) in dry DMF (10 mL) was added dropwise
to a solution of 3-(9-acridinylamino)-5-hydroxymethy-
laniline (8, 0.752 g, 2.0 mmol)17 in dry DMF (40 mL)
containing triethylamine (2.0 mL) at 0 C. After being
stirred for 18 h at room temperature, the reaction mix-
ture was evaporated to dryness in vacuo, the residue
was dissolved in a mixture of CHCl3/MeOH containing
silica gel (5.0 g) and then evaporated to dryness. The res-
idue was put on the top of a silica gel column (2 · 20 cm)
and puriﬁed by using CHCl3/MeOH (100:5 v/v) as an
eluent. The fractions containing the main product were
combined and evaporated in vacuo to dryness and the
residue was recrystallized from CHCl3/MeOH to give
24a, 618 mg (53.8%); mp 174–175 C; 1H NMR
(DMSO-d6) d 3.65–3.71 (8H, m, 4· CH2), 4.41 (2H, d,
J = 6.0 Hz, CH2), 5.16 (1H, t, J = 6.0 Hz, exchangeable,
OH), 6.37 ( 1H, s, ArH), 6.68 (2H, d, J = 9.1 Hz, 2·
ArH), 6.81 (1H, s, ArH), 7.01–7.05 (3H, m, 3· ArH),
7.24 (2H, d, J = 9.1 Hz, 2· ArH), 7.54 (4H, br s, 4·
ArH) 8.05 (2H, br s, 2· ArH), 8.25, 8.46 and 10.84 (each
1H, br s, exchangeable, 3· NH). Anal. (C31H29Cl2N5
O2Æ0.5H2O) C, H, N.
By following the same procedure the following com-
pounds were synthesized.
5.1.3 . 1-{4-[Bis(2-chloroethyl)amino]phenyl}-3-[3-hydro-
xymethyl-5-(4-methylacridin-9-ylamino)phenyl]urea (24b).
Compound 24b was synthesized from 10 (freshly pre-
pared from 9, 1.377 g, 4.5 mmol) and 5-hydroxymethyl
3-(4-methyl-9-acridinylamino)aniline (11, 0.988 g,
3.0 mmol)17 in dry DMF (25 mL) containing pyridine
(2.0 mL): yield 986 mg (55.2%); mp 251–252 C; 1H
NMR (DMSO-d6) d 2.79 (3H, s, Me), 3.66–3.69 (8H,
m, 4· CH2), 4.45 (2H, d, J = 5.9 Hz, CH2), 5.30 (1H,
br s, exchangeable, OH), 6.68 (2H, d, J = 8.8 Hz, 2·
ArH), 6.87 (1H, s, ArH), 7.24 (2H, d, J = 8.8 Hz, 2·
ArH), 7.34 (1H, s, ArH), 7.39–7.41 (1H, m, ArH),
7.47–7.48 (1H, m, ArH), 7.57 (1H, s, ArH), 7.86 (1H,
d, J = 7.0 Hz, ArH), 8.00 (1H, s, ArH), 8.21–8.26 (2H,
m, 2· ArH), 8.45 (1H, d, J = 8.5 Hz, ArH), 8.82, 9.62
and 11.49 (each 1H, br s, exchangeable, 3· NH). Anal.
(C32H31Cl2N5O2Æ3H2O) C, H, N.
5.1.4. 1-(5-(Acridin-9-ylamino)-2-methylphenyl)-3-(4-(bis-
(2-chloroethyl)amino)phenyl)urea (24c). Compound 24c
was synthesized from 10 (freshly prepared from 9,
1.683 g, 5.4 mmol) and N1-(acridin-9-yl)amino-4-meth-
ylbenzene-1,3-diamine (12, 0.898 g 3.0 mmol)19 in dry
DMF (15 mL) containing triethylamine (2.5 mL): yield
771 mg (57.1%); mp 271–272 C (dec); 1H NMR
(DMSO-d6) d 2.35 (3H, s, Me), 3.66–3.69 (8H, m, 4·
CH2), 6.69 (2H, d, J = 8.8 Hz, 2· ArH), 6.86–6.88 (1H,
m, ArH), 7.25–7.27 (1H, m, ArH), 7.28 (2H, d,
J = 8.8 Hz, 2· ArH), 7.42–7.45 (2H, m, 2· ArH), 7.90–
8.00 (4H, m, 4· ArH), 8.19 (1H, s, ArH), 8.26 (2H, m,
2· ArH), 8.30, 9.37 and 11.49 (each 1H, br s, exchange-
able, 3· NH). Anal. (C31H29Cl2N5OÆ2.5H2O) C, H, N.
5.1.5. 1-{4-[Bis(2-chloroethyl)amino]phenyl}-3-[2-methyl-
5-(4-methylacridin-9-ylamino)phenyl]urea (24d). Com-
pound 24d was synthesized from 10 (freshly prepared
from 9, 1.836 g, 6 mmol) and 4-methyl-N1-(4-methylac-
ridin-9-yl)benzene-1,3-diamine (13, 1.065 g, 3.4 mmol)19
in dry DMF (50 mL) containing pyridine (2.0 mL): yield
1.631 g (83.8%); mp 267–268 C; 1H NMR (DMSO-d6)
d 2.34 (3H, s, Me), 2.78 (3H, s, Me), 3.65–3.70 (8H,
m, 4· CH2), 6.68 (2H, d, J = 9.2 Hz, 2· ArH), 6.86–
6.89 (1H, m, ArH), 7.24–7.27 (1H, m, ArH), 7.28 (2H,
d, J = 9.2 Hz, 2· ArH), 7.37–7.41 (1H, m, ArH), 7.43–
7.48 (1H, m, ArH), 7.86–7.87 (1H, m, ArH), 7.97–8.01
(1H, m, ArH), 8.20–8.23 (3H, m, 3· ArH), 8.33 (1H,
br s, exchangeable, NH), 8.42–8.44 (1H, m, ArH), 9.35
and 11.51 (each 1H, br s, exchangeable, 2· NH). Anal.
(C32H31Cl2N5OÆ2H2O) C, H, N.
5.1.6. 1-[3-(Acridin-9-yl)amino-5-methylphenyl]-3-{4-
[bis(2-chloroethyl)amino]phenyl}urea (24e). Compound
24e was synthesized from 10 (freshly prepared from
9, 0.918 g, 3.0 mmol) and N1-(acridin-9-yl)amino-
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5-methylbenzene-1,3-diamine (14, 0.517 g, 1.7 mmol)19 in
dry DMF (25 mL) containing pyridine (2 mL): yield
375 mg (39%); mp > 280 C; 1H NMR (DMSO-d6) d
2.26 (3H, s, Me), 3.68 (8H, s, 4· CH 2), 6.68 (2H, d,
J = 9.0 Hz, 2· ArH), 6.79 (1H, s, ArH), 7.25–7.27
(3H, m, 3· ArH), 7.46–7.49 (2H, m, 2· ArH), 7.54
(1H, s, ArH), 8.00–8.07 (4H, m, 4· ArH), 8.28–8.30
(2H, m, 2· ArH), 8.95, 9.38 and 11.51 (each 1H, br
s, exchangeable, 3· NH). Anal. (C31H29Cl2N5OÆ2.9-
H2O) C, H, N.
5.1.7. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-methyl-
3-(4-methylacridin-9-ylamino)phenyl)urea (24f). Com-
pound 24f was synthesized from 10 (freshly prepared
from 9, 1.683 g, 5.4 mmol) and 6-methyl-N1-(4-methyl-
acridin-9-yl)benzene-1,3-diamine (15, 0.910 g 3.0 mmol)19
in dry DMF (15 mL) containing triethylamine (2.5 mL):
yield 576 mg (44%); mp 255–256 C (dec); 1H NMR
(DMSO-d6) d 2.34 (3H, s, Me), 2.78 (3H, s, Me), 3.65–
3.71 (8H, m, 4·CH2), 6.69 (2H, d, J = 9.0 Hz, 2· ArH),
6.81–6.83 (1H, m, ArH), 7.21–7.24 (1H, m, ArH), 7.28
(2H, d, J = 9.0 Hz, 2· ArH), 7.34–7.38 (1H, m, ArH),
7.41–7.45 (1H, m, ArH), 7.82–7.83 (1H, m, ArH), 7.93–
7.97 (1H, m, ArH), 8.15–8.22 (3H, m, 3· ArH), 8.31
(1H, br s, exchangeable, NH), 8.39–8.42 (1H, m, ArH),
9.40 and 12.45 (each 1H, br s, exchangeable, 2· NH).
Anal. (C32H31Cl2N5OÆ2.7H2O) C, H, N.
5.1.8. 9-[5-(3-{4-[Bis(2-chloroethyl)amino]phenyl}ureido)-
2-methylphenylamino]-5-methylacridine-4-carboxylic acid
(2-dimethylaminoethyl)amide (24g). Compound 24g was
synthesized from 10 (freshly prepared from 9, 0.918 g,
3.0 mmol) and 9-(5-amino-2-methylphenylamino)-5-
methylacridine-4-carboxylic acid (2-dimethylamino-
ethyl)amide (16 , 0.732 g, 1.7 mmol)19 in dry DMF
(25 mL) containing pyridine (2 mL): yield 385 mg
(32%); mp > 280 C; 1H NMR (DMSO-d6) d 2.19 (3H,
s, Me), 2.67 (6H, br s, 2· NMe), 2.85 (3H, s, Me),
3.14 (2H, br s, CH2), 3.63–3.70 (8H, m, 4· CH2), 3.85
(2H, s, CH2), 6.40–6.41 (1H, m, ArH), 6.65 (2H, d,
J = 9.0 Hz, 2· ArH), 6.97–6.99 (1H, s, ArH), 7.24 (2H,
d, J = 9.0 Hz, 2· ArH), 7.45 (1H, s, ArH), 7.51 (1H,
m, ArH), 7.74 (2H, br s, 2· ArH), 7.93 (1H, br s,
exchangeable, NH), 8.08–8.10 (1H, m, ArH), 8.39–8.41
(1H, m, ArH), 8.67–8.69 (1H, m, ArH), 9.04, 9.45 and
12.18 (each 1H, br s, exchangeable, 3· NH). Anal.
(C37H41Cl2N7O2Æ5.7H2O) C, H, N.
5.1.9. 1-(5-(Acridin-9-ylamino)-2-methoxyphenyl)-3-(4-
(bis(2-chloroethyl)amino)phenyl)urea (24h). Compound
24h was synthesized from 10 (freshly prepared from 9,
1.683 g, 5.4 mmol) N1-(acridin-9-yl)-4-methoxybenzene-
1,3-diamine (17, 0.946 g, 3.0 mmol),20 in dry DMF
(15 mL) containing triethylamine (2.5 mL): yield 923 mg
(70.2%); mp 263–264 C (dec); 1H NMR (DMSO-d6) d
3.67–3.68 (8H, m, 4· CH2), 3.96 (3H, s, OMe), 6.68 (2H,
d, J = 8.5 Hz, 2· ArH), 6.95–6.96 (1H, m, ArH), 7.12–
7.13 (1H, m, ArH), 7.26 (2H, d, J = 8.5 Hz, 2· ArH),
7.42–7.44 (2H, m, 2· ArH), 7.95–7.97 (2H, m, 2· ArH),
8.00–8.02 (2H, m, 2· ArH), 8.24–8.27 (2H, m, 2· ArH),
8.33 (1H, br s, ArH), 8.44, 9.29 and 11.47 (each 1H, br
s, exchangeable, 3·NH).Anal. (C31H29Cl2N5O2Æ2.6H2O)
C, H, N.
5.1.10. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(2-meth-
oxy-5-(4-methylacridin-9-ylamino)phenyl)urea (24i).
Compound 24i was synthesized from 10 (freshly pre-
pared from 9, 0.841 g, 2.7 mmol) and 4-methoxy-N1-
(4-methylacridin-9-yl)benzene-1,3-diamine (18, 0.493 g
1.5 mmol)20 in dry DMF (10 mL) containing triethyl-
amine (2.0 mL): yield 428 mg (60.2%); mp 255–256 C
(dec); 1H NMR (DMSO-d6) d 2.50 (3H, s, Me), 3.65–
3.68 (8H, m, 4· CH2), 3.94 (3H, s, OMe), 6.68 (2H, d,
J = 9.0 Hz, 2· ArH), 6.93–6.95 (1H, m, ArH), 7.10
(1H, m, ArH), 7.26 (2H, d, J = 9.0 Hz, 2· ArH), 7.35–
7.37 (1H, m, ArH), 7.41–7.43 (1H, m, ArH), 7.82–7.83
(1H, s, ArH), 7.94–7.96 (1H, m, ArH), 8.21–8.22 (2H,
m, 2· ArH), 8.31–8.32 (1H, m, ArH), 8.50 (1H, br s,
ArH), 8.51, 9.44 and 11.55 (each 1H, br s, exchangeable,
3· NH). Anal. (C32H31Cl2N5O2Æ2.4H2O) C, H, N.
5.1.11. 1-(3-(Acridin-9-ylamino)-5-methoxyphenyl)-3-(4-
(bis(2-chloroethyl)amino)phenyl)urea (24j). Compound
24j was synthesized from 10 (freshly prepared from 9,
0.841 g, 2.7 mmol) and N1-(acridin-9-yl)-5-methoxyben-
zene-1,3-diamine (19 , 0.473 g 1.5 mmol)20 in dry DMF
(10 mL) containing triethylamine (2.0 mL): yield 452 mg
(64.5%); mp 260–261 C (dec); 1H NMR (DMSO-d6) d
3.67 (3H, s, OMe), 3.68–3.70 (8H, m, 4· CH2), 6.56
(1H, s, ArH), 6.69 (2H, d, J = 8.9 Hz, 2· ArH), 7.15
(1H, s, ArH), 7.19 (1H, s, ArH), 7.25 (2H, d,
J = 8.9 Hz, 2· ArH), 7.47–7.50 (2H, m, 2· ArH),
7.98–8.00 (2H, m, 2· ArH), 8.04–8.06 (2H, m, 2·
ArH), 8.29–8.31 (2H, m, 2· ArH), 8.88, 9.39 and
11.45 (each 1H, br s, exchangeable, 3· NH). Anal.
(C31H29Cl2N5O2Æ2.2H2O): C, H, N.
5.1.12. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(3-meth-
oxy-5-(4-methylacridin-9-ylamino)phenyl)urea (24k).
Compound 24k was synthesized from 10 (freshly pre-
pared from 9, 0.841 g, 2.7 mmol) and 5-methoxy-N1-
(4-methylacridin-9-yl)benzene-1,3-diamine (20, 0.493 g
1.5 mmol), 20 in dry DMF (10 mL) containing triethyl-
amine (2.0 mL): yield 459 mg (63.7%); mp 253–254 C
(dec); 1H NMR (DMSO-d6) d 2.80 (3H, s, Me), 3.66
(3H, s, OMe), 3.67–3.70 (8H, m, 4· CH2), 6.54 (1H, s,
ArH), 6.69 (2H, d, J = 9.0 Hz, 2· ArH), 7.14 (1H, s,
ArH), 7.17 (1H, s, ArH), 7.25 (2H, d, J = 9.0 Hz, 2·
ArH), 7.40–7.42 (1H, m, ArH), 7.47–7.50 (1H, m,
ArH), 7.85–7.86 (1H, m, ArH), 7.98–8.00 (1H, m,
ArH), 8.23–8.27 (2H, m, 2· ArH), 8.48–8.50 (1H, m,
ArH), 8.97, 9.51 and 11.47 (each 1H, br s, exchangeable,
3· NH). Anal. (C32H31Cl2N5O2Æ2.5H2O) C, H, N.
5.1.13. 1-(3-(4-((2-(Dimethylamino)ethyl)carbamoyl)acri-
din-9-ylamino)-5-methoxyphenyl)-3-(4-(bis(2-chloroeth-
yl)amino)phenyl)urea (24l). Compound 24l was
synthesized from 10 (freshly prepared from 9, 0.550 g,
1.8 mmol) and 9-(3-amino-5-methoxyphenylamino)-N1-
(2-(dimethylamino)ethyl)acridine-4-carboxamide (21,
0.429 g 1.0 mmol)20 in dry DMF (10 mL) containing tri-
ethylamine (2.0 mL): yield 359 mg (61.8%); mp 188–
190 C (dec); 1H NMR (DMSO-d6) d 2.88 (6H, br s,
2· NMe), 3.44 (2H, s, CH2), 3.60–3.68 (11H, m, 4·
CH2, OMe), 3.73 (1H, br s, CH), 3.97 (1H, s, CH),
6.04 (1H, s, exchangeable, NH), 6.67–6.68 (2H, m, 2·
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ArH), 6.78–6.87 (1H, m, ArH), 7.21 (2H, br s, 2· ArH),
7.53–7.57 (2H, m, 2· ArH), 7.87 (1H, s, ArH), 8.24 (1H,
s, ArH), 8.34–8.43 (1H, m, ArH), 8.68 (1H, s, ArH), 8.86
(1H, br s, ArH), 9.11–9.33 (1H, m, ArH), 9.57 (1H, s,
ArH), 10.48 and 12.01 (each 1H, br s, exchangeable,
2· NH). Anal. (C36H39Cl2N7O3Æ6.9H2O) C, H, N.
5.1.14 . 1-(3-(Acridin-9-ylamino)-4-methoxyphenyl)-3-(4-
(bis(2-chloroethyl)amino)phenyl)urea (24m). Compound
24m was synthesized from 10 (freshly prepared from 9,
0.841 g, 2.7 mmol) and N1-(acridin-9-yl)-6-methoxyben-
zene-1,3-diamine (22, 0.473 g 1.5 mmol)20 in dry DMF
(10 mL) containing triethylamine (2.0 mL): yield
563 mg (80.4%); mp 268–269 C (dec); 1H NMR
(DMSO-d6) d 3.41 (3H, s, OMe), 3.67–3.70 (8H, m, 4·
CH2), 6.70 (2H, d, J = 9.0 Hz, 2· ArH), 7.14–7.15 (1H,
m, ArH), 7.28 (2H, d, J = 9.0 Hz, 2· ArH), 7.43–7.47
(3H, m, 3· ArH), 7.81 (1H, br s, ArH), 7.98–8.00 (2H,
m, 2· ArH), 8.04–8.06 (2H, m, 2· ArH), 8.26–8.28
(2H, m, 2· ArH), 8.88, 9.30 and 11.32 (each 1H, br s,
exchangeable, 3· NH). Anal. (C31H29Cl2N5O2Æ3.
4H2O) C, H, N.
5.1.15 . 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-meth-
oxy-3-(4-methylacridin-9-ylamino)phenyl)urea (24n).
Compound 24n was synthesized from 10 (freshly pre-
pared from 9, 0.841 g, 2.7 mmol) and 6-methoxy-N1-
(4-methylacridin-9-yl)benzene-1,3-diamine (23, 0.493 g
1.5 mmol)20 in dry DMF (10 mL) containing triethyl-
amine (2.0 mL): yield 347 mg (48.8%); mp 270–272 C
(dec); 1H NMR (DMSO-d6) d 2.79 (3H, s, Me), 3.39
(3H, s, OMe), 3.67–3.70 (8H, m, 4· CH2), 6.69 (2H, d,
J = 8.8 Hz, 2· ArH), 7.12–7.13 (1H, m, ArH), 7.28
(2H, d, J = 8.8 Hz, 2· ArH), 7.37–7.39 (1H, m, ArH),
7.42–7.45 (2H, m, 2· ArH), 7.78 (1H, br s, ArH),
7.85–7.86 (1H, m, ArH), 7.97–7.99 (1H, m, ArH),
8.18–8.23 (2H, m, 2· ArH), 8.46–8.50 (1H, m, ArH),
8.93, 9.35 and 11.32 (each 1H, br s, exchangeable, 3·
NH). Anal. (C32H31Cl2N5O2Æ3.2H2O) C, H, N.
5.1.16 . 1-Acridin-9-yl-3-{4-[bis-(2-chloroethyl)amino]-
phenyl}-urea (26). Compound 26 was synthesized from
10 (freshly prepared from 9, 0.306 g, 1 mmol) and 9-
aminoacridinehydrochloride (25, 0.248 g, 1 mmol) in
dry DMF (10 mL) containing triethylamine (0.5 mL):
yield 273 mg (60%); mp 184–186 C; 1H NMR
(DMSO-d6) d 3.69–3.71 (8H, m, 4· CH2), 6.72 (2H, d,
J = 8.8 Hz, 2· ArH), 7.10–7.14 (2H, m, 2· ArH),
7.39–7.48 (3H, m, 3· ArH), 7.58–7.62 (2H, m, 2·
ArH), 7.84–7.86 (1H, m, ArH), 8.14–8.16 (2H, m, 2·
ArH), 9.37 and 11.33 (each 1H, br s, exchangeable, 2·
NH). Anal. (C24H22Cl2N4O) C, H, N.
5.2. Biological experiments
5.2.1. Cytotoxicity assays. The eﬀects of the compounds
on cell growth were determined in T-cell acute lympho-
cytic leukemia (CCRF-CEM) and their resistant subcell
lines (CCRF-CEM/Taxol and CCRF-CEM/VBL) by
the XTT assay22 and human solid tumor cells (i.e.,
breast carcinoma MX-1 and colon carcinoma HCT-
116) the SRB assay23 in a 72 h incubation using a micro-
plate spectrophotometer as described previously.24 After
the addition of phenazine methosulfate-XTT solution at
37 C for 6 h, absorbance at 450 and 630 nm was de-
tected on a microplate reader (EL 340; Bio-Tek Instru-
ments Inc., Winooski, VT). IC50 values were
determined from dose–eﬀect relationship at six or seven
concentrations of each drug by using the CompuSyn
software by Chou and Martin25 based on the median-ef-
fect principle and plot.26,27 Ranges given for taxol and
vinblastine were mean ± SE (n = 4).
5.2.2. In vivo studies. Athymic nude mice bearing the nu/
nu gene were used for human breast tumor MX-1 and
human glioma U87 MG xenograft. Outbred Swiss-back-
ground mice were obtained from the National Cancer
Institute (Frederick, MD). Male mice 8 weeks old or
older weighing 22 g or more were used for most experi-
ments. Drug was administrated via the tail vein by iv
injection. Tumor volumes were assessed by measuring
length · width · height (or width) by using caliper.
Vehicle used was 50 lL DMSO and 40 lL Tween 80 in
160 lL saline. The maximal tolerate dose of the tested
compound was determined and applied for the in vivo
therapeutic eﬃcacy assay. All animal studies were con-
ducted in accordance with the guidelines of the National
Institutes of Health Guide for the Care and Use of Ani-
mals and the protocol approved by the Memorial Sloan-
Kettering Cancer Center’s Institutional Animal Care
and Use Committee.
5.2.3. Determination of half-life of 24d in rat plasma. The
chromatographic system consisted of a photodiode-ar-
ray system (Shimadzu SPD-M20A, Tokyo, Japan),
chromatographic pump (Shimadzu LC-20AT), an
auto-sampler (Shimadzu SIL-20AC) equipped with a
20 lL sample loop. Compound 24d was separated from
rat plasma using a revise phase column (Agilent RP-C8,
30 · 150 mm, particle size 5 lm, Palo Alto, CA, USA)
maintained at an ambient temperature (25 ± 1 C) to
perform the ideal chromatographic system. The detector
wavelength was set at 266 nm. The mobile phase com-
prised methanol:10 mM NaH2PO4 (60:40, v/v), which
was adjusted to pH 3.0 with 85% of H3PO4. Analysis
was run at a ﬂow rate of 0.8 mL/min and the samples
were quantiﬁed using peak area. An aliquot of plasma
sample (100 lL, with 24d 5 lg/mL) was vortex-mixed
with acetonitrile (1:2, v/v) for protein precipitation and
centrifuged at 10,000g for 10 min. The supernatant
was passed through a 0.45 lm ﬁlter for injecting into
the HPLC.
5.3. Determination of DNA interstrand cross-linking
The level of DNA interstrand cross-linking was deter-
mined using a modiﬁed comet assay.28,29 All steps were
carried out under subdued lighting. Brieﬂy, H1299 cells
(2 · 105 cells) were plated in a 60 mm dish and incu-
bated at 37 C with 5% CO2 for 32 h. The growing cells
were treated with alkylating agent (24d, mephalan or
cisplatin). After being treated for 1 h, the cells were ex-
posed to 20 Gy irradiation to induce DNA strand
breaks. An aliquot of 5 · 105 cells were suspended in
50 lL of phosphate-buﬀered saline, mixed with a
250 lL of 1.2% low melting point agarose, and
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subjected to comet assay. The tail moment of 100 cells
were analyzed for each treatment by aid of the
COMET assay software (Perceptive instruments,
Haverhill, UK). The degree of DNA interstrand
cross-linking presented at a drug-treated sample was
determined by comparing the tail moment of the
irradiated control, which was calculated by the following
formula. Percentage of DNA with interstrand cross-link-
ing = [1 (TMdi TMcu/TMci TMcu)]·100%, where
TMdi = tail moment of drug-treated irradiated sample,
TMcu = tail moment of untreated unirradiated control,
and TMci = tail moment of untreated irradiated
control.
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Appendix A
C, H, N analysis
Compound Molecular formula MW C, H, N analysis
Anal. Calcd Found
C% H% N% C% H% N%
24a C31H29Cl2N5O2Æ0.5H2O 583.53 63.81 5.18 12.00 64.07 5.26 11.67
24b C32H31Cl2N5O2Æ3H2O 642.59 59.81 5.80 10.89 59.74 5.79 10.67
24c C31H29Cl2N5OÆ2.5H2O 603.54 61.69 5.20 11.60 61.83 5.17 11.53
24d C32H31Cl2N5OÆ2H2O 608.57 63.15 3.42 11.00 63.38 3.52 10.97
24e C31H29Cl2N5OÆ2.9H2O 609.78 61.06 5.23 11.48 61.08 5.11 11.32
24f C32H31Cl2N5OÆ2.7H2O 621.18 61.87 5.43 11.27 61.84 5.44 11.43
24g C37H41Cl2N7O2Æ5.7H2O 789.38 56.21 6.69 11.42 56.25 6.72 11.44
24h C31H29Cl2N5O2Æ2.6H2O 601.36 61.92 5.23 11.64 61.96 5.21 11.59
24i C32H31Cl2N5O2Æ2.4H2O 631.75 60.83 5.24 11.08 60.89 5.25 10.93
24j C31H29Cl2N5O2Æ2.2H2O 614.15 60.62 5.05 11.40 60.64 5.05 11.24
24k C32H31Cl2N5O2Æ2.5H2O 633.56 60.66 5.22 11.05 60.64 5.23 10.95
24l C36H39Cl2N7O3Æ6.9H2O 812.96 53.19 5.57 12.06 53.18 5.56 12.03
24m C31H29Cl2N5O2Æ3.4H2O 635.77 58.56 5.22 11.01 58.50 5.24 11.09
24n C32H31Cl2N5O2Æ3.2H2O 646.17 59.48 5.32 10.84 59.49 5.35 10.82
26 C24H22Cl2N4O 453.38 63.58 4.89 12.36 63.35 5.05 12.09
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Abstract
Novel rearrangement was found by reacting anilines with HCHO/H2O2 resulting in the synthesis of various benzaldoximes.
The mechanism of the rearrangement is proposed and suggested that the rearrangement might proceed via unstable N-phenyloxazirane
intermediate followed by the transfer of aryl moiety from nitrogen to carbon atom leading to the formation of benzaldoxime.
 2008 Elsevier Ltd. All rights reserved.
Keywords: Rearrangement; Amines; Oxidation; Peroxides; Benzaldoximes
1. Introduction
During the course of our research on the synthesis of
heterocyclic compounds, we surprisingly found that ani-
lines were converted into the corresponding benzaldoximes
when heated in over-aged 1,4-dioxane (purchased 12 years
ago). It prompted us to investigate the actual reactant(s)
involved in this novel transformation, although benzaldox-
imes can be easily synthesized by reacting benzaldehydes
with hydroxylamine hydrochloride as described previ-
ously.1–3
It is known that 1,4-dioxane can induce a chain radical
reactions under thermal,4 chemical oxidation (i.e., NaClO,
O3/H2O2),
5,6 photochemical7–9 or sonolysis10,11 producing
several intermediates including aldehydes (formaldehyde,
acetaldehyde and glyoxal), organic acids (formic, methoxy-
acetic, acetic, glycolic, glyoxylic and oxalic acids) and the
mono- and diformate ester of ethylene glycol.12 In view
of the structures of benzaldoximes (3) generated from ani-
lines, one can envisage that the formation of these com-
pounds requires a one-carbon source. Hence, it suggested
that formaldehyde generated from long stored 1,4-dioxane
might be a key one-carbon source involved in the reaction.
To mimic the transformation of anilines to benzaldoximes,
we have reacted anilines with ethylene glycol or glycerol in
the presence of hydrogen peroxide. The results showed that
benzaldoximes (3) were obtained under these reaction con-
ditions. Finally, we found that compound 3 can also be
prepared by reacting anilines with paraformaldehyde
followed by the treatment of the products 1,3,5-triphenyl-
hexahydro-s-triazines (2) with H2O2. From these studies,
we found a novel oxidative nitrogen-to-carbon rearrange-
ment of the N-aryl group in compounds having N–C–C
system (Scheme 1). The results of the new synthetic route
for benzaldoximes (3) are reported herein.
0040-4039/$ - see front matter  2008 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetlet.2008.03.033
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2. Results and discussion
A mixture of an appropriate aniline (1a,d) in over-aged
1,4-dioxane was heated at 80 C. The reaction discontinued
after 12 h, but can be re-ignited by adding more 1,4-diox-
ane. After the removal of solvent, the residue was
chromatographed on a silica gel column to give benzaldox-
imes (3a,d) as the major products (Scheme 1). However,
when the same reactions carried out in the freshly distil-
lated 1,4-dioxane (pretreated with KOH), no reaction
was observed even in the presence H2O2. This indicated
that the reactants (formaldehyde or peroxides) appeared
in the over-aged 1,4-dioxane were removed during the
pretreatment with KOH and/or distillation processes.
To ﬁnd a way to reproduce benzaldoximes (3) directly
from anilines was necessary since we have limited amount
of over-aged 1,4-dioxane. One can anticipate that the con-
version of anilines to benzaldoximes required one carbon
source, such as formaldehyde. Many studies have been
reported concerning the production of formaldehyde from
polyhydroxy compounds. For example, polyhydroxylated
alcohols (i.e., glycerol) and vicinal diols (i.e., ethylene
glycol) were oxidized by microsomes isolated from rat liver
to formaldehyde together with an aldehyde with less
carbon atoms. The reaction was catalyzed in the presence
of H2O2 and iron.
13–15 These studies demonstrated that
H2O2 play an important role in the overall pathway for oxi-
dizing ethylene glycol or glycerol to formaldehyde. To
mimic the generation of formaldehyde in a biological sys-
tem, we treated anisidines (1b,c,d) and toluidines (1e–g)
with ethylene glycol or glycerol with 30% H2O2 in the
freshly distillated 1,4-dioxane. We were able to isolate ben-
zaldoximes (3b–g) in moderate yields from these experi-
ments (Table 1). In general, the amount of benzaldoximes
(3) generated from the reaction of ethylene glycol or glyc-
erol/H2O2 has no signiﬁcant diﬀerence. It demonstrates
that both agents can liberate formaldehyde upon treatment
with H2O2. To understand that 1,4-dioxane is not involved
in the reaction under the applied reaction conditions, we
used toluene as the solvent instead of 1,4-dioxane, similar
results were observed. It should be noted that the
known benzaldoximes (3) were isolated as mixture of E/Z
diastereomers, which were determined by 1H NMR
spectrophotometric analysis. It revealed that the E/Z ratio
of benzaldoximes (3b–g) synthesized by all three methods
were almost identical (Table 2).
The reaction of anilines with formaldehyde is of greater
interest. Giumanini and Verardo16,17 reported that reacting
anilines with paraformaldehyde aﬀorded 1,3,5-triphenyl-
perhydro-s-triazines (2, Scheme 1) in toluene under reﬂux.
Triazines 2 may be the key intermediate for constructing
benzaldoximes (3). To study the conversion of anilines to
benzaldoximes in a stepwise manner, we prepared triazines
by reacting anilines (1a–g) with paraformaldehyde
Table 1
Reaction of anilines (1b–g) with ethylene glycol or glycerol/H2O2 in freshly distillated 1,4-dioxane, reaction conditions and yields of compound 3
Reactant-1a Reactant-2b Solvent (mL) dioxane 30% H2O2 (mL) Reaction time (days) Product (yield, %) E/Z ratio mp (C)/Reference
Compound 3
1b Ac 100 10 3 3b (9.2) 100:18 3b (83–84)26
Bd 100 10 4 3b (6.6) 100:18
1c A 100 10 2 3c (33) 100:40 3c (43–44)27
B 100 10 4 3c (29) 100:40
1d A 20 2 1 3d (27.8) 100:29 3d (73–75)28
B 20 2 3 3d (31.2) 100:29
1e A 60 10 3 3e (25.1) 100:40 3e (52–54)29
B 60 6 3 3e (27.6) 100:40
1f A 20 4 2 3f (16.3) 100:38 3f (oil)30
B 60 6 3 3f (19.9) 100:38
1g A 20 4 1 3g (31.1) 100:33 3g (50–51)31
B 60 6 1 3g (43.9) 100:33
a Reactant-1 (1 equiv).
b Reactant-2 (4 equiv).
c A = Ethylene glycol.
d B = Glycerol.
NH2
R
over-aged 1,4-dioxane,
ethylene glycol, glycerol
[O]
HCHO
80 º C
N
OH
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N N
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R
R
R
HCHO/ Dioxane/Reflux
30% H2O2/
Dioxane/Reflux
2b,c,d,e,f,g
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Scheme 1. a: R = H; b: 2-OMe; c: 3-OMe; d: 4-OMe; e: 2-Me; f: 3-Me; g:
4-Me.
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(1.2 equiv) by following the method described previ-
ously.16,17 In some cases, we were able to isolate the tri-
azine derivatives (2a,d,g) as crystal form, which were
further treated with H2O2 in the freshly distillated 1,4-diox-
ane to give benzaldoximes (3a,d,g). The overall yields of
3a,d,g were better when the intermediate triazines (2a,d,g)
were not isolated and directly treated with H2O2. Thus,
the desired benzaldoximes (3b–g) were prepared in better
yields in comparison with what were obtained from other
synthetic routes by treating anilines (1b–g) with parafor-
maldehyde, followed by direct reacting with H2O2 (Table
2).
The Stieglitz rearrangement has been widely studied.
Compounds involved in this carbon-to-nitrogen rearrange-
ment usually consist of an ‘Ar-C–N’ skeleton. Hoﬀmann
et al. reported that the Stieglitz rearrangement of tritylam-
ines, benzhydrylamines and benzyl amines can be induced
by p-nitrobenzensulfonyl peroxide or N-(arylsulfon-
oxy)amine.18,19 They postulated a mechanism for the rear-
rangement and demonstrated that the aryl migration from
carbon to nitrogen atom is concerted with the loss of the
arylsulfonate leaving group to form arylenamines.
As previously described, benzaldoximes (3) can be pre-
pared by heating anilines in old-aged 1,4-dioxane, formal-
dehyde or with triazines 2 in the presence of H2O2 possibly
via an aryl migration. Early reports by Emmons20 and
others showed that triazines 2 were unstable and can be
thematically convert into Schiﬀ base 4 bearing an ‘Ar-N–C’
back bone. Thus, a plausible reaction mechanism for the
synthesis of compounds 3 is proposed as shown in Scheme
2. The initiate intermediate of the reaction would be the
Schiﬀ bases (4), which may be delivered from triazines 2
upon heating. Early studies showed that Schiﬀ base can
be oxidized by peracetic acid to oxazirane (5) in a similar
manner as of oxidation of alkenes to epoxides.19,20 The tri-
azine or Schiﬀ base is possibly transformed into oxaziranes
(5) upon treatment with hydrogen peroxide. Since the com-
mercially available hydrogen peroxide (30%) is acidic in
nature, under such reaction conditions, oxaziranes (5) are
subsequently converted into the unstable intermediates 6,
which lead to the formation of the transition state 7. This
proposed structure illustrates that the N-aryl moiety prefer-
entially migrates to the positively charged primary carbon,
leading to the formation of intermediates 8, which are
further converted into benzaldoximes (3).
3. Conclusion
In the current study, we surprisingly found an alternative
synthetic route for benzaldoximes (3) by the reaction of ani-
lines with paraformaldehyde/H2O2 or triazine/H2O2. These
were obtained in moderate yields in a mixture of diastereo-
meric E/Z isomers with a ratio of about 100:30 in most
cases. It indicated that the method lacks stereo-selectivity
for the formation of E/Z isomers. However, we found a
novel oxidative nitrogen-to-carbon rearrangement in oxa-
ziranes (5), from which benzaldoximes (3) were prepared.
4. Experimental
Melting points were determined on a Fargo melting
point apparatus and are uncorrected. Column chromato-
graphy was carried out on Silica Gel G60 (70–230 mesh,
ASTM; Merck and 230–400 mesh, Silicycle Inc.). Thin-
layer chromatography was performed on Silica Gel G60
F254 (Merck) with short-wavelength UV light for visualiza-
tion. Elemental analyses were done on a Heraeus CHN–O
Rapid instrument. 1H NMR spectra were recorded on a
600 MHz, Brucker AVANCE 600 DRX and 400 MHz,
Brucker Top-Spin spectrometers. The chemical shifts were
reported in ppm (d) relative to TMS.
4.1. Reaction of anilines (1a,d) with over-aged 1,4-dioxane
A mixture of aniline (1a, 10 mmol) in over-aged 1,4-
dioxane (50 mL) was heated at 80 C for 5 days. After all
aniline was consumed, the reaction mixture was evaporated
in vacuo to dryness and the residue was chromatographed
on a silica gel column using hexane/EtOAc (100:30 v/v) as
the eluent to give known benzaldoxime (3a): yield 0.427 g
(35%) as an oil.24,25
4.2. 4-Methoxybenzaldoxime (3d)
Compound 3d was prepared from 4-anisidine (1d,
10 mmol) in over-aged 1,4-dioxane (50 mL) by following
Table 2
Reaction of anilines (1b–g) (1 equiv), with paraformaldehyde (1.2 equiv)/
H2O2 in freshly distillated 1,4-dioxane: reaction conditions and yields of
compound 3
Anilines Solvent (mL)
dioxane
30% H2O2
(mL)
Reaction
time (h)
Product
(yield %)
E/Z
ratio
1b 70 2 3 3b (35.3) 100:18
1c 60 2 3 3c (21) 100:40
1d 50 2 2.5 3d (55.1) 100:29
1e 60 2 2.5 3e (46) 100:40
1f 60 2 3 3f (28) 100:38
1g 60 2 2.5 3g (61.2) 100:33
2
N H
H
R
N H
H
R
O
N H
H
R
HO
R
N
OH
H
HHN
H
O
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HN
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NH2
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H
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Scheme 2. The proposed mechanism for the rearrangement of aryl group
in phenyloxaziranes.
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the same procedure as that for 3a. Yield 0.805 g (53.3%),
mp 73–75 C (Lit.28 mp 73–74 C).
4.3. General procedure for the synthesis of benzaldoximes
(3b–g) by the reaction of anilines (1b–g) with ethylene
glycol or glycerol/H2O2
A mixture of an appropriate anilines (1b–g, 1 equiv),
ethylene glycol (4 equiv) or glycerol (4 equiv) and 30%
H2O2(0.5 mL/1 mmol of aniline) in freshly distillated 1,4-
dioxane was heated at reﬂux for an appropriate time as
indicated in Table 1. After the reaction is completed, the
reaction mixture was evaporated to dryness and the desired
product was isolated by column chromatography (SiO2,
hexane/EtOAc, 100:30 v/v). The yields of 3b–g are shown
in Table 1.
4.4. General procedure for the synthesis of benzaldoximes
(3a,d,g) by reacting 1,3,5-triphenylperhydro-s-triazines
(2a,d,g) with H2O2
To a solution of known 1,3,5-triphenylperhydro-s-tri-
azine (2a, 0.945 g, 3 mmol)21 in freshly distillated or newly
purchased 1,4-dioxane (50 mL) was added dropwise 30%
H2O2 (1 mL) at room temperature. The mixture was then
heated at reﬂux temperature until all starting material
was consumed (2–3 h). The reaction mixture was evapo-
rated to dryness under reduced pressure and the residue
was chromatographed on a silica gel column (solvent:
CHCl3/MeOH, 100:1 v/v). The fractions containing the
main product were combined and evaporated to dryness
to yield the corresponding benzaldoximes (3a), 0.197 g
(54.3%), which is identical with one previously synthesized.
By following the same procedure as that for 3a, the
following compounds were prepared.
4.5. 4-Methoxybenzaldoxime (3d)
Compound 3d was prepared from known 1,3,5-tris-(4-
methoxyphenyl)[1,3,5]triazine (2d, 0.810 g, 2 mmol)22 and
30% H2O2(1 mL). Yield: 0.157 g (51%).
4.6. 4-Methylbenzaldoxime (3g)
Compound 3g was Prepared from known 1,3,5-tri-p-
tolyl-[1,3,5]triazine (2g, 0.714 g, 2 mmol)23 and 30% H2O2
(1 mL). Yield: 0.174 g (64.5%).
4.7. General procedure for the reaction of anilines with
parafomaldehyde/H2O2
A mixture of an appropriate aniline (1b–g, 1 equiv) and
paraformaldehyde (1.2 equiv) in freshly distillated or newly
purchased 1,4-dioxane was heated at reﬂux temperature
until all anilines were consumed. Then reaction mixture
cooled to room temperature and then treated with 30%
H2O2 (0.5 mL/1 mmol of aniline). The resulting mixture
was again heated to reﬂux for 2–3 h. After completion of
reaction, the reaction mixture was evaporated to dryness
under reduced pressure and the residue was chromato-
graphed on a silica gel column (solvent: CHCl3/MeOH,
100:1 v/v). The fractions containing the main product were
combined and evaporated to dryness to yield the corre-
sponding benzaldoximes (3b–g). The yields of each product
are shown in Table 2.
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